¹**Dysregulated FOXO1 activity drives skeletal muscle intrinsic dysfunction in amyotrophic** ²**lateral sclerosis**

Mónica Zufiría^{1,2,*}, Oihane Pikatza-Menoio^{1,2,\$}*, Maddi Garciandia-Arcelus^{1,*}, Xabier
4 Bengoetxea^{1,†}, Andrés Jiménez^{1,2,†}, Amaia Elicegui^{1,2,\$}, Maria Levchuk¹, Olatz Arnold-García^{1,2}, Bengoetxea^{1,†}, Andrés Jiménez^{1,2,†}, Amaia Elicegui^{1,2,\$}, Maria Levchuk¹, Olatz Arnold-García^{1,2}, 5 Pablo Iruzubieta^{1,2,3}, Jon Ondaro^{1,2}, Uxoa Fernández-Pelayo¹, Mikel Muñoz-Oreja^{1,2,4}, Ana 6 Aiastui^{1,2,5}, José Manuel García-Verdugo^{2,6,7}, Vicente Herranz-Pérez^{2,6,7}, Miren Zulaica^{1,2}, Juan
7 José Poza^{1,2,3}, Rebeca Ruiz-Onandi^{8,9}, Roberto Fernández-Torrón^{1,2,3}, Juan Bautista Espinal³, José Poza^{1,2,3}, Rebeca Ruiz-Onandi^{8,9}, Roberto Fernández-Torrón^{1,2,3}, Juan Bautista Espinal³,
8 Mario Bonilla¹⁰, Ana Lersundi^{10,11}, Gorka Fernández-Eulate^{3,12,13}, Javier Riancho^{2,14,15}, Ainara Mario Bonilla¹⁰, Ana Lersundi^{10,11}, Gorka Fernández-Eulate^{3,12,13}, Javier Riancho^{2,14,15}, Ainara
9 Valleio-Illarramendi^{1,2,4}, Ian James Holt^{1,2,16,17}, Amets Sáenz^{1,2}, Edoardo Malfatti^{18,19}, Stéphanie Vallejo-Illarramendi^{1,2,4}, Ian James Holt^{1,2,16,17}, Amets Sáenz^{1,2}, Edoardo Malfatti^{18,19}, Stéphanie
10 Duguez^{20,21}, Lorea Blázquez^{1,2,16}, Adolfo López de Munain^{1,2,3,22,23,24}, Gorka Gerenu^{1,2,16,25,#}. 10 Duguez^{20,21}, Lorea Blázquez^{1,2,16}, Adolfo López de Munain^{1,2,3,22,23,24}, Gorka Gerenu^{1,2,16,25,#},
11 Francisco Gil-Bea^{1,2,16,26,#}, Sonia Alonso-Martín^{1,2,\$#@} Francisco Gil-Bea^{1,2,16,26,#}, Sonia Alonso-Martín^{1,2,\$#@} ¹Neurosciences Area, Biogipuzkoa Health Research Institute, 20014 Donostia/San Sebastian, 13 Spain ²CIBERNED, ISCIII (CIBER, Carlos III Institute, Spanish Ministry of Sciences and 15 Innovation), 28031, Madrid, Spain ³ Department of Neurology, Donostialdea Integrated Health Organization, Osakidetza Basque
¹⁷ Health Service, 20014 Departic/Sep Sebestian, Spein 17 Health Service, 20014 Donostia/San Sebastian, Spain ⁴ 18Department of Pediatrics, Faculty of Medicine and Nursery, University of the Basque Country
 $\frac{10}{2}$ UDV/EUU 20014 Deposite (Sep Sebestian Spain) ¹⁹UPV/EHU, 20014, Donostia/San Sebastian, Spain ⁵ 20Cell Culture Platform, Biodonostia Health Research Institute, 20014 Donostia/San Sebastian, 21 Spain ⁶ 22 ⁶ Laboratory of Comparative Neurobiology, Cavanilles Institute of Biodiversity and ²³Evolutionary Biology, University of Valencia, 46980 Paterna, Spain ⁷ 24⁷ ⁷ Department of Cell Biology, Functional Biology and Physical Anthropology, University of 25 Valencia, 46100 Burjassot, Spain ⁸Department of Pathological Anatomy, Galdakao-Usansolo University Hospital, Osakidetza 27 Basque Health Service, 48960 Galdakao, Spain ⁹ 28⁹ Department of Medical-Surgical Specialties, Faculty of Medicine and Nursery, University of $\frac{100}{100}$ the Baseus Country UBV/EUU 48040 Leise. Special 29 the Basque Country UPV/EHU, 48940 Leioa, Spain 10^{10} Department of Traumatology and Orthopedic Surgery, Donostialdea Integrated Health 31 Organization, Osakidetza Basque Health Service, 20014 Donostia/San Sebastian, Spain ¹¹ Department of Surgery, Faculty of Medicine and Nursery, University of the Basque Country
 $1000 \times 1000 \times 1000 \times 1000$
 $\frac{1000 \times 1000 \times 1000 \times 1000 \times 1000 \times 1000}{\sqrt{25}}$ ³³UPV/EHU, 20014 Donostia/San Sebastián, Spain ¹² Nord/Est/Ile-de-France Neuromuscular Reference Center, Institut de Myologie, Pitié-35 Salpêtrière Hospital, 75012 Paris, France

7

- ¹³Institut Necker-Enfants Malades, INSERM U1151, BioSPC (ED562), Université Paris Cité,
- 37 75015 Paris, France.
- ¹⁴ Department of Neurology, Hospital de Sierrallana-IDIVAL, 39300 Torrelavega, Cantabria, Spain 39 Spain
- ¹⁵ 15 Department of Psychiatry and Medicine, Faculty of Medicine, University of Cantabria, 39011
41 Santander Spain 41 Santander, Spain.
- ¹⁶ IKERBASQUE, Basque Foundation for Science, 48013 Bilbao, Spain
- 17 17 Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of 44 Neurology, Royal Free Campus, London, NW3 2PF, UK
- ¹⁸ Université Paris Est Créteil, INSERM, IMRB, F-94010 Créteil, France Hôpital Henri-46 Mondor, 94010 Créteil, France
- ¹⁹ Paris Reference Center for Neuromuscular Disorders, APHP Henri Mondor University 48 Hospital, 94010 Créteil, France
- ²⁰Personalised Medicine Centre, School of Medicine, Ulster University, Derry BT47 6SB, UK
- 2^{11} Northern Ireland Center for Stratified Medicine, Biomedical Sciences Research Institute, 51 Londonderry, UK
- 22 ⁵²Department of Neurosciences, Faculty of Medicine and Nursery, University of the Basque 53 Country UPV/EHU, 20014 Donostia/San Sebastian, Spain
- 2^{3} Department of Medicine, Faculty of Health Sciences, University of Deusto, 48007 Bilbao, Spain 55 Spain
- 56 ²⁴ Biodonostia Health Research Institute, 20014 Donostia/San Sebastian, Spain
- 25 Department of Physiology, Faculty of Medicine and Nursery, University of the Basque 58 Country UPV/EHU, 48940 Leioa, Spain
- 2^{26} Department of Health Sciences, Public University of Navarra (UPNA), 31006 Pamplona, Spain 60 Spain
- ^{\$} Fresent address: Stem Cells and Aging Group, Biogipuzkoa Health Research Institute, 20014
62 Donostia/San Sebastian Spain 62 Donostia/San Sebastian, Spain
- ⁶³*Equal contribution
- ⁶⁴†Equal contribution
- 65 $*$ Equal contribution
- 66
- **@** ⁶⁷**Correspondence to:**
- ⁶⁸Sonia Alonso-Martin (sonia.alonsomartin@bio-gipuzkoa.eus) T. +34 943006029

70

⁷¹**Author Contributions**

72 ALM, FG-B and SA-M designed the study in collaboration with MZuf (*in vitro* and metabolic
73 experiments) and GG (*Drosophila* experiments). MZuf. OP-M. MG-A. AE. ML, MZul. AS. GG 73 experiments) and GG (*Drosophila* experiments). MZuf, OP-M, MG-A, AE, ML, MZul, AS, GG
74 and SA-M performed experiments with ALS patient-derived primary cultures and MZuf, OP-M, 74 and SA-M performed experiments with ALS patient-derived primary cultures and MZuf, OP-M,
75 MG-A, XB, PI, JO, UF-P, MM-O, GF-E, AV-I, IJH and FG-B with 8220 immortalised human 75 MG-A, XB, PI, JO, UF-P, MM-O, GF-E, AV-I, IJH and FG-B with 8220 immortalised human
76 control myoblasts. MZuf, MG-A, GF-E and AA performed SeaHorse experiments. JMG-V and 76 control myoblasts. MZuf, MG-A, GF-E and AA performed SeaHorse experiments. JMG-V and
77 VH-P designed and performed *TEM* experiments. OA, LB and FG-B analysed NGS data. PI, 77 VH-P designed and performed *TEM* experiments. OA, LB and FG-B analysed NGS data. PI,
78 JJP, RR-O, RF-T, JBE, MB, AL, GF-E, JR, EM, SD and ALM clinically identified and 78 JJP, RR-O, RF-T, JBE, MB, AL, GF-E, JR, EM, SD and ALM clinically identified and
79 characterised patients and collected muscle samples. AJ and GG performed and analysed 79 characterised patients and collected muscle samples. AJ and GG performed and analysed
80 Drosophila experiments. ALM, FG-B and SA-M supervised and coordinated all work. ALM, 80 *Drosophila* experiments. ALM, FG-B and SA-M supervised and coordinated all work. ALM, FG-B and SA-M contributed to the preparation of the manuscript. FG-B and SA-M contributed to the preparation of the manuscript.

82

⁸³**ABSTRACT**

84 Amyotrophic Lateral Sclerosis (ALS) is a multisystemic neurodegenerative disorder, with
85 accumulating evidence indicating metabolic disruptions in the skeletal muscle preceding disease 85 accumulating evidence indicating metabolic disruptions in the skeletal muscle preceding disease
86 symptoms, rather than them manifesting as a secondary consequence of motor neuron (MN) 86 symptoms, rather than them manifesting as a secondary consequence of motor neuron (MN)
87 degeneration. Hence, energy homeostasis is deeply implicated in the complex physiopathology 87 degeneration. Hence, energy homeostasis is deeply implicated in the complex physiopathology
88 of ALS and skeletal muscle has emerged as a key therapeutic target. Here, we describe intrinsic 88 of ALS and skeletal muscle has emerged as a key therapeutic target. Here, we describe intrinsic
89 abnormalities in ALS skeletal muscle, both in patient-derived muscle cells and in muscle cell 89 abnormalities in ALS skeletal muscle, both in patient-derived muscle cells and in muscle cell
90 lines with genetic knockdown of genes related to familial ALS, such as *TARDBP* (TDP-43) and 90 lines with genetic knockdown of genes related to familial ALS, such as *TARDBP* (TDP-43) and
91 *FUS*. We found a functional impairment of myogenesis that parallels defects of glucose ⁹¹*FUS*. We found a functional impairment of myogenesis that parallels defects of glucose 92 oxidation in ALS muscle cells. We identified FOXO1 transcription factor as a key mediator of
93 these metabolic and functional features in ALS muscle, via gene expression profiling and 93 these metabolic and functional features in ALS muscle, via gene expression profiling and
94 biochemical surveys in TDP-43 and FUS silenced muscle progenitors. Strikingly, inhibition of 94 biochemical surveys in TDP-43 and FUS silenced muscle progenitors. Strikingly, inhibition of
95 FOXO1 mitigated the impaired myogenesis in both the genetically modified and the primary 95 FOXO1 mitigated the impaired myogenesis in both the genetically modified and the primary
96 ALS myoblasts. In addition, specific in vivo conditional knockdown of TDP-43 or FUS 96 ALS myoblasts. In addition, specific *in vivo* conditional knockdown of TDP-43 or FUS
97 orthologs (*TBPH* or *caz*) in *Drosophila* muscle precursor cells resulted in decreased innervation 97 orthologs (*TBPH* or *caz*) in *Drosophila* muscle precursor cells resulted in decreased innervation
98 and profound dysfunction of motor nerve terminals and neuromuscular synapses, accompanied 98 and profound dysfunction of motor nerve terminals and neuromuscular synapses, accompanied
99 by motor abnormalities and reduced lifespan. Remarkably, these phenotypes were partially 99 by motor abnormalities and reduced lifespan. Remarkably, these phenotypes were partially
100 corrected by $f(xo)$ inhibition, bolstering the potential pharmacological management of muscle 100 corrected by *foxo* inhibition, bolstering the potential pharmacological management of muscle
101 intrinsic abnormalities associated with ALS. The findings demonstrate an intrinsic muscle 101 intrinsic abnormalities associated with ALS. The findings demonstrate an intrinsic muscle
102 dysfunction in ALS, which can be modulated by targeting FOXO factors, paying the way for 102 dysfunction in ALS, which can be modulated by targeting FOXO factors, paving the way for
103 novel therapeutic approaches that focus on the skeletal muscle as complementary target tissue. novel therapeutic approaches that focus on the skeletal muscle as complementary target tissue.

104

¹⁰⁵**Keywords**

106 Amyotrophic lateral sclerosis; myogenesis; glycolysis; TDP-43; FUS; FOXO1.

¹⁰⁸**INTRODUCTION**

109 Amyotrophic lateral sclerosis (ALS) is a devastating disorder characterised by a progressive
110 degeneration of upper and lower motor neurons (MN) that leads to the death of the patient 110 degeneration of upper and lower motor neurons (MN) that leads to the death of the patient
111 within an average of 36 months from onset [10, 78]. Major symptoms, including weakness, 111 within an average of 36 months from onset [10, 78]. Major symptoms, including weakness,
112 motor disability, paralysis, and ultimately death, arise from the progressive waste of the skeletal 112 motor disability, paralysis, and ultimately death, arise from the progressive waste of the skeletal
113 muscle. Although MN loss and the subsequent dismantling of the neuromuscular iunctions 113 muscle. Although MN loss and the subsequent dismantling of the neuromuscular junctions
114 (NMJ) are considered the primary cause of muscle atrophy, recent evidence suggests that 114 (NMJ) are considered the primary cause of muscle atrophy, recent evidence suggests that
115 muscle pathology may be an active player in ALS disease. These data include pathological 115 muscle pathology may be an active player in ALS disease. These data include pathological
116 accumulation of phospho-TDP-43 within muscle fibres [42], as well as in distal axons within 116 accumulation of phospho-TDP-43 within muscle fibres [42], as well as in distal axons within
117 intramuscular nerve bundles of patients [28]. Indeed, studies carried out in SOD1 mouse models 117 intramuscular nerve bundles of patients [28]. Indeed, studies carried out in SOD1 mouse models
118 have evidenced that early metabolic alterations occur in the skeletal muscle before the onset of 118 have evidenced that early metabolic alterations occur in the skeletal muscle before the onset of
119 MN degeneration [12, 13, 33, 51]. Moreover, the overexpression of mutated SOD1 restricted 119 MN degeneration [12, 13, 33, 51]. Moreover, the overexpression of mutated SOD1 restricted
120 exclusively to skeletal muscle cells is able to induce some of the ALS phenotypes, including exclusively to skeletal muscle cells is able to induce some of the ALS phenotypes, including
121 loss of spinal MNs [37, 84]. Collectively, these findings support a central role of the skeletal 121 loss of spinal MNs [37, 84]. Collectively, these findings support a central role of the skeletal
122 muscle in ALS pathogenesis. This aligns with the disease-modifying effect that vigorous 122 muscle in ALS pathogenesis. This aligns with the disease-modifying effect that vigorous
123 bhysical exercise appears to exert on ALS, as described in genetic and epidemiologic studies 123 physical exercise appears to exert on ALS, as described in genetic and epidemiologic studies
124 [18, 24]. $[18, 24]$.

125 Muscle fibre homeostasis in adulthood is fundamentally supported by intrinsic repair
126 mechanisms that involve a sequence of metabolically fine-tuned steps, ranging from the 126 mechanisms that involve a sequence of metabolically fine-tuned steps, ranging from the
127 activation and proliferation of skeletal muscle resident stem cells (known as satellite cells) to the 127 activation and proliferation of skeletal muscle resident stem cells (known as satellite cells) to the
128 differentiation and fusion into multinucleated syncytia, the myotubes, which will mature into 128 differentiation and fusion into multinucleated syncytia, the myotubes, which will mature into
129 new myofibers [59]. Several works have shown that satellite cells isolated from ALS patients new myofibers [59]. Several works have shown that satellite cells isolated from ALS patients
130 exhibit changes in different myogenic markers [23, 57, 69], as well as a reduced ability to form 130 exhibit changes in different myogenic markers [23, 57, 69], as well as a reduced ability to form
131 mature myotubes under *in vitro* conditions [57, 69]. Likewise, myogenic defects have also been 131 mature myotubes under *in vitro* conditions [57, 69]. Likewise, myogenic defects have also been
132 reported in cultured myoblasts derived from mouse models expressing mutations in either 132 reported in cultured myoblasts derived from mouse models expressing mutations in either
133 SOD1 [36, 80] or VAPB [80]. Although these myogenic defects may be legitimately considered 133 SOD1 [36, 80] or VAPB [80]. Although these myogenic defects may be legitimately considered
134 secondary to changes in the denervated stem cell niche, the recent discovery of the 134 secondary to changes in the denervated stem cell niche, the recent discovery of the moonlighting activity of *TARDBP* (a major ALS-causative gene) in muscle regeneration has 135 moonlighting activity of *TARDBP* (a major ALS-causative gene) in muscle regeneration has
136 bolstered the argument for the implication of myogenesis in the pathophysiology of ALS [81]. 136 bolstered the argument for the implication of myogenesis in the pathophysiology of ALS [81].
137 In that study, the protein expressed by *TARDBP* gene. TDP-43, was proven to be essential for 137 In that study, the protein expressed by *TARDBP* gene, *TDP-43*, was proven to be essential for skeletal muscle formation and regeneration by recruiting specific mRNAs that encode 138 skeletal muscle formation and regeneration by recruiting specific mRNAs that encode
139 sarcomeric proteins into cytoplasmic amyloid-like granules [81]. In this line, Le Gall and 139 sarcomeric proteins into cytoplasmic amyloid-like granules [81]. In this line, Le Gall and
140 collaborators demonstrated a neurotoxic paracrine role of muscle cells via secretion of 140 collaborators demonstrated a neurotoxic paracrine role of muscle cells via secretion of
141 extracellular vesicles in recipient cells such as the MNs, with a FUS-dependent mechanism [17]. 141 extracellular vesicles in recipient cells such as the MNs, with a FUS-dependent mechanism [17].
142 Furthermore, two French families carrying a missense (G376V) and a C \Box terminal frameshift Furthermore, two French families carrying a missense (G376V) and a C \Box terminal frameshift

143 variant of TDP \Box 43 have lately been identified to be affected by autosomal dominant myopathies $[14, 90]$.

myopathies [14, 90].

145 In light of this evidence, we postulate that abnormalities of muscle turnover in ALS might stem
146 from intrinsic metabolic defects in muscle progenitors that eventually aggravate muscle wasting 146 from intrinsic metabolic defects in muscle progenitors that eventually aggravate muscle wasting
147 in ALS. in ALS.

148 Based on the growing hypothesis that muscle defects contribute to MN degeneration through a
149 dying-back mechanism [64], we sought to decipher the mechanisms underlying myogenic 149 dying-back mechanism [64], we sought to decipher the mechanisms underlying myogenic
150 derangements in ALS. Our goal was to identify therapeutic targets that can mitigate or alleviate 150 derangements in ALS. Our goal was to identify therapeutic targets that can mitigate or alleviate
151 neuronal degeneration. For this purpose, we studied the contribution of two major ALS genes, 151 neuronal degeneration. For this purpose, we studied the contribution of two major ALS genes,
152 TARDBP and FUS, in the metabolic regulation during myogenesis and differentiation, by using 152 *TARDBP* and *FUS*, in the metabolic regulation during myogenesis and differentiation, by using
153 human immortalised myoblasts with induced loss-of-function (LoF) of such genes and ALS 153 human immortalised myoblasts with induced loss-of-function (LoF) of such genes and ALS
154 patient-derived primary myoblasts. Moreover, we analysed the functional *in vivo* consequences 154 patient-derived primary myoblasts. Moreover, we analysed the functional *in vivo* consequences
155 in *Drosophila melanogaster* ALS models with muscle-specific LoF of *TBPH* and *caz*, human 155 in *Drosophila melanogaster* ALS models with muscle-specific LoF of *TBPH* and *caz*, human
156 *TARDBP* and *FUS* ortholog genes, respectively. Indeed, we found a general reduction in TDP-156 *TARDBP* and *FUS* ortholog genes, respectively. Indeed, we found a general reduction in TDP-
157 43 and FUS proteins which associated with impaired differentiation and increased expression of 15743 and FUS proteins which associated with impaired differentiation and increased expression of atrophic markers in patient-derived muscle cells, as well as repressed glycolysis as a consistent 158 atrophic markers in patient-derived muscle cells, as well as repressed glycolysis as a consistent
159 metabolic feature linking energy defects with the impaired myogenic capacity induced by TDP-159 metabolic feature linking energy defects with the impaired myogenic capacity induced by TDP-
160 43 or FUS LoF. In addition, gene expression surveys and rescue experiments identified 160 43 or FUS LoF. In addition, gene expression surveys and rescue experiments identified
161 dysregulation of FOXO1 transcription factor as a mediator of the myogenic defects caused by 161 dysregulation of FOXO1 transcription factor as a mediator of the myogenic defects caused by
162 TDP-43 or FUS knockdown. Inhibition of FOXO1 not only mitigated myogenic and metabolic 162 TDP-43 or FUS knockdown. Inhibition of FOXO1 not only mitigated myogenic and metabolic
163 abnormalities in ALS myoblast cells but also in other two MN disorders with muscle 163 abnormalities in ALS myoblast cells but also in other two MN disorders with muscle
164 involvement, such as Spinal Muscular Atrophy (SMA) or Spinal Bulbar Muscular Atrophy 164 involvement, such as Spinal Muscular Atrophy (SMA) or Spinal Bulbar Muscular Atrophy
165 (SBMA). Furthermore, it also rescued ALS-associated phenotypes in *Drosophila* models that 165 (SBMA). Furthermore, it also rescued ALS-associated phenotypes in *Drosophila* models that 166 bear the conditional knockdown of *TBPH* and *caz* genes specifically in muscle progenitor cells. 166 bear the conditional knockdown of *TBPH* and *caz* genes specifically in muscle progenitor cells.
167 Strikingly, muscle-nerve connections were disrupted in these fly models but corrected at the 167 Strikingly, muscle-nerve connections were disrupted in these fly models but corrected at the
168 synapse level by *foxo* inhibition. Therefore, in this study, we propose FOXO transcription 168 synapse level by *foxo* inhibition. Therefore, in this study, we propose FOXO transcription
169 factors as pharmacological targets for the treatment of ALS through the mitigation of skeletal 169 factors as pharmacological targets for the treatment of ALS through the mitigation of skeletal
170 muscle metabolic and functional defects, which could improve the associated MN function. muscle metabolic and functional defects, which could improve the associated MN function.

¹⁷¹**MATERIAL AND METHODS**

¹⁷²**Patients, clinical management and muscle biopsies**

173 Neurologists from the ALS Unit of Donostia University Hospital were in charge of performing
174 diagnoses, patients' examination and muscle biopsies. Samples and clinical data from patients 174 diagnoses, patients' examination and muscle biopsies. Samples and clinical data from patients
175 included in this study were provided by the Basque Biobank (www.biobancovasco.org) and 175 included in this study were provided by the Basque Biobank (www.biobancovasco.org) and
176 processed following standard procedures with appropriate approval by the Clinical Research 176 processed following standard procedures with appropriate approval by the Clinical Research
177 Ethics Committees of the Basque Country and Donostia University Hospital (codes: ALM-177 Ethics Committees of the Basque Country and Donostia University Hospital (codes: ALM-
178 EMP-2015-01. PI2016075. PI2019198). Informed consent was obtained from all the subjects. 178 EMP-2015-01, PI2016075, PI2019198). Informed consent was obtained from all the subjects.
179 This research project was conducted following the requirements of The European Regulation of 179 This research project was conducted following the requirements of The European Regulation of
180 Data Protection and Digital Rights guarantee. All samples were anonymized, only keeping the 180 Data Protection and Digital Rights guarantee. All samples were anonymized, only keeping the necessary gender and age information. necessary gender and age information.

182 All muscle biopsies were performed using the open minor surgery technique at the neurologist's
183 consulting room, except for the *post mortem*, which was recovered at the autopsy room, 21 183 consulting room, except for the *post mortem*, which was recovered at the autopsy room. 21
184 muscle biopsies were used in this study, as summarised next (Table 1): 8 Controls (CTRL), 30-184 muscle biopsies were used in this study, as summarised next (Table 1): 8 Controls (CTRL), 30-
185 75 years-old: 3 Familial ALS (fALS), 45-71 years-old: 5 Sporadic ALS (sALS), 47-66 years-185 75 years-old; 3 Familial ALS (fALS), 45-71 years-old; 5 Sporadic ALS (sALS), 47-66 years-
186 old; 3 MN disorders (SMA3, caused by mutations in SMN1; SBMA, also known as Kennedy's 186 old; 3 MN disorders (SMA3, caused by mutations in SMN1; SBMA, also known as Kennedy's
187 disease, related to pathogenic GCC expansions in the androgen receptor: CMT4, Charcot-187 disease, related to pathogenic GCC expansions in the androgen receptor; CMT4, Charcot-
188 Marie-Tooth type 4, a recessive and demvelinating disease): and 2 muscular disorders with 188 Marie-Tooth type 4, a recessive and demyelinating disease); and 2 muscular disorders with
189 protein aggregates (sporadic Inclusion Body Myositis-IBM and a vacuolar myopathy related to 189 protein aggregates (sporadic Inclusion Body Myositis-IBM and a vacuolar myopathy related to
190 Valosin-Containing Protein-VCP). CMT4 myoblasts were provided by the MYOBANK-AFM 190 Valosin-Containing Protein-VCP). CMT4 myoblasts were provided by the MYOBANK-AFM
191 (Myology Institute) (Table 1). $(Myology Institute)$ (Table 1).

¹⁹²**Haematoxylin and Eosin Staining in histological cryosections**

193 Muscle biopsies were recovered and cleared of vessels and connective tissue. Several pieces
194 from each biopsy were snap-frozen in liquid nitrogen-cooled isopentane to be processed for 194 from each biopsy were snap-frozen in liquid nitrogen-cooled isopentane to be processed for
195 histological analysis. 8 µm cryosections were obtained and fixed in 4% paraformaldehyde 195 histological analysis. 8 µm cryosections were obtained and fixed in 4% paraformaldehyde
196 (PFA) and processed for Haematoxylin and Eosin staining as previously described [65]. The 196 (PFA) and processed for Haematoxylin and Eosin staining as previously described [65]. The
197 histological preparations were mounted with DPX Mountant (Sigma-Aldrich) and scanned at 197 histological preparations were mounted with DPX Mountant (Sigma-Aldrich) and scanned at 198 10X magnification on Pannoramic MIDI II (3DHistech). ¹⁹⁸10X magnification on Pannoramic MIDI II (3DHistech).

Sample	Diagnosis	Onset	Genetics	Sex	Age Onset		Age Biopsy Status Biopsy	Age Death	Muscle	CNS - Autopsy
CTRL-1	Control	$\rm NA$	$\ensuremath{\text{NP}}\xspace$	\mathbf{M}		30-35 yr	alive	alive	Deltoideus	$\ensuremath{\mathbf{NP}}\xspace$
CTRL-2	Control	$\rm NA$	$\ensuremath{\mathbf{NP}}\xspace$	$\mathbf M$	$\overline{}$	30-35 yr	alive	alive	Deltoideus	$\ensuremath{\mathbf{NP}}\xspace$
CTRL-3	Control	NA	$\ensuremath{\text{NP}}\xspace$	\mathbf{M}	$\overline{}$	$40-45$ yr	alive	alive	Gastrocnemius	$\ensuremath{\mathsf{NP}}\xspace$
CTRL-4	Control	$\rm NA$	$\ensuremath{\mathbf{NP}}\xspace$	${\bf F}$	\blacksquare	46-50 yr	alive	alive	Deltoideus	$\ensuremath{\mathbf{NP}}\xspace$
CTRL-5	Control	$\rm NA$	$\ensuremath{\mathbf{NP}}\xspace$	M		46-50 yr	alive	alive	Vastus lateralis	$\ensuremath{\mathbf{NP}}\xspace$
CTRL-6	Control	NA	$\ensuremath{\mathbf{NP}}\xspace$	${\bf F}$	\blacksquare	70-75 yr	alive	alive	Deltoideus	$\ensuremath{\mathbf{NP}}\xspace$
CTRL-7	Control	$\rm NA$	$\ensuremath{\text{NP}}\xspace$	$\mathbf M$	$\overline{}$	70-75 yr	alive	alive	Gluteus medius	$\ensuremath{\mathbf{NP}}\xspace$
CTRL-8	Control	$\rm NA$	$\ensuremath{\mathbf{NP}}\xspace$	\mathbf{M}	\blacksquare	70-75 yr	alive	alive	Deltoideus	$\ensuremath{\mathsf{NP}}\xspace$
$fALS_1$	Familial ALS	Spinal	HET pathogenic variant in TARDBP: (c.1055A>G p.[N352S])	$\mathbf M$	65-69 yr	70-75 yr	alive	70-75 yr	Tibialis anterior	$\ensuremath{\mathsf{NP}}\xspace$

199 **Table 1. Clinical characteristics of participants and their biological samples.**

disease)

²⁰²**Cell culture assays**

²⁰³*Primary myoblasts from patients' muscle biopsies*

204 Human proximal muscle biopsies were minced and explants were cultured to obtain myogenic
205 precursors in a monolaver as described previously [61]. To obtain highly purified myoblasts 205 precursors in a monolayer as described previously [61]. To obtain highly purified myoblasts
206 (CD56+), primary cultures were sorted by immunomagnetic selection based on the presence of 206 (CD56+), primary cultures were sorted by immunomagnetic selection based on the presence of
207 the early cell surface marker CD56 (separator and reagents from Miltenyi Biotec, Bergisch 207 the early cell surface marker CD56 (separator and reagents from Miltenyi Biotec, Bergisch
208 Gladbach, Germany). Cells' myogenicity was confirmed by Desmin immunolabeling, and all 208 Gladbach, Germany). Cells´ myogenicity was confirmed by Desmin immunolabeling, and all
209 cultures were used at *nassages* 3 and 4. Finally, myoblasts were grown up to the desired density 209 cultures were used at *passages* 3 and 4. Finally, myoblasts were grown up to the desired density
210 in an incubator at 37°C, with 5% CO₂ and a humidified atmosphere. The proliferation medium 210 in an incubator at 37°C, with 5% CO_2 and a humidified atmosphere. The proliferation medium
211 used from this moment was the Skeletal Growth Medium (SGM, PromoCell), supplemented as 211 used from this moment was the Skeletal Growth Medium (SGM, PromoCell), supplemented as
212 stated below. For *post mortem* samples, different reports have demonstrated that muscle 212 stated below. For *post mortem* samples, different reports have demonstrated that muscle
213 progenitor cells, while retaining their regenerative capacity, grow and differentiate as well as 213 progenitor cells, while retaining their regenerative capacity, grow and differentiate as well as those obtained from fresh biopsies [30, 50, 54]. those obtained from fresh biopsies $[30, 50, 54]$.

²¹⁵*Immortalised human control myoblasts (line 8220)*

216 The immortalised human myoblast control cell line 8220 was generated at the Platform for the
217 Immortalization of Human Cells / Myology Institute (Paris, France) and kindly provided by Dr. 217 Immortalization of Human Cells / Myology Institute (Paris, France) and kindly provided by Dr.
218 Vincent Mouly [29]. These myoblasts were grown and transduced as previously described [29]. 218 Vincent Mouly [29]. These myoblasts were grown and transduced as previously described [29],
219 with minor modifications. Briefly, the proliferation medium consisted of SGM supplemented 219 with minor modifications. Briefly, the proliferation medium consisted of SGM supplemented
220 with 10% FBS. 1% Glutamax and 1% gentamicin (all from Gibco-Invitrogen). Gene silencing 220 with 10% FBS, 1% Glutamax and 1% gentamicin (all from Gibco-Invitrogen). Gene silencing
221 was carried out by transduction with lentiviral particles containing short hairpin RNA (shRNA). was carried out by transduction with lentiviral particles containing short hairpin RNA (shRNA).
222 The plasmids used to create these particles were: SHC001 (shRNA Empty Vector Control 222 The plasmids used to create these particles were: SHC001 (shRNA Empty Vector Control
223 Plasmid DNA), TRCN000016038 (human, *TARDBP* MISSION shRNA), TRCN0000288639 223 Plasmid DNA), TRCN000016038 (human, *TARDBP* MISSION shRNA), TRCN0000288639
224 (human, *FUS* MISSION shRNA), TRCN0000010333 (human, *FOXO* MISSION shRNA) 224 (human, *FUS* MISSION shRNA), TRCN0000010333 (human, *FOXO* MISSION shRNA)
225 (MISSION® pLKO.1-Pure) (all from Sigma-Aldrich). Viral particles were produced and titled 225 (MISSION® pLKO.1-Pure) (all from Sigma-Aldrich). Viral particles were produced and titled
226 by the Viral Vector Unit of CNIC (Madrid, Spain). Myoblasts were seeded in 6-well plates at a 226 by the Viral Vector Unit of CNIC (Madrid, Spain). Myoblasts were seeded in 6-well plates at a
227 density of 80,000 cells/well, and the next day viral particles were added at a MOI of 10. 24 227 density of 80,000 cells/well, and the next day viral particles were added at a MOI of 10. 24
228 hours after transduction, the medium was removed and replaced by fresh SGM proliferation 228 hours after transduction, the medium was removed and replaced by fresh SGM proliferation
229 medium. To verify the degree of gene silencing. TDP-43 and FUS protein expression was 229 medium. To verify the degree of gene silencing, TDP-43 and FUS protein expression was
230 measured by Western blot. measured by Western blot.

²³¹*Induction and assessment of myogenic differentiation*

232 Either primary or immortalised myoblasts were cultured in SGM medium supplemented with
233 10% FBS, 1% Glutamax and 1% gentamicin, and differentiation occurred spontaneously 233 10% FBS, 1% Glutamax and 1% gentamicin, and differentiation occurred spontaneously
234 without medium refreshing by cell-cell contact when cultures were at high confluence. The 234 without medium refreshing by cell-cell contact when cultures were at high confluence. The
235 differentiation index was calculated as the percentage of nuclei in MyHC-positive cells out of ²³⁵differentiation index was calculated as the percentage of nuclei in MyHC-positive cells out of

-
- 236 the total (DAPI-positive) nuclei. The fusion index was calculated as the percentage of nuclei
237 fused into myotubes (MyHC-positive syncytia with at least two nuclei) out of the total nuclei.
- 237 fused into myotubes (MyHC-positive syncytia with at least two nuclei) out of the total nuclei.
238 Mvogenicity was assessed as the percentage of MYOD-positive or MYOG-positive nuclei, out 238 Myogenicity was assessed as the percentage of MYOD-positive or MYOG-positive nuclei, out
239 of the total nuclei. Over 3 wells and 3-10 fields were evaluated per each group.
- of the total nuclei. Over 3 wells and 3-10 fields were evaluated per each group.

²⁴⁰*2-Deoxy-D-glucose (2-DG) treatment*

241 For Western blot analysis, cells were seeded at 60% of confluence in 6-well plates in 2 mL of 242 SGM, allowing them to adhere overnight (O/N). The next day, cells were treated with 100 uM 242 SGM, allowing them to adhere overnight (O/N). The next day, cells were treated with 100 μ M
243 2-DG and kept for 4 days, when untreated cells were at 100% of confluence. For 243 2-DG and kept for 4 days, when untreated cells were at 100% of confluence. For
244 immunofluorescence analysis cells were seeded at 100% of confluence in u-slide wells (Ibidi) 244 immunofluorescence analysis, cells were seeded at 100% of confluence in μ -slide wells (Ibidi)
245 in 60 μ l of SGM, and allowed to adhere O/N. The next day, cells were treated with 100 μ M 2-245 in 60 µl of SGM, and allowed to adhere O/N. The next day, cells were treated with 100 μ M 2-246 DG for 48h. DG for 48h.

²⁴⁷*Proliferation curves*

248 2,000 cells/well of primary human myoblasts or 2,500 cells/well per silenced human control
249 myoblasts (shRNA, shTDP-43 and shFUS) were plated in u-slide wells (Ibidi), and fixed at 249 myoblasts (shRNA, shTDP-43 and shFUS) were plated in μ -slide wells (Ibidi), and fixed at 250 three time points: day 1, day 3 and day 5. DAPI staining was used to quantify cell numbers at 250 three time points: day 1, day 3 and day 5. DAPI staining was used to quantify cell numbers at 251 all times. Images were taken with ZEISS LSM 900 confocal microscope, and quantification of 251 all times. Images were taken with ZEISS LSM 900 confocal microscope, and quantification of 252 DAPI+ cells was performed with ImageJ v2.9. $DAPI+$ cells was performed with ImageJ v2.9.

²⁵³*iFOXO1 treatment*

254 33 nM (IC50) of FOXO1 inhibitor *AS1842856* (Astella Pharma; Shelleck; # S8222) was used in
255 all *in vitro* experiments. For Seahorse experiments, myoblasts were treated with iFOXO1 255 all *in vitro* experiments. For Seahorse experiments, myoblasts were treated with iFOXO1
256 inhibitor after seeding them in a 96-well XF cell culture microplate (Agilent) for 24 h. For 256 inhibitor after seeding them in a 96-well XF cell culture microplate (Agilent) for 24 h. For
257 differentiation experiments, after fusion, silenced or ALS patient-derived myoblasts were kept 257 differentiation experiments, after fusion, silenced or ALS patient-derived myoblasts were kept
258 with the inhibitor for 8 days. For proliferation experiments, cells were treated with iFOXO1 or 258 with the inhibitor for 8 days. For proliferation experiments, cells were treated with iFOXO1 or the corresponding amount of DMSO, refreshing it every 3 days. Finally, for *in vivo* experiments 259 the corresponding amount of DMSO, refreshing it every 3 days. Finally, for *in vivo* experiments
260 in *Drosophila*, 30 uM iFOXO1 was diluted in the food. in *Drosophila*, 30 µM iFOXO1 was diluted in the food.

²⁶¹*Drosophila melanogaster* **models and functional assays**

262 One *Drosophila* strain where Cabeza (*caz*) gene is silenced in muscle cells (*UAS-Dicer2-icaz-*263 *Mef2-GAL4,* iCaz) and three *Drosophila* strains where *TBPH* gene is silenced at different locus
264 in muscle cells were generated: *UAS-Dicer2-iTBPHattp40-Mef2-GAL4* (iTBPH^{attp40}): *UAS-*264 in muscle cells were generated: *UAS-Dicer2-iTBPHattp40-Mef2-GAL4* (iTBPH^{attp40}); *UAS-*
265 *Dicer2-iTBPHp(GD6943)-Mef2-GAL4*, (iTBPH^{p(GD6943)}); and *UAS-Dicer2-*265 *Dicer2-iTBPHp(GD6943)-Mef2-GAL4,*
266 *iTBPHp(pkk108354)-Mef2-GAL4*, (iTB *iTBPHp(pkk108354)-Mef2-GAL4*, (iTBPH^{pkk108354}) were generated. As control flies, the strain
267 *UAS-Dicer2-+-Mef2-GAL4* was used. To generate these genotypes, stocks from Vienna Stock 267 *UAS-Dicer2-+-Mef2-GAL4* was used. To generate these genotypes, stocks from Vienna Stock
268 Center (VDRC, Austria) (caz. #100291: *TBPH^{GD6943}* #38377 and *TBPH^{pkk(108354)* #104401) and} Center (VDRC, Austria) (*caz*, #100291; *TBPH^{GD6943}* #38377 and *TBPH^{pkk(108354)* #104401) and}

Bloomington Stock Centre (Indiana, USA) (*TBPH^{attP40}* #39014 and *Dicer2-Mef2* #25756) were
270 acquired. Flies were housed at 23°C, 70% humidity and 12 h/12 h light/darkness cycle. For 270 acquired. Flies were housed at 23° C, 70% humidity and 12 h/12 h light/darkness cycle. For
271 longevity assays, one hundred adult flies (five per tube) were selected from each strain. Dead 271 longevity assays, one hundred adult flies (five per tube) were selected from each strain. Dead
272 flies were counted every 2 days. Kaplan–Meier method was used to plot the results. A log-rank 272 flies were counted every 2 days. Kaplan–Meier method was used to plot the results. A log-rank
273 test was used to analyse results and Bonferroni correction for multiple comparisons. For 273 test was used to analyse results and Bonferroni correction for multiple comparisons. For
274 locomotor activity, adult flies on days 5, 10 and 15 were analysed in groups of five. They were 274 locomotor activity, adult flies on days 5, 10 and 15 were analysed in groups of five. They were
275 placed in a tube with a line drawn outside the tube at 8 cm height from the bottom. The number 275 placed in a tube with a line drawn outside the tube at 8 cm height from the bottom. The number
276 of flies that passed the line in 10 seconds was counted (3 trials per tube). Adult pharate survival 276 of flies that passed the line in 10 seconds was counted (3 trials per tube). Adult pharate survival
277 was expressed as a percentage of the adult flies counted over the total number of pupae in each 277 was expressed as a percentage of the adult flies counted over the total number of pupae in each
278 tube where adult pharate survival of control flies was around 100%. 6 tubes were counted per 278 tube where adult pharate survival of control flies was around 100%. 6 tubes were counted per 279 group in $iTBPH^{pkk(108354)}$ flies. group in $iTBPH^{pkk(108354)}$ flies.

²⁸⁰**Western blotting**

281 Bulk protein extraction from cell cultures was done with a sample buffer containing 62 mM Tris
282 (pH 7.5), 5% glycerol, 2% SDS, 5mg/ml bromophenol blue and 5% β-mercaptoethanol. In some 282 (pH 7.5), 5% glycerol, 2% SDS, 5mg/ml bromophenol blue and 5% β-mercaptoethanol. In some experiments, cell fractionation was carried out using the NE-PER kit (Thermo Scientific, 283 experiments, cell fractionation was carried out using the NE-PER kit (Thermo Scientific, 284 Catalog Code 78833) before adding the sample buffer. Samples were run in CriterionTM gels Catalog Code 78833) before adding the sample buffer. Samples were run in CriterionTM gels
285 (Bio-Rad. Life Sciences, CA. USA) by SDS-PAGE electrophoresis. Proteins were transferred to 285 (Bio-Rad, Life Sciences, CA, USA) by SDS-PAGE electrophoresis. Proteins were transferred to
286 BioTraceTM Nitrocellulose membranes (Pall Corporation, NY, USA). Primary antibodies are $BioTrace^{TM}$ Nitrocellulose membranes (Pall Corporation, NY, USA). Primary antibodies are summarised in Supplementary Table 1. Secondary antibodies conjugated to Alexa fluor plus 287 summarised in Supplementary Table 1. Secondary antibodies conjugated to Alexa fluor plus
288 fluorophores (Invitrogen) were diluted to 1/10,000 in TBS-T (tris buffered saline with 1:1000 288 fluorophores (Invitrogen) were diluted to 1/10,000 in TBS-T (tris buffered saline with 1:1000
289 Tween 20) with 5% BSA (both from Sigma-Aldrich). Bands were visualised using iBright 289 Tween 20) with 5% BSA (both from Sigma-Aldrich). Bands were visualised using iBright
290 FL1000 Imaging System and quantified with Image Studio Lite v5.2. B-actin or B-tubulin were 290 FL1000 Imaging System and quantified with Image Studio Lite v5.2. β-actin or β-tubulin were
291 used as loading control. Results were expressed as optical density (O.D.). used as loading control. Results were expressed as optical density (O.D.).

²⁹²**Immunofluorescence**

293 Myoblasts or myotubes grown on μ -slide or μ -plate wells (Ibidi) were fixed after several
294 washes in PBS, with 4% paraformaldehyde (PFA) for 10 min. After several washes, fixed cells 294 washes in PBS, with 4% paraformaldehyde (PFA) for 10 min. After several washes, fixed cells
295 were blocked in a solution containing 5% BSA, 2% horse serum (HS, Gibco-Invitrogen), 0.02% 295 were blocked in a solution containing 5% BSA, 2% horse serum (HS, Gibco-Invitrogen), 0.02%
296 sodium azide and 0.5% Triton X-100 in TBS-T, for 30 min. Cells were incubated with primary 296 sodium azide and 0.5% Triton X-100 in TBS-T, for 30 min. Cells were incubated with primary
297 antibodies O/N at 4°C diluted in blocking solution. Primary antibodies are summarised in 297 antibodies O/N at 4°C diluted in blocking solution. Primary antibodies are summarised in
298 Supplementary Table 1. The next day, cells were rinsed three times in TBS-T. Secondary 298 Supplementary Table 1. The next day, cells were rinsed three times in TBS-T. Secondary
299 antibodies conjugated to Alexa fluor plus fluorophores (Invitrogen) were diluted to 1/1.000 in 299 antibodies conjugated to Alexa fluor plus fluorophores (Invitrogen) were diluted to $1/1,000$ in 300 blocking solution and incubated for 2 h at room temperature (RT) in the dark. DAPI was added 300 blocking solution and incubated for 2 h at room temperature (RT) in the dark. DAPI was added
301 together with the secondary antibody to visualise the cell nuclei. ZEISS LSM 900 laser 301 together with the secondary antibody to visualise the cell nuclei. ZEISS LSM 900 laser
302 scanning confocal microscope (Carl Zeiss, Inc., Germany) and Fluorescent Nikon 80i 302 scanning confocal microscope (Carl Zeiss, Inc., Germany) and Fluorescent Nikon 80i
303 microscope were used to analyse the immunostaining. Levels of nuclear protein expression were microscope were used to analyse the immunostaining. Levels of nuclear protein expression were

304 assessed by quantifying the integrated densities of nuclei by ImageJ v2.9 using DAPI staining to
305 delimit nuclei. For the assessment of MYOD-. MYOG- and FOXO1-positive nuclei. integrated 305 delimit nuclei. For the assessment of MYOD-, MYOG- and FOXO1-positive nuclei, integrated
306 density values above the cut-off point (set as the value of mean +1*SD of control cells) were 306 density values above the cut-off point (set as the value of mean $+1*SD$ of control cells) were
307 considered positive. For the assessment of nuclear depletion of TDP-43 or FUS, nuclei with 307 considered positive. For the assessment of nuclear depletion of TDP-43 or FUS, nuclei with
308 integrated density values below the cut-off point (set as the value of mean -1*SD of control 308 integrated density values below the cut-off point (set as the value of mean -1*SD of control
309 cells) were considered negative. To evaluate the nuclear expression of FOXO3, the integrated 309 cells) were considered negative. To evaluate the nuclear expression of FOXO3, the integrated
310 density values of each nucleus were quantified and plotted. density values of each nucleus were quantified and plotted.

³¹¹**Transmission electron microscopy**

312 Cells were postfixed in 1% osmium tetroxide, 7% sucrose in 0.1 M PB for 30 min at RT,
313 washed in deionized water, and partially dehydrated in ethanol. Cells were then stained in 2% 313 washed in deionized water, and partially dehydrated in ethanol. Cells were then stained in 2%
314 uranyl acetate in 70% ethanol in the dark for 2 h 30 min at 4° C. Cells were further dehydrated in 314 uranyl acetate in 70% ethanol in the dark for 2 h 30 min at 4° C. Cells were further dehydrated in ethanol, and infiltrated O/N in Durcupan ACM epoxy resin (Fluka, Sigma-Aldrich, St. Louis, ethanol, and infiltrated O/N in Durcupan ACM epoxy resin (Fluka, Sigma-Aldrich, St. Louis, 316 USA). Following resin hardening, embedded cell cultures were detached from the chamber slide
317 and glued to resin blocks. Serial semi-thin sections (1.5 µm) were cut with an Ultracut UC-7 317 and glued to resin blocks. Serial semi-thin sections $(1.5 \mu m)$ were cut with an Ultracut UC-7
318 ultramicrotome (Leica, Heidelberg, Germany) and mounted onto glass microscope slides and 318 ultramicrotome (Leica, Heidelberg, Germany) and mounted onto glass microscope slides and
319 lightly stained with 1% toluidine blue. Selected semi-thin sections were glued with Super Glue-319 lightly stained with 1% toluidine blue. Selected semi-thin sections were glued with Super Glue-
320 3. Loctite (Henkel. Düsseldorf. Germany) to resin blocks and subsequently detached from the 320 3, Loctite (Henkel, Düsseldorf, Germany) to resin blocks and subsequently detached from the
321 glass-slides by repeated freezing (in liquid nitrogen) and thawing. Ultra-thin sections (70-80 321 glass-slides by repeated freezing (in liquid nitrogen) and thawing. Ultra-thin sections (70-80
322 nm) were obtained with the ultramicrotome from detached semi-thin sections, and further 322 nm) were obtained with the ultramicrotome from detached semi-thin sections, and further stained with lead citrate (Reynolds' solution) [60]. Finally, cells were imaged at 80 kV on a FEI 323 stained with lead citrate (Reynolds' solution) [60]. Finally, cells were imaged at 80 kV on a FEI
324 Tecnai G² Spirit transmission electron microscope (FEI Europe, Eindhoven, Netherlands) Tecnai G^2 Spirit transmission electron microscope (FEI Europe, Eindhoven, Netherlands)
325 equipped with a Morada CCD digital camera (Olympus Soft Image Solutions GmbH, Münster, 325 equipped with a Morada CCD digital camera (Olympus Soft Image Solutions GmbH, Münster, 326 Germany). Germany).

³²⁷**Histopathological analysis of** *Drosophila melanogaster* **muscle**

328 Immunofluorescence was used to study the motoneurons and the integrity of the neuromuscular
329 iunction in the indirect flight muscles of the iTBPH^{pkk108354} and control *Drosophila* models. junction in the indirect flight muscles of the iTBPH^{pkk108354} and control *Drosophila* models.
330 Flies were anaesthetised with CO₂-enriched air. Fly thoraces were isolated and immersed into 330 Flies were anaesthetised with CO_2 -enriched air. Fly thoraces were isolated and immersed into
331 70% EtOH for 1 min. and placed in PBS for dissection. Samples were fixed with 4% PFA for 331 70% EtOH for 1 min. and placed in PBS for dissection. Samples were fixed with 4% PFA for
332 30 min. After 3 washes in PBS with 0.5% Triton X-100 (PBS-T), samples were immersed into 332 30 min. After 3 washes in PBS with 0.5% Triton X-100 (PBS-T), samples were immersed into
333 liquid nitrogen for 10 seconds and transferred into cold PBS. Thoraces were divided 333 liquid nitrogen for 10 seconds and transferred into cold PBS. Thoraces were divided
334 longitudinally, washed 4 x 5 min in PBS-T, and incubated for 30 mins in blocking solution (5% 334 longitudinally, washed 4 x 5 min in PBS-T, and incubated for 30 mins in blocking solution (5% BSA and 0.02% NaN₃ in PBS-T) at RT. Subsequently, thoraces were incubated O/N at 4°C with 335 BSA and 0.02% NaN₃ in PBS-T) at RT. Subsequently, thoraces were incubated O/N at 4^oC with
336 the primary antibody solution (HRP and nc82 (Supplementary Table 1) in blocking solution at 336 the primary antibody solution (HRP and nc82 (Supplementary Table 1) in blocking solution at 4° C. After 4 x 20 min washes with PBS-T, samples were incubated O/N at 4° C with the 337 4°C. After 4 x 20 min washes with PBS-T, samples were incubated O/N at 4°C with the
338 secondary antibodies conjugated to Alexa fluor plus fluorophores (Invitrogen) and InvitrogenTM secondary antibodies conjugated to Alexa fluor plus fluorophores (Invitrogen) and Invitrogen™

 339 Alexa Fluor[™] 647 Phalloidin 1:1000 in blocking solution. Samples were mounted in 340 ProLong[™] Diamond Antifade Mountant (Invitrogen). Images were obtained in a confocal 340 ProLongTM Diamond Antifade Mountant (Invitrogen). Images were obtained in a confocal
341 microscope LS900 (Zeiss) by z-stack scanning (total thickness of 15 um with a step size of 0.5 341 microscope LS900 (Zeiss) by z-stack scanning (total thickness of 15 μm with a step size of 0.5
342 um per slice) of the whole-mount thoraces (halves). Quantification of muscle area covered by μ m per slice) of the whole-mount thoraces (halves). Quantification of muscle area covered by
343 HRP staining was carried out by using ImageJ v2.9, whereas quantification of nc82-positive 343 HRP staining was carried out by using ImageJ v2.9, whereas quantification of nc82-positive
344 svnaptic boutons size was performed by using SynPAnal software [11]. synaptic boutons size was performed by using SynPAnal software [11].

³⁴⁵**RNA-seq analysis**

³⁴⁶*RNA preparation and RNA-seq performance*

347 Total RNA was extracted from three independent experimental replicates using the RNeasy
348 Mini Kit (Ref. 74104, QIAGEN), followed by DNase I treatment. RNA integrity (3 shRNA, 3 348 Mini Kit (Ref. 74104, QIAGEN), followed by DNase I treatment. RNA integrity (3 *shRNA*, 3
349 *shTDP-43*, 3 *shFUS*) was assessed (Agilent 2100 Bioanalyzer) before ribosomal RNA depletion ³⁴⁹*shTDP-43*, 3 *shFUS*) was assessed (Agilent 2100 Bioanalyzer) before ribosomal RNA depletion 350 (Illumina Ribo-Zero Plus) and library preparation following a Stranded Full-length Total RNA
351 orocedure. Sequencing was performed on Illumina NextSeq 2000 platform at a sequencing depth 351 procedure. Sequencing was performed on Illumina NextSeq2000 platform at a sequencing depth
352 of at least 20M paired-end 100 nucleotide long reads (PE100). After sequencing, raw reads were 352 of at least 20M paired-end 100 nucleotide long reads (PE100). After sequencing, raw reads were
353 filtered to remove adaptor sequences and low-quality reads (phred quality score below Q33). filtered to remove adaptor sequences and low-quality reads (phred quality score below Q33).

³⁵⁴*RNA-seq data processing and analysis*

355 RNA-seq reads were quasi-mapped to the reference transcriptome hg38 and the abundance of each transcript was quantified using Salmon v.1.5.2, with default options for paired-end reads 356 each transcript was quantified using Salmon v.1.5.2. with default options for paired-end reads
357 [53]. Transcriptomes were indexed using the decov-aware method in Salmon. Output quants 357 [53]. Transcriptomes were indexed using the decoy-aware method in Salmon. Output quants
358 files were then processed in R Studio v.4.0.4 (RStudio Team. 2020: http://www.rstudio.com/). 358 files were then processed in R Studio v.4.0.4 (RStudio Team, 2020; http://www.rstudio.com/).
359 Tximport package was used for non-normalized gene-level counts estimation from transcript-359 Tximport package was used for non-normalized gene-level counts estimation from transcript-
360 level counts using the "*bias corrected counts without an offset*" method [73]. R package 360 level counts using the "*bias corrected counts without an offset*" method [73]. R package
361 Normalization was performed using DEsea2 R package [34] to account for technical variability 361 Normalization was performed using DEseq2 R package [34] to account for technical variability
362 and estimate size factors for accurate comparisons of gene expression between samples. A log2 362 and estimate size factors for accurate comparisons of gene expression between samples. A log2
363 fold change (Log2FC) threshold of greater than or equal to 1 (corresponding to a fold change of 363 fold change (Log2FC) threshold of greater than or equal to 1 (corresponding to a fold change of 364 2 or greater) was used to identify genes with statistically significant changes in expression after 364 2 or greater) was used to identify genes with statistically significant changes in expression after
365 adjusting for multiple testing using the Beniamini-Hochberg method (adjusted *n*-value < 0.001). 365 adjusting for multiple testing using the Benjamini-Hochberg method (adjusted p -value < 0.001).
366 Functional pathway analysis was performed by Hallmark Pathway enrichment of differential 366 Functional pathway analysis was performed by Hallmark Pathway enrichment of differential
367 eene expression signatures using GSEA v.4.3.2 as previously described [77]. Classic weighting 367 gene expression signatures using GSEA v.4.3.2 as previously described [77]. Classic weighting
368 was used as the enrichment statistics, and the permutation type was based on a gene set, using a 368 was used as the enrichment statistics, and the permutation type was based on a gene set, using a
369 total of 1,000 iterations. A gene set is considered significantly enriched if its Normalized 369 total of 1,000 iterations. A gene set is considered significantly enriched if its Normalized
370 Enrichment Score (NES) has a False Discovery Rate (FDR) *p*-value below 0.05 (Beniamini-370 Enrichment Score (NES) has a False Discovery Rate (FDR) *p*-value below 0.05 (Benjamini-
371 Hochberg method) and a nominal *p*-value below 0.001. A GSEA score (based on multiplying ³⁷¹Hochberg method) and a nominal *p*-value below 0.001. A GSEA score (based on multiplying

372 NES by −log₁₀FDR *p*-value) was calculated for each gene set, and their values for each gene list were plotted. were plotted.

374 Transcription factor (TF) activity analysis was performed using ISMARA (Integrated System
375 for Motif Activity Response), an online tool for automatically inferring regulatory networks 375 for Motif Activity Response), an online tool for automatically inferring regulatory networks
376 from gene expression data [1]. Quality and adaptor trimmed fastq.gz RNA-seq files were 376 from gene expression data [1]. Quality and adaptor trimmed fastq.gz RNA-seq files were
377 uploaded to www.ismara.unibas.ch for processing, followed by sample average. For each 377 uploaded to www.ismara.unibas.ch for processing, followed by sample average. For each
378 enriched TF motif identified. the ISMARA score was calculated based on the z-score and 378 enriched TF motif identified, the ISMARA score was calculated based on the z-score and average gene target expression change. average gene target expression change.

³⁸⁰*Data availability*

381 Sequencing data have been deposited in GEO under accession code GSE227573.

³⁸²**Analysis of metabolic flux by SeaHorse**

383 Metabolic pathways were studied using the Seahorse XF96 Extracellular Flux Analyzer
384 (Agilent). This equipment allows simultaneous study of the two main energy pathways. 384 (Agilent). This equipment allows simultaneous study of the two main energy pathways,
385 mitochondrial respiration and glycolysis, in living cells and in real time. The analyzer measures 385 mitochondrial respiration and glycolysis, in living cells and in real time. The analyzer measures
386 the ratio of oxygen consumption (OCR, Oxygen Consumption Rate), as an indicator of the ratio of oxygen consumption (OCR, Oxygen Consumption Rate), as an indicator of 387 mitochondrial respiration; and the ratio of extracellular acidification (ECAR, ExtraCellular 388 Acidification Rate), as an indicator of glycolysis and lactate production. The day before the 388 Acidification Rate), as an indicator of glycolysis and lactate production. The day before the
389 experiment, 15,000 primary myoblasts/well were seeded in a 96-well XF cell culture microplate 389 experiment, 15,000 primary myoblasts/well were seeded in a 96-well XF cell culture microplate
390 (Agilent) to reach 100% confluence. Before starting with the Glvco-stress experiment, media 390 (Agilent) to reach 100% confluence. Before starting with the Glyco-stress experiment, media
391 was changed to glucose-free Seahorse XF MEM media (pH 7.4) (Agilent #103575-100) for 1 h. 391 was changed to glucose-free Seahorse XF MEM media (pH 7.4) (Agilent #103575-100) for 1 h,
392 and it was incubated at 37°C in an incubator without CO₂. Then, continuous measurements of 392 and it was incubated at 37° C in an incubator without CO_2 . Then, continuous measurements of ECAR or OCR started. The data were normalised to cell number, which was measured by 393 ECAR or OCR started. The data were normalised to cell number, which was measured by
394 Cresyl violet staining (0.1% solution for 15 min). Cresyl violet staining $(0.1\%$ solution for 15 min).

395 All metabolic tests using the Seahorse technique were performed when myoblasts were at a
396 confluence of 100%. For the study of metabolism across muscle differentiation, cell seeding 396 confluence of 100%. For the study of metabolism across muscle differentiation, cell seeding
397 was carried out at different stages (myoblast, myocyte, 3-day, and 8-day myotubes) in order to 397 was carried out at different stages (myoblast, myocyte, 3-day, and 8-day myotubes) in order to
398 obtain, in the same Seahorse plate, the different phases of the process. One hour before the test, 398 obtain, in the same Seahorse plate, the different phases of the process. One hour before the test,
399 cells were incubated at 37° C without CO₂ and in the glucose-free Seahorse XF MEM medium at 399 cells were incubated at 37°C without CO_2 and in the glucose-free Seahorse XF MEM medium at 400 pH 7.4. pH 7.4.

⁴⁰¹**Statistical analysis**

402 Unless otherwise indicated, data were analysed and visualised by GraphPad Prism 7. Normality
403 was verified by the Shapiro-Wilks test $(p<0.05)$. The choice of statistical test for group 403 was verified by the Shapiro-Wilks test $(p<0.05)$. The choice of statistical test for group
404 comparisons was guided by the normality of the data distribution. For pairwise comparisons comparisons was guided by the normality of the data distribution. For pairwise comparisons

- 405 between two groups, the Mann-Whitney *U* test was employed when the data exhibited a non-
406 normal distribution. In contrast, when the data followed a normal distribution, Student's t-test
- 406 normal distribution. In contrast, when the data followed a normal distribution, Student's t-test
407 was utilized. For comparisons involving more than two groups, one-way or two-way ANOVA
- was utilized. For comparisons involving more than two groups, one-way or two-way ANOVA
408 was followed by Dunnett's test. Unless otherwise indicated, the data are expressed as the mean
- was followed by Dunnett's test. Unless otherwise indicated, the data are expressed as the mean \pm the Standard Error of the Mean (SEM).
- $±$ the Standard Error of the Mean (SEM).

⁴¹¹**RESULTS**

⁴¹²**Myogenesis is impaired in ALS patients' cells independently of the motoneuron input**

413 Histopathological analysis of muscle biopsies from age-matched control (CTRL) and ALS
414 patients, familial (fALS) and sporadic (sALS) patients, revealed chronic muscle affectation, 414 patients, familial (fALS) and sporadic (sALS) patients, revealed chronic muscle affectation,
415 including myofiber atrophy, a few necrotic myofibers and either pyknotic or centralized nuclei 415 including myofiber atrophy, a few necrotic myofibers and either pyknotic or centralized nuclei
416 and cell infiltration in ALS cases (Supplementary Fig. 1). These findings indicate an already and cell infiltration in ALS cases (Supplementary Fig. 1). These findings indicate an already
417 impaired muscle homeostasis across all ALS biopsies analysed. To further investigate these 417 impaired muscle homeostasis across all ALS biopsies analysed. To further investigate these
418 alterations, we isolated muscle progenitor cells derived from 16 different subjects (8 CTRL, 3 418 alterations, we isolated muscle progenitor cells derived from 16 different subjects (8 CTRL, 3
419 fALS and 5 sALS cases: Table 1) and performed in vitro studies, devoid of inputs from MNs or fALS and 5 sALS cases; Table 1) and performed *in vitro* studies, devoid of inputs from MNs or
420 any other external stimuli able to modify the intrinsic properties of muscle cells. This approach 420 any other external stimuli able to modify the intrinsic properties of muscle cells. This approach
421 allowed for a comprehensive characterization of the myogenic process *per se* in ALS. We first 421 allowed for a comprehensive characterization of the myogenic process *per se* in ALS. We first
422 assessed the myogenic capacity of the expanded cells through differentiation assays. Our results 422 assessed the myogenic capacity of the expanded cells through differentiation assays. Our results
423 showed that most ALS myoblasts exhibited impaired differentiation, characterized by decreased 423 showed that most ALS myoblasts exhibited impaired differentiation, characterized by decreased
424 differentiation and fusion indices, as well as the formation of fewer and thinner myotubes. 424 differentiation and fusion indices, as well as the formation of fewer and thinner myotubes,
425 compared to controls (Fig. 1a. b). Notably, one patient's myoblasts (fALS 2) demonstrated 425 compared to controls (Fig. 1a, b). Notably, one patient's myoblasts (fALS_2) demonstrated
426 elevated and comparable differentiation levels to controls. Interestingly, this patient's disease elevated and comparable differentiation levels to controls. Interestingly, this patient's disease
427 progression was particularly slow (Table 1). It is noteworthy that myogenic differentiation 427 progression was particularly slow (Table 1). It is noteworthy that myogenic differentiation
428 capacity is variable among controls, and this variability can be attributed to age, as there was a 428 capacity is variable among controls, and this variability can be attributed to age, as there was a
429 negative correlation between differentiation index and age (Fig. 1c). However, in ALS patient negative correlation between differentiation index and age (Fig. 1c). However, in ALS patient
430 myoblasts myogenesis was affected regardless of age (Fig. 1c). Furthermore, myogenesis was 430 myoblasts myogenesis was affected regardless of age (Fig. 1c). Furthermore, myogenesis was
431 already impaired before differentiation and fusion events began, as evidenced by a significant 431 already impaired before differentiation and fusion events began, as evidenced by a significant
432 and consistent reduction in the expression of MYOD (Supplementary Fig. 2a), the key 432 and consistent reduction in the expression of MYOD (Supplementary Fig. 2a), the key
433 transcription factor regulating myoblast differentiation, and myogenin (MYOG) 433 transcription factor regulating myoblast differentiation,
434 (Supplementary Fig. 2b), a crucial factor for myoblast differentia 434 (Supplementary Fig. 2b), a crucial factor for myoblast differentiation and fusion. Consistently,
435 fALS 2 cells did not display altered MYOG expression, which may account for the lack of 435 fALS_2 cells did not display altered MYOG expression, which may account for the lack of myogenic defects observed in these cells (Supplementary Fig. 2a). myogenic defects observed in these cells (Supplementary Fig. 2a).

437 On top of that, ALS-derived myoblasts exhibited decreased proliferation rates overall
438 (Supplementary Fig. 2c, d). Furthermore, we analysed regulators of atrophy pathways in the 438 (Supplementary Fig. 2c, d). Furthermore, we analysed regulators of atrophy pathways in the
439 skeletal muscle, such as the muscle-specific E3 ubiquitin ligases MURF1 and MAFbx/Atrogin-439 skeletal muscle, such as the muscle-specific E3 ubiquitin ligases MURF1 and MAFbx/Atrogin-
440 1, and found an increase in ALS samples (Supplementary Fig. 2e), suggesting an activation of 440 1, and found an increase in ALS samples (Supplementary Fig. 2e), suggesting an activation of the ubiquitin/proteasome system, leading to protein degradation. the ubiquitin/proteasome system, leading to protein degradation.

Finally, the levels of the two proteins closely associated with ALS pathology, TDP-43 and FUS,
443 were evaluated. We observed a significant decrease in total TDP-43 levels and decreased FUS were evaluated. We observed a significant decrease in total TDP-43 levels and decreased FUS
444 levels by immunoblotting (Fig. 1d). Both TDP-43 and FUS are nuclear ribonucleoproteins that levels by immunoblotting (Fig. 1d). Both TDP-43 and FUS are nuclear ribonucleoproteins that

445 shuttle between the nucleus and cytoplasm. Under certain pathological conditions or in response
446 to stress, they can accumulate in the cytoplasm [7]. However, in myoblasts, all the detectable to stress, they can accumulate in the cytoplasm [7]. However, in myoblasts, all the detectable
447 TDP-43 was located in the nucleus in patient- and control-derived myoblasts, including in cells TDP-43 was located in the nucleus in patient- and control-derived myoblasts, including in cells
448 carrying a *TARDBP* mutation (fALS 1 patient) (Supplementary Fig. 3a), and while some FUS 448 carrying a *TARDBP* mutation (fALS_1 patient) (Supplementary Fig. 3a), and while some FUS
449 was found in cytoplasmic granules, these were of equal abundance in CTRL and ALS was found in cytoplasmic granules, these were of equal abundance in CTRL and ALS
450 mvoblasts (Supplementary Fig. 3b). Thus, the only discernible differences in TDP43 and FUS 450 myoblasts (Supplementary Fig. 3b). Thus, the only discernible differences in TDP43 and FUS
451 were protein abundance. were protein abundance.

452 Overall, these data reflect that muscle is intrinsically affected in ALS, independently of the inputs from MNs and other environmental signals, and that downregulation of TDP-43 and FUS 453 inputs from MNs and other environmental signals, and that downregulation of TDP-43 and FUS
454 may be contributing to this. may be contributing to this.

⁴⁵⁵**Dynamic expression of TDP-43 and FUS is required for myogenesis**

456 To further understand the implication of TDP-43 and FUS in ALS-related myogenic alterations,
457 we knocked these genes down in an established human myoblast cell line (8220) to further we knocked these genes down in an established human myoblast cell line (8220) to further
458 analyse changes in the myogenic capacity as well as the underlying mechanisms (Fig. 2a). analyse changes in the myogenic capacity as well as the underlying mechanisms (Fig. 2a).
459 Lentiviral delivered shRNAs to TDP-43 or FUS decreased expression of the target gene by 80% 459 Lentiviral delivered shRNAs to TDP-43 or FUS decreased expression of the target gene by 80%
460 after 2 days (Fig. 2b). *TARDBP* silencing reduced FUS levels (40%) as well (Fig. 2b), implying 460 after 2 days (Fig. 2b). *TARDBP* silencing reduced FUS levels (40%) as well (Fig. 2b), implying
461 an upstream regulation of TDP-43 on FUS expression. This result aligns with previous CLIPan upstream regulation of TDP-43 on FUS expression. This result aligns with previous CLIP-462 seq studies that identified *FUS* mRNA as a target of TDP-43 [56]. Both TDP-43- and FUS-463 silenced myoblasts displayed ultrastructure abnormalities revealed by transmission electron
464 microscopy (TEM) images (Supplementary Fig. 4a). Compared to scramble RNA-transduced 464 microscopy (TEM) images (Supplementary Fig. 4a). Compared to scramble RNA-transduced
465 (shRNA) mvoblasts. shTDP-43 mvoblasts showed a rounded and enlarged shape accompanied 465 (shRNA) myoblasts, shTDP-43 myoblasts showed a rounded and enlarged shape accompanied
466 by mildly expanded nuclei. Organelles were arranged in perinuclear clusters, containing very 466 by mildly expanded nuclei. Organelles were arranged in perinuclear clusters, containing very
467 short rough endoplasmic reticulum (RER) but a high number of smaller mitochondria 467 short rough endoplasmic reticulum (RER) but a high number of smaller mitochondria
468 (Supplementary Fig. 4a, b). Similarly, shFUS myoblasts were elongated with abundant 468 (Supplementary Fig. 4a, b). Similarly, shFUS myoblasts were elongated with abundant mitochondria and dilated RER (Supplementary Fig. 4a, b). Despite these changes in cellular 469 mitochondria and dilated RER (Supplementary Fig. 4a, b). Despite these changes in cellular
470 morphology and distribution of intracellular components, all silenced myoblasts were viable. morphology and distribution of intracellular components, all silenced myoblasts were viable.

471 We then studied the effect of TDP-43 or FUS silencing on myogenesis. First, we analysed the
472 expression of the myogenic factors MYOD and MYOG, which in most patient-derived primary 472 expression of the myogenic factors MYOD and MYOG, which in most patient-derived primary
473 myoblasts and myotubes appeared downregulated (Supplementary Fig. 2a, b). Indeed, shTDP-473 myoblasts and myotubes appeared downregulated (Supplementary Fig. 2a, b). Indeed, shTDP-
474 43 and shFUS myogenic cells displayed a dramatic decrease in the total levels of both factors 474 43 and shFUS myogenic cells displayed a dramatic decrease in the total levels of both factors
475 (Fig. 2b). Both silenced myoblasts were more sensitive to growth factor deprivation, so when 475 (Fig. 2b). Both silenced myoblasts were more sensitive to growth factor deprivation, so when
476 differentiation was induced in such a way, shTDP-43 and shFUS myoblasts were not able to 476 differentiation was induced in such a way, shTDP-43 and shFUS myoblasts were not able to
477 survive the differentiation challenge, implying an extreme susceptibility to starvation. For this 477 survive the differentiation challenge, implying an extreme susceptibility to starvation. For this
478 reason, we switched to a more physiological myogenesis model, allowing spontaneous reason, we switched to a more physiological myogenesis model, allowing spontaneous

479 differentiation and fusion by cell-to-cell contact once myoblasts reach 100% confluence. In this
480 scenario, control myoblasts differentiated and formed multinucleated myotubes (positive for 480 scenario, control myoblasts differentiated and formed multinucleated myotubes (positive for
481 myosin heavy chain. MyHC) three days after reaching 100% confluence. In contrast, TDP-43 481 myosin heavy chain, MyHC) three days after reaching 100% confluence. In contrast, TDP-43
482 and FUS knockdown displayed a dramatic impairment in differentiation and fusion, with barely and FUS knockdown displayed a dramatic impairment in differentiation and fusion, with barely
483 any myotube formation (Fig. 2c). Furthermore, proliferation assays showed that the proliferative 483 any myotube formation (Fig. 2c). Furthermore, proliferation assays showed that the proliferative
484 capacity of shTDP-43 and shFUS myoblasts was strongly reduced as well (Fig. 2d). Finally, as 484 capacity of shTDP-43 and shFUS myoblasts was strongly reduced as well (Fig. 2d). Finally, as
485 in patient-derived myoblasts (Supplementary Fig. 2e), we confirmed that the pro-atrophic 485 in patient-derived myoblasts (Supplementary Fig. 2e), we confirmed that the pro-atrophic
486 proteins Atrogin-1 and MURF1 were significantly increased in silenced myoblasts, particularly 486 proteins Atrogin-1 and MURF1 were significantly increased in silenced myoblasts, particularly
487 in shTDP-43 myoblasts (Fig. 2e). Together, these results confirm an essential function of TDP-487 in shTDP-43 myoblasts (Fig. 2e). Together, these results confirm an essential function of TDP-
488 43 and FUS on myogenic differentiation and regeneration process. 43 and FUS on myogenic differentiation and regeneration process.

489 It has been previously shown in mouse muscle progenitors that the nuclear exit of TDP-43 to
490 form cytoplasmic granules in early myotubes is required for muscle differentiation and 490 form cytoplasmic granules in early myotubes is required for muscle differentiation and
491 regeneration [81]. Thus, we performed different analyses to characterise TDP-43 and FUS 491 regeneration [81]. Thus, we performed different analyses to characterise TDP-43 and FUS
492 localization patterns along the human myogenic process. We studied the immortalised human 492 localization patterns along the human myogenic process. We studied the immortalised human
493 myoblast cell line 8220 [29] at five different stages: 30% confluence (proliferation): 100% 493 myoblast cell line 8220 [29] at five different stages: 30% confluence (proliferation); 100%
494 confluence: fusion (myocytes); and early phases of differentiation until myotube formation 494 confluence; fusion (myocytes); and early phases of differentiation until myotube formation
495 (days D3 and D8 post-fusion) (Supplementary Fig. 5a). The analysis of the expression of the 495 (days D3 and D8 post-fusion) (Supplementary Fig. 5a). The analysis of the expression of the myogenic regulatory factors MYOD and MYOG showed an increase on MYOD levels prior to 496 myogenic regulatory factors MYOD and MYOG showed an increase on MYOD levels prior to
497 first fusion events followed by a decrease during fusion and myotube maturation, while MYOG 497 first fusion events followed by a decrease during fusion and myotube maturation, while MYOG
498 appeared increased during fusion events and early phases of myotube formation (Supplementary 498 appeared increased during fusion events and early phases of myotube formation (Supplementary
499 Fig. 5b), as previously reported in rodent and human myogenesis [47, 62]. Regarding TDP-43 499 Fig. 5b), as previously reported in rodent and human myogenesis [47, 62]. Regarding TDP-43
500 and FUS localization across myogenesis. TDP-43 appears mainly limited to the nucleus 500 and FUS localization across myogenesis, TDP-43 appears mainly limited to the nucleus
501 throughout the myogenic process, with a slighter increment in later stages, whereas nuclear FUS 501 throughout the myogenic process, with a slighter increment in later stages, whereas nuclear FUS
502 decreases throughout differentiation, being totally absent in early myotubes at D8 502 decreases throughout differentiation, being totally absent in early myotubes at D8
503 (Supplementary Fig. 5c, d). Although there was no cytoplasmic TDP-43 in myoblasts, TDP-43 503 (Supplementary Fig. 5c, d). Although there was no cytoplasmic TDP-43 in myoblasts, TDP-43
504 appeared in cytoplasmic puncta in differentiating myotubes at D8 (Supplementary Fig. 5d), in 504 appeared in cytoplasmic puncta in differentiating myotubes at D8 (Supplementary Fig. 5d), in
505 agreement with the previous study of Vogler and collaborators showing cytoplasmic 505 agreement with the previous study of Vogler and collaborators showing cytoplasmic
506 translocation of TDP-43 into RNA myogranules at this stage [811. Together, our data confirm 506 translocation of TDP-43 into RNA myogranules at this stage [81]. Together, our data confirm
507 changes in the subcellular localization of both TDP-43 and FUS along myogenesis, suggesting 507 changes in the subcellular localization of both TDP-43 and FUS along myogenesis, suggesting
508 their involvement in the regulation of gene expression programs along muscle differentiation. ⁵⁰⁸their involvement in the regulation of gene expression programs along muscle differentiation.

509 **TDP-43 or FUS deficiency curtails anaerobic glucose metabolism and induces pro-**⁵¹⁰**atrophic pathways**

511 Myogenesis poses a metabolic challenge for cells as the reliance on different metabolic
512 pathways changes throughout the differentiation process to meet specific energy demands. 512 pathways changes throughout the differentiation process to meet specific energy demands.
513 Moreover, disturbances in energy metabolism have been repeatedly associated with the ⁵¹³Moreover, disturbances in energy metabolism have been repeatedly associated with the

514 pathogenesis of ALS [91] and TDP-43 is a recognized regulator of skeletal muscle glucose
515 homeostasis [9, 75]. Thus, we first investigated the extent of the metabolic reconfigurations that 515 homeostasis [9, 75]. Thus, we first investigated the extent of the metabolic reconfigurations that
516 occur in control myoblasts during myogenesis (Supplementary Fig. 6). Metabolic flux analysis 516 occur in control myoblasts during myogenesis (Supplementary Fig. 6). Metabolic flux analysis
517 confirmed that glycolysis was the predominant metabolic pathway to produce basal ATP for 517 confirmed that glycolysis was the predominant metabolic pathway to produce basal ATP for
518 myoblast proliferation, as indicated by higher extracellular acidification rates (ECAR) and 518 myoblast proliferation, as indicated by higher extracellular acidification rates (ECAR) and
519 lower oxygen consumption rates (OCR) (Supplementary Fig. 6a-c). However, differentiating 519 lower oxygen consumption rates (OCR) (Supplementary Fig. 6a-c). However, differentiating
520 and fusing myocytes as well as early myotubes switch their metabolism from glycolytic ATP 520 and fusing myocytes as well as early myotubes switch their metabolism from glycolytic ATP
521 production to oxidative phosphorylation (Supplementary Fig. 6a-c). To assess the impact of 521 production to oxidative phosphorylation (Supplementary Fig. 6a-c). To assess the impact of changes in metabolism, we treated proliferating myoblasts with 2-deoxyglucose (2-DG) to 522 changes in metabolism, we treated proliferating myoblasts with 2-deoxyglucose (2-DG) to
523 reduce glvcolvsis-dependent ATP production. 2-DG induced a myogenesis blockade (Fig. 3a. 523 reduce glycolysis-dependent ATP production. 2-DG induced a myogenesis blockade (Fig. 3a, 524 b), and decreased MYOD and MYOG levels followed by an increase in Atrogin-1 (Fig. 3 c-e). b), and decreased MYOD and MYOG levels followed by an increase in Atrogin-1 (Fig. 3 c-e).

525 Thus, we sought to investigate the metabolic effects of TDP-43/FUS knockdown on human
526 mvoblasts, and whether the mvogenic defects induced by loss of TDP-43/FUS may be 526 myoblasts, and whether the myogenic defects induced by loss of TDP-43/FUS may be
527 explained by glucose metabolism abnormalities. We found that basal glycolysis, maximal 527 explained by glucose metabolism abnormalities. We found that basal glycolysis, maximal
528 elvcolytic capacity and glycolysis-derived ATP production, as calculated from ECAR values. 528 glycolytic capacity and glycolysis-derived ATP production, as calculated from ECAR values,
529 were consistently repressed after silencing TDP-43 or FUS (Fig. 3f). The knockdown of FUS, 529 were consistently repressed after silencing TDP-43 or FUS (Fig. 3f). The knockdown of FUS,
530 and to a lesser extent of TDP-43, also affected mitochondrial respiration, as observed by a 530 and to a lesser extent of TDP-43, also affected mitochondrial respiration, as observed by a
531 reduction in basal OCR and mitochondrial-derived ATP production (Fig. 3g, h). However, the 531 reduction in basal OCR and mitochondrial-derived ATP production (Fig. 3g, h). However, the
532 maximal and spare respiratory capacity was found increased in TDP-43-silenced myoblasts 532 maximal and spare respiratory capacity was found increased in TDP-43-silenced myoblasts
533 (Fig. 3g), although this could be due to the higher number of mitochondria (Supplementary Fig. 533 (Fig. 3g), although this could be due to the higher number of mitochondria (Supplementary Fig. 534 4 a. b) that would respond under experimental conditions to the uncoupler of mitochondrial 534 4 a, b) that would respond under experimental conditions to the uncoupler of mitochondrial
535 oxidative phosphorylation FCCP. oxidative phosphorylation FCCP.

536 These findings suggest that both TDP-43 and FUS silencing resulted in overall abnormalities in
537 energy metabolism during myogenic differentiation. However, the impact was particularly 537 energy metabolism during myogenic differentiation. However, the impact was particularly
538 pronounced in the glycolytic flux, linking disturbances in glycolytic metabolism with myogenic 538 pronounced in the glycolytic flux, linking disturbances in glycolytic metabolism with myogenic
539 deficiencies in silenced myoblasts. Thus, collectively, these data suggest that glucose energy 539 deficiencies in silenced myoblasts. Thus, collectively, these data suggest that glucose energy
540 homeostasis may be a key factor underlying the effects that TDP-43 or FUS silencing have on 540 homeostasis may be a key factor underlying the effects that TDP-43 or FUS silencing have on
541 muscle formation, essentially by impairing myogenesis but also by inducing pro-atrophic 541 muscle formation, essentially by impairing myogenesis but also by inducing pro-atrophic
542 programs. programs.

⁵⁴³**TDP-43 and FUS silencing dysregulates FOXO transcription factors and related signalling** ⁵⁴⁴**pathways**

545 Since TDP-43 and FUS LoF are associated with extensive changes in gene expression and
546 splicing events [26], we employed RNA sequencing to define the global gene expression 546 splicing events [26], we employed RNA sequencing to define the global gene expression
547 profiles of silenced myoblasts in an attempt to gain insights into the pathways and processes profiles of silenced myoblasts in an attempt to gain insights into the pathways and processes

548 modulated by TDP-43 and FUS that might be relevant for muscle homeostasis. Overall, 1,468
549 and 357 genes were upregulated (log_2 fold change >1, false discovery rate [FDR]< 0.001). 549 and 357 genes were upregulated (log₂ fold change \geq 1, false discovery rate [FDR] \leq 0.001),
550 whereas 1.597 and 883 genes were downregulated (log₂ fold change \leq -1, FDR \leq 0.001) 550 whereas 1,597 and 883 genes were downregulated (log₂ fold change \leq -1, FDR \leq 0.001)
551 (Supplementary Table 2) in shTDP-43 and shFUS cells, respectively. Almost two-thirds of the 551 (Supplementary Table 2) in shTDP-43 and shFUS cells, respectively. Almost two-thirds of the differentially expressed genes in shFUS myoblasts overlapped those in shTDP-43 myoblasts 552 differentially expressed genes in shFUS myoblasts overlapped those in shTDP-43 myoblasts
553 (62%: 767 out of 1.240): representation factor: 4.03: ν <0.001) (Fig. 4a), of which 95% (730 out 553 (62%; 767 out of 1,240); representation factor: 4.03; *p*<0.001) (Fig. 4a), of which 95% (730 out of 767) had the same pattern of dysregulation and similar degree of fold change (Fig. 4b). To 554 of 767) had the same pattern of dysregulation and similar degree of fold change (Fig. 4b). To
555 characterise the functional effects of TDP-43 or FUS scarcity in myoblasts, we carried out 555 characterise the functional effects of TDP-43 or FUS scarcity in myoblasts, we carried out
556 GSEA using the Hallmark Pathway. Interestingly, we found consistent gene sets enrichment in 556 GSEA using the Hallmark Pathway. Interestingly, we found consistent gene sets enrichment in
557 myogenesis with negative gene regulation across TDP-43 and FUS-silenced myoblasts (Fig. 4c; 557 myogenesis with negative gene regulation across TDP-43 and FUS-silenced myoblasts (Fig. 4c;
558 Supplementary Table 3). Enrichment using the GO biological process. GO molecular function 558 Supplementary Table 3). Enrichment using the GO biological process, GO molecular function
559 and KEGG pathways with GSEA confirmed the significant enrichment with negative gene 559 and KEGG pathways with GSEA confirmed the significant enrichment with negative gene
560 regulation of sarcomere organisation, muscle organ development, striated muscle contraction 560 regulation of sarcomere organisation, muscle organ development, striated muscle contraction
561 and striated muscle cell differentiation among others (Supplementary Fig. 7a-c and 561 and striated muscle cell differentiation among others (Supplementary Fig. 7a-c and 562 Supplementary Table 3). Furthermore, the Hallmark GSEA also revealed significant enrichment 562 Supplementary Table 3). Furthermore, the Hallmark GSEA also revealed significant enrichment
563 with negative gene regulation of Myc-related targets and MTORC1 signalling gene sets (Fig. 563 with negative gene regulation of Myc-related targets and MTORC1 signalling gene sets (Fig. 564 4c), which can contribute to the dysregulation of the fine tuning between metabolism and cell 564 4c), which can contribute to the dysregulation of the fine tuning between metabolism and cell
565 differentiation during myogenesis [63]. To delineate the transcriptional regulators controlling 565 differentiation during myogenesis [63]. To delineate the transcriptional regulators controlling
566 these altered gene programs of muscle development/differentiation, we performed a motif-566 these altered gene programs of muscle development/differentiation, we performed a motif-
567 centric transcription factors (TF) activity analysis by ISMARA (Integrated System for Motif 567 centric transcription factors (TF) activity analysis by ISMARA (Integrated System for Motif
568 Activity Response Analysis [1]) to characterise the TFs whose motifs' activities most 568 Activity Response Analysis [1]) to characterise the TFs whose motifs' activities most
569 significantly change by TDP-43 or FUS knockdown. This analysis identified a deactivation 569 significantly change by TDP-43 or FUS knockdown. This analysis identified a deactivation
570 across shTDP-43 and shFUS-silenced myoblasts of transcriptional regulators related to the 570 across shTDP-43 and shFUS-silenced myoblasts of transcriptional regulators related to the
571 functional programs identified by GSEA, myogenesis and muscle contraction, including 571 functional programs identified by GSEA, myogenesis and muscle contraction, including
572 MEF2A, MEF2C, MEF2D, MYOD1 and MYOG (Fig. 4d and Supplementary Table 4); these 572 MEF2A, MEF2C, MEF2D, MYOD1 and MYOG (Fig. 4d and Supplementary Table 4); these
573 last two are in agreement with the substantial decreases in their protein levels (Fig. 2b). Thus. 573 last two are in agreement with the substantial decreases in their protein levels (Fig. 2b). Thus,
574 our robust transcriptomic analysis reflects the molecular and functional experimental 574 our robust transcriptomic analysis reflects the molecular and functional experimental
575 phenotypes, thus offering reliability to any mechanistic predictions obtained from this dataset. 575 phenotypes, thus offering reliability to any mechanistic predictions obtained from this dataset.
576 In this line, we sought candidates among the top transcriptional regulators (identified by 576 In this line, we sought candidates among the top transcriptional regulators (identified by
577 ISMARA) with consistent activation across shTDP-43 and shFUS-silenced myoblasts for 577 ISMARA) with consistent activation across shTDP-43 and shFUS-silenced myoblasts for
578 abnormal transcriptional activity related to the associated phenotypes (Fig. 4d and 578 abnormal transcriptional activity related to the associated phenotypes (Fig. 4d and 579 Supplementary Table 4). The enrichment of FOXO1/FOXO6 TF motifs was expected because 579 Supplementary Table 4). The enrichment of FOXO1/FOXO6 TF motifs was expected because
580 myogenesis and muscle growth require the repression of muscle atrophy programs regulated by 580 myogenesis and muscle growth require the repression of muscle atrophy programs regulated by
581 FOXO1 [22, 68], and because transcriptional activity of FOXO1 can be pharmacologically 581 FOXO1 [22, 68], and because transcriptional activity of FOXO1 can be pharmacologically
582 modulated 1431. Moreover, FOXO TFs are also implicated in cell metabolism, and they 582 modulated [43]. Moreover, FOXO TFs are also implicated in cell metabolism, and they
583 integrate insulin signalling with glucose and linid metabolism to orchestrate cellular processes 583 integrate insulin signalling with glucose and lipid metabolism to orchestrate cellular processes
584 such as cell differentiation and autophagy [31, 85]. Thus, we next sought to explore the link such as cell differentiation and autophagy [31, 85]. Thus, we next sought to explore the link

585 between the family of FOXO TFs (focusing on FOXO1 and FOXO3 due to their involvement in
586 the skeletal muscle) and the two main functional phenotypes observed after TDP-43 and FUS 586 the skeletal muscle) and the two main functional phenotypes observed after TDP-43 and FUS
587 silencing: the defects in myogenic differentiation, including upregulation of pro-atrophic 587 silencing: the defects in myogenic differentiation, including upregulation of pro-atrophic
588 pathways, and metabolism. pathways, and metabolism.

589 FOXO1 is particularly identified as key negative regulator of muscle growth, metabolism, and
590 differentiation but is crucial for myoblast fusion [4, 46, 85]. Specifically, FOXO1 activation in 590 differentiation but is crucial for myoblast fusion [4, 46, 85]. Specifically, FOXO1 activation in
591 muscle cells upregulates Atrogin-1 and MURF1 genes and downregulates MYOD expression 591 muscle cells upregulates Atrogin-1 and MURF1 genes and downregulates MYOD expression
592 [27, 39, 401, which mimics the effects of TDP-43 or FUS knockdown in myoblasts (Fig. 2b, e). 592 [27, 39, 40], which mimics the effects of TDP-43 or FUS knockdown in myoblasts (Fig. 2b, e).
593 Since transcriptional activation of FOXO requires its translocation to the nucleus, we analysed 593 Since transcriptional activation of FOXO requires its translocation to the nucleus, we analysed
594 and quantified the nuclear localization of FOXO proteins across the myogenic process as well 594 and quantified the nuclear localization of FOXO proteins across the myogenic process as well
595 as after TDP-43 or FUS silencing in myoblasts. In control conditions, nuclear expression of 595 as after TDP-43 or FUS silencing in myoblasts. In control conditions, nuclear expression of
596 FOXO1 in proliferative myoblasts was low, but it increased during the fusion events, with a 596 FOXO1 in proliferative myoblasts was low, but it increased during the fusion events, with a
597 concomitant decrease in cytoplasmic expression in early myotubes, which suggests 597 concomitant decrease in cytoplasmic expression in early myotubes, which suggests
598 translocation to the nucleus (Supplementary Fig. 8a). This result agrees with previous findings 598 translocation to the nucleus (Supplementary Fig. 8a). This result agrees with previous findings
599 showing that FOXO1 impedes myogenic re-activation in myotubes [49]. However, nuclear 599 showing that FOXO1 impedes myogenic re-activation in myotubes [49]. However, nuclear
500 FOXO1 became abnormally elevated in shTDP-43 and shFUS proliferating myoblasts, 600 FOXO1 became abnormally elevated in shTDP-43 and shFUS proliferating myoblasts,
601 indicated by a rise in the percentage of cells with FOXO1-positive nuclei compared to shRNA 601 indicated by a rise in the percentage of cells with FOXO1-positive nuclei compared to shRNA
602 cells (3.19-fold and 12.14-fold change, respectively) (Fig. 4e)., corroborating the activation of 602 cells (3.19-fold and 12.14-fold change, respectively) (Fig. 4e)., corroborating the activation of the FOXO1 TF motif inferred by ISMARA analysis. To investigate whether glycolytic 603 the FOXO1 TF motif inferred by ISMARA analysis. To investigate whether glycolytic
604 repression activates FOXO1, we treated control myoblasts with 2-DG. This resulted in an 604 repression activates FOXO1, we treated control myoblasts with 2-DG. This resulted in an
605 increase in the number of cells with nuclear FOXO1 (8.26-fold), comparable to the effect 605 increase in the number of cells with nuclear FOXO1 (8.26-fold), comparable to the effect
606 observed upon FUS silencing (Supplementary Fig. 8b and Fig. 4e). Thus, the 2-DG-induced 606 observed upon FUS silencing (Supplementary Fig. 8b and Fig. 4e). Thus, the 2-DG-induced
607 changes in MYOD and Atrogin-1 (Fig. 3d, e) are likely mediated by FOXO1 activation, and 607 changes in MYOD and Atrogin-1 (Fig. 3d, e) are likely mediated by FOXO1 activation, and
608 equally. FOXO1 activation after TDP-43/FUS silencing can be attributed to glycolytic 608 equally, FOXO1 activation after TDP-43/FUS silencing can be attributed to glycolytic repression. repression.

610 In contrast to FOXO1, FOXO3, crucial for proliferation, exhibited a predominantly nuclear
611 localization in control myoblasts (Supplementary Fig. 8a) as previously described in murine 611 localization in control myoblasts (Supplementary Fig. 8a) as previously described in murine
612 myoblasts [22], with decreased levels during differentiation (Supplementary Fig. 8a). However, 612 myoblasts [22], with decreased levels during differentiation (Supplementary Fig. 8a). However,
613 levels of nuclear FOXO3 were also increased in shTDP-43 cells (2.86-fold) and in shFUS cells 613 levels of nuclear FOXO3 were also increased in shTDP-43 cells (2.86-fold) and in shFUS cells (3.32-fold) when compared to shRNA-proliferating myoblasts (Supplementary Fig. 9a). ⁶¹⁴(2.32-fold) when compared to shRNA-proliferating myoblasts (Supplementary Fig. 9a).

615 Together, our data point to an early activation of FOXO1 activity in myoblasts with TDP-43 or
616 FUS silencing, most likely related to defects in glucose utilization pathways with deleterious 616 FUS silencing, most likely related to defects in glucose utilization pathways with deleterious consequences for myogenesis. consequences for myogenesis.

⁶¹⁸**FOXO1 inhibition rescues myogenic and metabolic defects in ALS myoblasts**

619 We next tested whether FOXO1 inhibition rescues the underlying effects of TDP-43/FUS
620 deficiency in myoblasts. Targeting FOXO1 mRNA with shRNAs (shFOXO) reduced FOXO1 620 deficiency in myoblasts. Targeting FOXO1 mRNA with shRNAs (shFOXO) reduced FOXO1
621 levels in TDP-43 and FUS-knockdown myoblasts (Supplementary Fig. 10), and improved their 621 levels in TDP-43 and FUS-knockdown myoblasts (Supplementary Fig. 10), and improved their
622 myogenic capacity as evidenced by increased differentiation and fusion indices (Fig. 5a). To 622 myogenic capacity as evidenced by increased differentiation and fusion indices (Fig. 5a). To
623 elucidate further the role of FOXO1, we employed AS1842856 (iFOXO1), a quinolone-derived 623 elucidate further the role of FOXO1, we employed AS1842856 (iFOXO1), a quinolone-derived
624 molecule that selectively inhibits FOXO1 transactivation. With 100-fold greater potency in 624 molecule that selectively inhibits FOXO1 transactivation. With 100-fold greater potency in
625 targeting FOXO1 DNA interaction than other FOXO factors, iFOXO1 effectively disrupted 625 targeting FOXO1 DNA interaction than other FOXO factors, iFOXO1 effectively disrupted
626 FOXO1-mediated transactivation [43]. Strikingly, iFOXO1 treatment (33 nM) significantly 626 FOXO1-mediated transactivation [43]. Strikingly, iFOXO1 treatment (33 nM) significantly
627 improved the myogenic capacity of TDP-43-silenced myoblasts. This was evidenced by a 627 improved the myogenic capacity of TDP-43-silenced myoblasts. This was evidenced by a
628 increase in the differentiation index $(4.08\text{-}fold)$ and in the fusion index $(6.59\text{-}fold)$ in shTDP-43 628 increase in the differentiation index (4.08-fold) and in the fusion index (6.59-fold) in shTDP-43
629 myoblasts. Furthermore. iFOXO1 treatment activated myogenesis in shFUS-silenced myoblasts 629 myoblasts. Furthermore, iFOXO1 treatment activated myogenesis in shFUS-silenced myoblasts
630 (Fig. 5b). These effects were similar to those observed in shFOXO1 knockdown (Fig. 5b). In 630 (Fig. 5b). These effects were similar to those observed in shFOXO1 knockdown (Fig. 5b). In addition, iFOXO1 treatment led to a significant increase in MYOD1 protein levels in shTDP-43 631 addition, iFOXO1 treatment led to a significant increase in MYOD1 protein levels in shTDP-43
632 myoblasts (2.01-fold) and in shFUS myoblasts (3.02-fold) (Fig. 5c). Finally, as muscle 632 myoblasts (2.01-fold) and in shFUS myoblasts (3.02-fold) (Fig. 5c). Finally, as muscle
633 dysfunction of silenced myoblasts was accompanied by altered energy metabolism (Fig. 3f), we 633 dysfunction of silenced myoblasts was accompanied by altered energy metabolism (Fig. 3f), we
634 also analysed the effect of FOXO1 inhibition in this context. Indeed, iFOXO1 rescued the 634 also analysed the effect of FOXO1 inhibition in this context. Indeed, iFOXO1 rescued the elycolytic flux impairment caused by TDP-43 or FUS silencing, resulting in a significant 635 glycolytic flux impairment caused by TDP-43 or FUS silencing, resulting in a significant
636 increase in basal glycolysis (1.61-fold and 1.67-fold, respectively) (Fig. 5d). In addition, 636 increase in basal glycolysis (1.61-fold and 1.67-fold, respectively) (Fig. 5d). In addition,
637 iFOXO1 treatment also improved the mitochondrial ATP production (Fig. 5d), thus, exerting 637 iFOXO1 treatment also improved the mitochondrial ATP production (Fig. 5d), thus, exerting
638 thorough benefits in the pathways of energy production in the absence of TDP-43 or FUS. ⁶³⁸thorough benefits in the pathways of energy production in the absence of TDP-43 or FUS.

639 We next analysed FOXO expression in ALS patient-derived myoblasts by immunofluorescence.
640 Nuclear FOXO1 levels were significantly elevated in ALS compared to CTRL myoblasts. 640 Nuclear FOXO1 levels were significantly elevated in ALS compared to CTRL myoblasts,
641 evidenced by an increase in the percentage of cells with FOXO1-positive nuclei (2.85-fold) 641 evidenced by an increase in the percentage of cells with FOXO1-positive nuclei (2.85-fold)
642 (Fig. 6a). We also observed a slight increase in the levels of nuclear FOXO3 (Supplementary 642 (Fig. 6a). We also observed a slight increase in the levels of nuclear FOXO3 (Supplementary 643 Fig. 9b). Hence, ALS and TDP-43 or FUS silenced myoblasts share the same nuclear 643 Fig. 9b). Hence, ALS and TDP-43 or FUS silenced myoblasts share the same nuclear
644 distribution of FOXO1/3 (Fig. 4e). Additionally, FOXO1 protein was also found to be increased 644 distribution of FOXO1/3 (Fig. 4e). Additionally, FOXO1 protein was also found to be increased
645 in the cytoplasm of ALS patient-derived myoblasts compared to controls (3.26-fold) (Fig. 6a). 645 in the cytoplasm of ALS patient-derived myoblasts compared to controls (3.26-fold) (Fig. 6a).
646 iFOXO1 treatment specifically improved myogenic capacity in ALS myoblasts, as evidenced by 646 iFOXO1 treatment specifically improved myogenic capacity in ALS myoblasts, as evidenced by
647 the enhanced myogenic differentiation and fusion indices in ALS myoblasts. Compared to 647 the enhanced myogenic differentiation and fusion indices in ALS myoblasts. Compared to
648 control myoblasts, ALS myoblasts exhibited a marked increase in the differentiation index 648 control myoblasts, ALS myoblasts exhibited a marked increase in the differentiation index
649 (3.32-fold) and fusion index (3.47-fold). Notably, 7 out of 8 ALS myoblasts responded 649 (3.32-fold) and fusion index (3.47-fold). Notably, 7 out of 8 ALS myoblasts responded
650 positively to the treatment (Fig. 6b). Conversely, CTRL myoblasts displayed a weaker increase 650 positively to the treatment (Fig. 6b). Conversely, CTRL myoblasts displayed a weaker increase
651 in differentiation (1.61-fold) and fusion (1.59-fold) indices. The treatment also boosted 651 in differentiation (1.61-fold) and fusion (1.59-fold) indices. The treatment also boosted
652 glycolytic flux in the sALS myoblasts (Fig. 6c). Together these data suggest that FOXO1 652 glycolytic flux in the sALS myoblasts (Fig. 6c). Together these data suggest that FOXO1
653 inhibition improves myogenic and metabolic outcomes in ALS muscle cells. inhibition improves myogenic and metabolic outcomes in ALS muscle cells.

654 To determine whether these findings extended to other neurogenic atrophies, we studied
655 primary myoblasts from different disorders including other MN diseases, such as SMA3 or 655 primary myoblasts from different disorders including other MN diseases, such as SMA3 or
656 SBMA. As an example of neuropathy, we also analysed primary myoblasts from a patient with 656 SBMA. As an example of neuropathy, we also analysed primary myoblasts from a patient with
657 Charcot-Marie-Tooth type 4 (CMT4; recessive and demyelinating disease) (Supplementary Fig. 657 Charcot-Marie-Tooth type 4 (CMT4; recessive and demyelinating disease) (Supplementary Fig. 658 11). We first examined the proliferation rates of these samples, which, collectively, were not 658 11). We first examined the proliferation rates of these samples, which, collectively, were not 659 affected in the disease group. However, at the individual level, we observed an apparent 659 affected in the disease group. However, at the individual level, we observed an apparent decrease in SMA3 sample (Supplementary Fig. 11a). We then compared the total protein levels 660 decrease in SMA3 sample (Supplementary Fig. 11a). We then compared the total protein levels
661 of TDP-43 and FUS by immunoblotting, finding some variability, but no general pattern of 661 of TDP-43 and FUS by immunoblotting, finding some variability, but no general pattern of
662 change. However, SMA3 and SBMA myoblasts displayed FUS downregulation, whereas 662 change. However, SMA3 and SBMA myoblasts displayed FUS downregulation, whereas
663 CMT4 myoblasts showed TDP-43 upregulation (Supplementary Fig. 11b). Expression of 663 CMT4 myoblasts showed TDP-43 upregulation (Supplementary Fig. 11b). Expression of 664 FOXO1 in these cells was similar to CTRL myoblasts, with a low nuclear percentage (<15%; 664 FOXO1 in these cells was similar to CTRL myoblasts, with a low nuclear percentage (<15%;
665 Supplementary Fig. 11c), suggesting a specific pathological mechanism for ALS (65%; Fig. 6a). 665 Supplementary Fig. 11c), suggesting a specific pathological mechanism for ALS (65%; Fig. 6a).
666 Finally, differentiation assays did not suggest any appreciable impairment when comparing this 666 Finally, differentiation assays did not suggest any appreciable impairment when comparing this
667 group of diseases with the CTRL group. However, SMA3 and, particularly, CMT4, as well as 667 group of diseases with the CTRL group. However, SMA3 and, particularly, CMT4, as well as the aged CTRL (CTRL 6, 7 and 8) myoblasts, displayed a low myogenic capacity 668 the aged CTRL (CTRL_6, 7 and 8) myoblasts, displayed a low myogenic capacity
669 (Supplementary Fig. 11d, e). Interestingly, FOXO1 inhibition with iFOXO1 rescued the 669 (Supplementary Fig. 11d, e). Interestingly, FOXO1 inhibition with iFOXO1 rescued the myogenic deficit only in SMA3 (Supplementary Fig. 11f). myogenic deficit only in SMA3 (Supplementary Fig. 11f).

671 Finally, we studied myoblasts from patients with muscular disorders characterized by protein
672 aggregates resembling those found in ALS, such as a sporadic Inclusion Body Myositis (IBM) 672 aggregates resembling those found in ALS, such as a sporadic Inclusion Body Myositis (IBM)
673 and a vacuolar myopathy related to Valosin-Containing Protein (VCP) mutations (devoid of 673 and a vacuolar myopathy related to Valosin-Containing Protein (VCP) mutations (devoid of 674 ALS/FTD manifestations). While FOXO1 inhibition enhanced the myogenic program in both 674 ALS/FTD manifestations). While FOXO1 inhibition enhanced the myogenic program in both
675 ALS and VCP-myopathy myoblasts (Supplementary Fig. 11f), particularly in VCP-myopathy 675 ALS and VCP-myopathy myoblasts (Supplementary Fig. 11f), particularly in VCP-myopathy
676 with a 2.75-fold increase in the differentiation index, we did not observe mislocalization of 676 with a 2.75-fold increase in the differentiation index, we did not observe mislocalization of 677 FOXO1 to the nucleus (Supplementary Fig. 11c) or a negative impact on myogenesis 677 FOXO1 to the nucleus (Supplementary Fig. 11c) or a negative impact on myogenesis (Supplementary Fig. 11d, e). (Supplementary Fig. 11d, e).

679 These results suggest that a marked increase of nuclear FOXO1 in myoblasts represents a
680 specific ALS signature, not observed in other MN diseases such as SMA and SBMA, or 680 specific ALS signature, not observed in other MN diseases such as SMA and SBMA, or
681 neuropathies like CMT4. On the other hand, FOXO1 inhibition improved differentiation and 681 neuropathies like CMT4. On the other hand, FOXO1 inhibition improved differentiation and
682 fusion indices in diseases exhibiting FUS downregulation, including SMA type 3, SBMA, and 682 fusion indices in diseases exhibiting FUS downregulation, including SMA type 3, SBMA, and
683 VCP disease (Supplementary Fig. 11b). In contrast, no such rescue effect was observed in 683 VCP disease (Supplementary Fig. 11b). In contrast, no such rescue effect was observed in CMT4 myoblasts, which correlated with unchanged FUS expression levels (Supplementary Fig. 684 CMT4 myoblasts, which correlated with unchanged FUS expression levels (Supplementary Fig. 685 11b). $11b$).

⁶⁸⁶**Inhibition of FOXO1 improves neuromuscular function and lifespan in** *Drosophila* **models**

687 Our *in vitro* findings highlight the dysregulation of FOXO1 as a shared feature of ALS patient-688 derived myoblasts and synthetic TDP-43 and FUS deficient myoblasts. Notably, FOXO1
689 inhibition improved myogenic performance and metabolic fitness in these cells. Based on these 689 inhibition improved myogenic performance and metabolic fitness in these cells. Based on these
690 results, we aimed to assess the effects of targeting FOXO factors on muscle function *in vivo*, 690 results, we aimed to assess the effects of targeting FOXO factors on muscle function *in vivo*,
691 generating different *Drosophila melanogaster* models with conditional silencing of either 691 generating different *Drosophila melanogaster* models with conditional silencing of either
692 Cabeza (caz) or *TBPH* genes (human *FUS* or *TARDBP* orthologs, respectively) by dsRNA 692 Cabeza (*caz*) or *TBPH* genes (human *FUS* or *TARDBP* orthologs, respectively) by dsRNA
693 specifically in muscle tissue (Fig. 7a and Supplementary Fig. 12a). *caz* and *TBPH* knockdown 693 specifically in muscle tissue (Fig. 7a and Supplementary Fig. 12a). *caz* and *TBPH* knockdown
694 were conditioned to the expression of the Myocyte enhancer factor 2 (*Dmel/Mef2*) gene, a TF 694 were conditioned to the expression of the Myocyte enhancer factor 2 (*DmeI/Mef2*) gene, a TF
695 whose expression is mostly restricted to both muscle differentiated and muscle precursor cells 695 whose expression is mostly restricted to both muscle differentiated and muscle precursor cells
696 and which is essential for myogenesis [5, 56]. With this approach, we silenced *caz* or *TBPH* 696 and which is essential for myogenesis [5, 56]. With this approach, we silenced *caz* or *TBPH*
697 specifically in the skeletal muscle of *Drosophila* flies using different long-hairpin iRNA 697 specifically in the skeletal muscle of *Drosophila* flies using different long-hairpin iRNA
698 libraries (Supplementary Fig. 12a). Each generated fly model silenced a single and different 698 libraries (Supplementary Fig. 12a). Each generated fly model silenced a single and different
699 locus of *caz* or *TBPH* genes. Respectively, *caz* or *TBPH* gene expression is significantly 699 locus of *caz* or *TBPH* genes. Respectively, *caz* or *TBPH* gene expression is significantly
700 reduced in iCaz or iTBPH models (Supplementary Fig. 12b). Notably, fly models from KK 700 reduced in iCaz or iTBPH models (Supplementary Fig. 12b). Notably, fly models from KK
701 libraries (iCaz and iTBPH^{pkk(108354)}) silenced more efficiently *caz* or *TBPH* (by ca 50%) libraries (iCaz and iTBPH^{pkk(108354)}) silenced more efficiently *caz* or *TBPH* (by ca 50%)
702 (Supplementary Fig. 12b). Moreover, the iTBPH^{pkk(108354)} fly model showed not only a (Supplementary Fig. 12b). Moreover, the iTBPH^{pkk(108354)} fly model showed not only a
703 prominent *TBPH* expression decrease but also a subsequent and significant reduction of *caz* 703 prominent *TBPH* expression decrease but also a subsequent and significant reduction of *caz*
704 gene expression (Supplementary Fig. 12b), as we showed for FUS in TDP-43-silenced 704 gene expression (Supplementary Fig. 12b), as we showed for FUS in TDP-43-silenced
705 mvoblasts (Fig. 2b). This result confirms the functional co-regulation between *TBPH* and *caz* 705 myoblasts (Fig. 2b). This result confirms the functional co-regulation between *TBPH* and *caz*
706 gene expression [82], as it also occurs in human orthologs TDP-43 and FUS [56]. gene expression [82], as it also occurs in human orthologs TDP-43 and FUS [56].

While *caz*-silenced (*icaz*) flies and two different lines of *TBPH*-silencing (iTBPH^{attp40} and
708 iTBPH^{p(GD6943)}) were viable, the third TBPH-silenced line (iTBPH^{pkk(108354)}) exhibited lethality in TOB iTBPH^{p(GD6943)}) were viable, the third TBPH-silenced line (iTBPH^{pkk(108354)}) exhibited lethality in
709 newly metamorphosed adults (pharate), not even being able to hatch out of its pupa (Fig. 7a). 709 newly metamorphosed adults (pharate), not even being able to hatch out of its pupa (Fig. 7a).
710 Adult iTBPH^{attp40} and iCaz flies exhibited the most pronounced motor phenotypes, detectable as Adult iTBPH^{attp40} and iCaz flies exhibited the most pronounced motor phenotypes, detectable as
711 early as 10 days old. This was evidenced by a climbing ability of only 30-40% of flies in the 711 early as 10 days old. This was evidenced by a climbing ability of only 30-40% of flies in the
712 locomotor activity test. (Fig. 7b). However, adult iTBPH^{p(GD6943)} flies displayed such phenotype locomotor activity test. (Fig. 7b). However, adult iTBPH^{p(GD6943)} flies displayed such phenotype
713 at 15-day old (Fig. 7b). Finally, to complete the phenotypical-functional characterization of the 713 at 15-day old (Fig. 7b). Finally, to complete the phenotypical-functional characterization of the
714 models, we performed longevity assays, demonstrating a significantly decreased lifespan across 714 models, we performed longevity assays, demonstrating a significantly decreased lifespan across
715 Caz and iTBPH fly models (Fig. 7c). iCaz and iTBPH fly models (Fig. 7c).

⁷¹⁶*Drosophila* has only one ortholog for mammalian FOXO transcription factors, named *foxo*. 717 Although the affinity of the AS1842856 compound (iFOXO1) for *Drosophila*'s *foxo* has never
718 been tested, as FOXO binding sites for this compound are well conserved (Supplementary Fig. 718 been tested, as FOXO binding sites for this compound are well conserved (Supplementary Fig. 719 12c), we first tested its efficacy in our models. After verifying that $FOXO1$ (30 μ M) showed no 719 12c), we first tested its efficacy in our models. After verifying that iFOXO1 (30 μ M) showed no
720 toxicity on motor function and lifespan in control flies (Supplementary Fig. 12d, e), we applied 720 toxicity on motor function and lifespan in control flies (Supplementary Fig. 12d, e), we applied
721 iFOXO1 treatment in *icaz* and *iTBPH* flies. Strikingly, *foxo* inhibition resulted notably 721 iFOXO1 treatment in *icaz* and *iTBPH* flies. Strikingly, *foxo* inhibition resulted notably
722 improved muscle function, as evidenced by a significant increase in climbing activity. This improved muscle function, as evidenced by a significant increase in climbing activity. This

723 effect was more pronounced in iTBPH flies (approximately 80% climbed) compared to iCaz
724 flies (approximately 60% climbed) (Fig. 7d and Supplementary Videos 1-7). Furthermore, 724 flies (approximately 60% climbed) (Fig. 7d and Supplementary Videos 1-7). Furthermore,
725 treated flies significantly increased their survival, particularly for the iCaz and iTBPH^{attp40} fly treated flies significantly increased their survival, particularly for the iCaz and iTBPH^{attp40} fly
726 lines (Fig. 7e-g). lines (Fig. 7e-g).

As mentioned above, iTBP $H^{pkk(108354)}$ flies displayed adult pharate lethality, presumably due to
728 insufficient muscle strength to exit the pupa once metamorphosis is complete. Noteworthily, insufficient muscle strength to exit the pupa once metamorphosis is complete. Noteworthily,
729 iFOXO1 treatment significantly reduced pharate lethality in iTBPH^{pkk(108354)} flies. This was iFOXO1 treatment significantly reduced pharate lethality in iTBPH^{pkk(108354)} flies. This was
730 evidenced by a substantial increase in survival rate, from 2% to 20%, at the pharate pupal stage 730 evidenced by a substantial increase in survival rate, from 2% to 20%, at the pharate pupal stage
731 (Fig. 7h). Indeed, histopathological analysis revealed a dramatic denervation of iTBPH^{pkk(108254)} (Fig. 7h). Indeed, histopathological analysis revealed a dramatic denervation of iTBPH^{pkk(108254)}
732 thoracic muscles, as observed by both a decrease in the number of HRP-positive neuronal thoracic muscles, as observed by both a decrease in the number of HRP-positive neuronal
733 branches (-7.14-fold) and in the size of neuromuscular synapses (-1.4-fold) (*bruchpilot*+, a 733 branches (-7.14-fold) and in the size of neuromuscular synapses (-1.4-fold) (*bruchpilot*+, a
734 marker of mature and functional synapses in *Drosophila*) (Fig. 7i-k), confirming a deneryation 734 marker of mature and functional synapses in *Drosophila*) (Fig. 7i-k), confirming a denervation
735 phenotype in these *TBPH* muscle-silenced flies. Surprisingly, the treatment with iFOXO1 735 phenotype in these *TBPH* muscle-silenced flies. Surprisingly, the treatment with iFOXO1
736 induced a significant increase in the size of the neuromuscular synapses of the remaining MNs 736 induced a significant increase in the size of the neuromuscular synapses of the remaining MNs
737 (1.25-fold) (Fig. 7i, j), correlating with the survival increase. However, the treatment was unable 737 (1.25-fold) (Fig. 7i, j), correlating with the survival increase. However, the treatment was unable
738 to show signs of improvement in the number of terminal MN innervating the muscle (Fig. 7k). to show signs of improvement in the number of terminal MN innervating the muscle (Fig. 7k).

Together, the combined data obtained from the *in vivo* models and *in vitro* experiments suggest
740 a hopeful prospect for using FOXO1 inhibition to restore muscle homeostasis challenged by 740 a hopeful prospect for using FOXO1 inhibition to restore muscle homeostasis challenged by
741 TDP-43 or FUS LoF, suggesting a potential benefit to reduce muscle wasting in ALS patients. ⁷⁴¹TDP-43 or FUS LoF, suggesting a potential benefit to reduce muscle wasting in ALS patients. 742 Providing this initial evidence, these data also promote that therapies aimed at preserving
743 muscle function could potentially offer protection to MNs. muscle function could potentially offer protection to MNs.

⁷⁴⁴**DISCUSSION**

745 ALS is a complex and devastating disease that affects MNs and involves a multitude of altered
746 orocesses and pathways, making the development of effective therapeutic strategies challenging 746 processes and pathways, making the development of effective therapeutic strategies challenging
747 [91]. Recent research has highlighted the implication of skeletal muscle in the disease, not only 747 [91]. Recent research has highlighted the implication of skeletal muscle in the disease, not only
748 as a consequence but also as a potential contributor to the origin and spread of the pathology 218 as a consequence but also as a potential contributor to the origin and spread of the pathology
219 [17, 55, 70]. In this work, we have sought to provide further evidence of the molecular bases 749 [17, 55, 70]. In this work, we have sought to provide further evidence of the molecular bases
750 underlying the intrinsic muscle abnormalities of ALS to pinpoint mechanisms that can be 750 underlying the intrinsic muscle abnormalities of ALS to pinpoint mechanisms that can be
751 targeted to improve muscle health and, ultimately, slow down the disease pathology. In this 751 targeted to improve muscle health and, ultimately, slow down the disease pathology. In this
752 sense, we demonstrate that myogenesis, glucose metabolism and pro-atrophic pathways are 752 sense, we demonstrate that myogenesis, glucose metabolism and pro-atrophic pathways are
753 affected in ALS muscle progenitor cells independently of the MN input, being the role of TDP-753 affected in ALS muscle progenitor cells independently of the MN input, being the role of TDP-
754 43 and FUS essential in these processes. Aberrant hyperactivation of FOXO transcription 754 43 and FUS essential in these processes. Aberrant hyperactivation of FOXO transcription
755 factors was identified as an underlying mechanism, evidenced by FOXO1 nuclear translocation 755 factors was identified as an underlying mechanism, evidenced by FOXO1 nuclear translocation
756 and FOXO1 motif activity upregulation. We evidence that FOXO1 activity can be 756 and FOXO1 motif activity upregulation. We evidence that FOXO1 activity can be
757 bharmacologically modulated to recover muscle homeostasis in ALS cells and to improve the 757 pharmacologically modulated to recover muscle homeostasis in ALS cells and to improve the
758 neuromuscular function in ALS *Drosophila* models with muscle-specific TDP-43 and FUS 758 neuromuscular function in ALS *Drosophila* models with muscle-specific TDP-43 and FUS
759 silencing. silencing.

760 To decipher the molecular basis of muscle contribution to ALS pathology, we have focused our
761 study on the capacity of muscle resident precursor cells (the myoblasts) to fulfil their 761 study on the capacity of muscle resident precursor cells (the myoblasts) to fulfil their
762 compromise for muscle regeneration. The skeletal muscle has an extraordinary regenerative 762 compromise for muscle regeneration. The skeletal muscle has an extraordinary regenerative
763 capacity to recover from severe damage and even atrophy under physiological conditions [59], 763 capacity to recover from severe damage and even atrophy under physiological conditions [59],
764 by activating the myogenic program in muscle progenitor cells. However, ALS muscle atrophy 764 by activating the myogenic program in muscle progenitor cells. However, ALS muscle atrophy
765 is irreversible and follows a progressive pattern that determines the disease severity, being 765 is irreversible and follows a progressive pattern that determines the disease severity, being
766 disabling and fatal for the patients [38]. A plausible hypothesis is that the regenerative capacity 766 disabling and fatal for the patients [38]. A plausible hypothesis is that the regenerative capacity
767 of ALS muscle is impaired, to the point of not compensating for denervation-induced atrophy. 767 of ALS muscle is impaired, to the point of not compensating for denervation-induced atrophy.
768 According to this hypothesis, we found defects in the process of muscle regeneration in almost 768 According to this hypothesis, we found defects in the process of muscle regeneration in almost
769 all ALS samples, in agreement with previous studies [57, 69], which were further accompanied 2013 all ALS samples, in agreement with previous studies [57, 69], which were further accompanied
270 by changes in the levels of the myogenic regulatory factors (MRF) MYOD and MYOG. 770 by changes in the levels of the myogenic regulatory factors (MRF) MYOD and MYOG.
771 Initially, we elucidated whether two of the most implicated factors in ALS pathology, TDP-43 771 Initially, we elucidated whether two of the most implicated factors in ALS pathology, TDP-43
772 and FUS, might be involved in such myogenic defects. Indeed, we identified a faint presence of 272 and FUS, might be involved in such myogenic defects. Indeed, we identified a faint presence of
273 cytoplasmic TDP-43 granules as early as day 3 after human myocyte fusion in human control 773 cytoplasmic TDP-43 granules as early as day 3 after human myocyte fusion in human control
774 myotubes. Accordingly, a previous study reported that TDP-43 forms physiological cytoplasm 774 myotubes. Accordingly, a previous study reported that TDP-43 forms physiological cytoplasm
775 granules in murine C2C12 myotubes at late stages of differentiation, which are critical for 775 granules in murine C2C12 myotubes at late stages of differentiation, which are critical for
776 regulating sarcomeric protein translation and myotube maturation in mice [81] cytoplasmic 776 regulating sarcomeric protein translation and myotube maturation in mice [81] cytoplasmic
777 TDP-43 protein granules in myoblasts from either ALS patients or control subjects. This ⁷⁷⁷TDP-43 protein granules in myoblasts from either ALS patients or control subjects. This 778 suggests that during the early stages of myogenesis, cytoplasmic TDP-43 may play a minimal

779 role. However, TDP-43 total levels appeared decreased in ALS myoblasts, suggesting that
780 nuclear TDP-43 may also play a significant role in the early stages of differentiation by 780 nuclear TDP-43 may also play a significant role in the early stages of differentiation by
781 regulating myogenic gene programs. This hypothesis can also be extended to FUS, as ALS 781 regulating myogenic gene programs. This hypothesis can also be extended to FUS, as ALS
782 myoblasts demonstrate decreased FUS expression, which is normally localized primarily to the 782 myoblasts demonstrate decreased FUS expression, which is normally localized primarily to the
783 nuclei of proliferating myoblasts but is absent from differentiated myotubes. Nonetheless, we 783 nuclei of proliferating myoblasts but is absent from differentiated myotubes. Nonetheless, we
784 must consider some variability in myogenesis among ALS patients. For instance, in fALS2, the 784 must consider some variability in myogenesis among ALS patients. For instance, in fALS2, the
785 only patient without differentiation problems presents a familial form with slower disease 785 only patient without differentiation problems presents a familial form with slower disease
786 progression. There is also more variability in healthy individuals, where we observed a clear 786 progression. There is also more variability in healthy individuals, where we observed a clear
787 correlation with aging. As this correlation is lost in ALS, we anticipate that myogenic 787 correlation with aging. As this correlation is lost in ALS, we anticipate that myogenic
788 impairments are genuinely associated with ALS pathology, thus, suggesting premature aging 788 impairments are genuinely associated with ALS pathology, thus, suggesting premature aging
789 [52]. Since we reported general decreased TDP-43 and FUS expression in the ALS samples, we 789 [52]. Since we reported general decreased TDP-43 and FUS expression in the ALS samples, we
790 investigated the mechanisms and processes related to myogenesis impacted by TDP-43 or FUS 790 investigated the mechanisms and processes related to myogenesis impacted by TDP-43 or FUS
791 knockdown in proliferating myoblasts. knockdown in proliferating myoblasts.

792 TDP-43 or FUS knockdown was sufficient to replicate the myogenic defects observed in
793 patients' cells. These results are in agreement with those achieved by the silencing of other 793 patients´ cells. These results are in agreement with those achieved by the silencing of other
794 ALS-causative genes. For instance, OPTN silencing delayed muscle regeneration in mice and 794 ALS-causative genes. For instance, OPTN silencing delayed muscle regeneration in mice and
795 impaired myogenic differentiation in C2C12 mouse myoblasts [72], and RNA-binding proteins 795 impaired myogenic differentiation in C2C12 mouse myoblasts [72], and RNA-binding proteins
796 whose mutations cause ALS, such as hnRNPA1, hnRNPA2B1 or MATR3, control myogenic 796 whose mutations cause ALS, such as hnRNPA1, hnRNPA2B1 or MATR3, control myogenic
797 cell fate transitions during differentiation by regulating the expression and alternative splicing 797 cell fate transitions during differentiation by regulating the expression and alternative splicing
798 of muscle-related genes [2, 32, 50, 83]. Hence, the diversity of ALS-associated genes 798 of muscle-related genes [2, 32, 50, 83]. Hence, the diversity of ALS-associated genes
799 influencing myogenic cell fate transitions highlights the potential for various triggers to cause 799 influencing myogenic cell fate transitions highlights the potential for various triggers to cause
800 myogenic alterations in ALS. While our knockdown model represents a simplified approach to 800 myogenic alterations in ALS. While our knockdown model represents a simplified approach to
801 the complex TDP-43 proteinopathy, it is important to note that the loss of TDP-43 function, 801 the complex TDP-43 proteinopathy, it is important to note that the loss of TDP-43 function,
802 particularly its role in cryptic splicing repression, is thought to precede the formation of TDP-802 particularly its role in cryptic splicing repression, is thought to precede the formation of TDP-
803 43-positive inclusions [8]. Therefore, our silencing approach mimics an early stage of the 803 43-positive inclusions [8]. Therefore, our silencing approach mimics an early stage of the disease, making it valuable for studying the underlying pathogenic mechanisms. disease, making it valuable for studying the underlying pathogenic mechanisms.

805 The myogenic process requires a series of consecutive steps that demand a fine-tuned regulation
806 of metabolism and a flexible use of energy resources [15, 50], as we confirmed in the human 806 of metabolism and a flexible use of energy resources [15, 50], as we confirmed in the human
807 immortalised myoblast cell line used in this work. In the earliest stages of myoblast 807 immortalised myoblast cell line used in this work. In the earliest stages of myoblast
808 differentiation, the reliance on glycolvsis is critical, as we demonstrated after inhibiting 808 differentiation, the reliance on glycolysis is critical, as we demonstrated after inhibiting
809 myoblasts with 2-DG resulting in myogenic repression, whereas in later stages of myotube 809 myoblasts with 2-DG resulting in myogenic repression, whereas in later stages of myotube
810 maturation, energy is mostly supplied by mitochondrial oxidative phosphorylation [50, 79]. 810 maturation, energy is mostly supplied by mitochondrial oxidative phosphorylation [50, 79].
811 Indeed, glycolysis not only provides a rapid source of energy and carbon sources to underpin 811 Indeed, glycolysis not only provides a rapid source of energy and carbon sources to underpin
812 myoblast growth but also acts as an epigenetic regulator of myoblast proliferation through myoblast growth but also acts as an epigenetic regulator of myoblast proliferation through 813 modulation of histone acetylation [87]. As alterations in glucose metabolism are major within

814 the overall metabolic disturbances of ALS [3, 91], it is plausible to anticipate that these may
815 impinge on the myogenic process and, in turn, affect muscle function. Interestingly, the 815 impinge on the myogenic process and, in turn, affect muscle function. Interestingly, the
816 knockdown of TDP-43 or FUS in myoblasts dramatically reduced the ability to use glucose, and 816 knockdown of TDP-43 or FUS in myoblasts dramatically reduced the ability to use glucose, and
817 pro-atrophic pathways became consequently activated. These results fit previous studies 817 pro-atrophic pathways became consequently activated. These results fit previous studies
818 describing the role of TDP-43 in the regulation of skeletal muscle glucose homeostasis, which 818 describing the role of TDP-43 in the regulation of skeletal muscle glucose homeostasis, which
819 involves glucose uptake facilitation mediated by the interaction between TBC1D1 and the 819 involves glucose uptake facilitation mediated by the interaction between TBC1D1 and the
820 glucose transporter GLUT4 [9, 75]. This highlights the important role that TDP-43 and FUS 820 glucose transporter GLUT4 [9, 75]. This highlights the important role that TDP-43 and FUS
821 play in glucose oxidation pathways to regulate muscle function, avoiding the induction of pro-821 play in glucose oxidation pathways to regulate muscle function, avoiding the induction of pro-
822 atrophic programs. atrophic programs.

823 Through the analysis for enriched TF motifs from RNA-seq data, specific genes related to muscle differentiation and growth appeared to be deactivated, confirming the intrinsic muscle 824 muscle differentiation and growth appeared to be deactivated, confirming the intrinsic muscle
825 dysfunction. Among these factors, we found MYOD and MYOG (essential for myogenesis). 825 dysfunction. Among these factors, we found *MYOD* and *MYOG* (essential for myogenesis),
826 which we confirmed to be downregulated in ALS samples, and *MEF2* TF, whose inactivation 826 which we confirmed to be downregulated in ALS samples, and *MEF2* TF, whose inactivation
827 induces skeletal muscle atrophy [45, 71]. Regarding the activated genes, besides *FOXO1*, *TP53* 827 induces skeletal muscle atrophy [45, 71]. Regarding the activated genes, besides *FOXO1*, *TP53*
828 appeared as another plausible candidate to be further studied, as its upregulation also suppresses 828 appeared as another plausible candidate to be further studied, as its upregulation also suppresses
829 cell growth, specifically by repressing $MYOG$ in the skeletal muscle, leading to the inhibition of 829 cell growth, specifically by repressing *MYOG* in the skeletal muscle, leading to the inhibition of 830 late differentiation markers [86]. As such, further analysis of these factors should be done to 830 late differentiation markers [86]. As such, further analysis of these factors should be done to
831 decipher their impact in ALS pathophysiology. However, based on the TF and our expertise in 831 decipher their impact in ALS pathophysiology. However, based on the TF and our expertise in
832 the molecular regulation of muscle stem cells [19], we uncovered dysregulation of FOXO 832 the molecular regulation of muscle stem cells [19], we uncovered dysregulation of FOXO
833 transcription factors as a converging molecular mechanism linking the impaired myogenesis 833 transcription factors as a converging molecular mechanism linking the impaired myogenesis
834 and the altered glycolysis in the absence of TDP-43 and FUS. Although FOXO1 must be 834 and the altered glycolysis in the absence of TDP-43 and FUS. Although FOXO1 must be
835 excluded from the nucleus becoming inactive in myoblasts during myogenesis [22], we found 835 excluded from the nucleus becoming inactive in myoblasts during myogenesis [22], we found
836 FOXO1 expressed in the nuclei of all ALS patient myoblasts as well as in TDP-43- or FUS-836 FOXO1 expressed in the nuclei of all ALS patient myoblasts as well as in TDP-43- or FUS-
837 silenced myoblasts, suggesting this change as a consistent pathogenic feature in ALS muscle. 837 silenced myoblasts, suggesting this change as a consistent pathogenic feature in ALS muscle.
838 Indeed, such activation of nuclear FOXO1 did not appear in the other diseases, such as SMA3. 838 Indeed, such activation of nuclear FOXO1 did not appear in the other diseases, such as SMA3,
839 SBMA, CMT4, IBM, or VCP. FOXO1 induction may occur as a cellular response to the 839 SBMA, CMT4, IBM, or VCP. FOXO1 induction may occur as a cellular response to the
840 inability to obtain energy from glucose oxidation. Although FOXO1 inhibits glycolysis *per se* 840 inability to obtain energy from glucose oxidation. Although FOXO1 inhibits glycolysis *per se*
841 by regulating PDK4 expression [16, 20, 58], and thus controlling the activity of the main 841 by regulating PDK4 expression [16, 20, 58], and thus controlling the activity of the main
842 elvcolvsis-limiting enzyme, pyruvate dehydrogenase (PDH), the fact that FOXO1 was activated 842 glycolysis-limiting enzyme, pyruvate dehydrogenase (PDH), the fact that FOXO1 was activated
843 after repressing glycolysis with 2-DG or after TDP-43 or FUS silencing could be explained by 843 after repressing glycolysis with 2-DG or after TDP-43 or FUS silencing could be explained by
844 the role of FOXO1 in nutrient switching during glucose shortage [66]. Indeed, our results 844 the role of FOXO1 in nutrient switching during glucose shortage [66]. Indeed, our results
845 indicate that FOXO1 inhibition facilitates glucose metabolism, shown as an increased lactate 845 indicate that FOXO1 inhibition facilitates glucose metabolism, shown as an increased lactate
846 production and basal mitochondrial respiration. On the other hand, TDP-43 directly represses 846 production and basal mitochondrial respiration. On the other hand, TDP-43 directly represses
847 nuclear FOXO1 transactivation [88]; therefore, a dysfunction of TDP-43 would release such 847 nuclear FOXO1 transactivation [88]; therefore, a dysfunction of TDP-43 would release such
848 repression leading to an increase in FOXO1 activity and, consequently, to the inhibition of 848 repression leading to an increase in FOXO1 activity and, consequently, to the inhibition of
849 vlocolysis. Together, our data point to abnormal FOXO1 activation in ALS muscle due to TDP-849 glycolysis. Together, our data point to abnormal FOXO1 activation in ALS muscle due to TDP-

850 43 or FUS knockdown, which ultimately impairs the muscle regenerative capacity. This
851 FOXO1 overactivation may occur due to the release of FOXO1 repression in the absence of 851 FOXO1 overactivation may occur due to the release of FOXO1 repression in the absence of 852 TDP-43, secondary to alterations in glucose metabolism, or both. Actually, the overactivation of 852 TDP-43, secondary to alterations in glucose metabolism, or both. Actually, the overactivation of
853 FOXO1 in ALS muscle could explain the switch from glucose to muscle lipid utilisation 853 FOXO1 in ALS muscle could explain the switch from glucose to muscle lipid utilisation
854 described at early stages in the SOD1-G93A mouse, prior to symptoms onset and MN loss [12, 854 described at early stages in the SOD1-G93A mouse, prior to symptoms onset and MN loss [12, 855 51]. 51].

856 Importantly, there are several studies that have underscored the critical role of FOXO TF in
857 muscle atrophy [68]. Conversely, myostatin treatment, known for its negative regulation of 857 muscle atrophy [68]. Conversely, myostatin treatment, known for its negative regulation of
858 muscle growth, reverses the IGF-1/PI3K/AKT hypertrophy pathway by inhibiting AKT 858 muscle growth, reverses the IGF-1/PI3K/AKT hypertrophy pathway by inhibiting AKT
859 phosphorylation, thereby elevating active FOXO1 levels and promoting the expression of 859 phosphorylation, thereby elevating active FOXO1 levels and promoting the expression of atrophy-related genes [39]. Furthermore, FOXO1's negative regulatory influence on skeletal 860 atrophy-related genes [39]. Furthermore, FOXO1´s negative regulatory influence on skeletal
861 muscle mass and type I fibre gene expression has been proposed, potentially contributing to 861 muscle mass and type I fibre gene expression has been proposed, potentially contributing to
862 sarcopenia, obesity, and diabetes in humans [25]. Additionally, FOXO3 activation, which leads 862 sarcopenia, obesity, and diabetes in humans [25]. Additionally, FOXO3 activation, which leads
863 to significant muscle atrophy via the transcription of atrophy-related genes, including crucial 863 to significant muscle atrophy via the transcription of atrophy-related genes, including crucial
864 ubiquitin ligases [89], emerges as a potential therapeutic target for muscle wasting disorders and 864 ubiquitin ligases [89], emerges as a potential therapeutic target for muscle wasting disorders and
865 degenerative diseases involving autophagy [35], further supported by research indicating 865 degenerative diseases involving autophagy [35], further supported by research indicating
866 enhanced FOXO-dependent muscle mass loss associated with a decline in PGC1-alpha during 866 enhanced FOXO-dependent muscle mass loss associated with a decline in PGC1-alpha during
867 atrophy [67]. Finally, Nakashima and Yakabe stated that when AMPK signalling pathway is 867 atrophy [67]. Finally, Nakashima and Yakabe stated that when AMPK signalling pathway is
868 enhanced by AICAR in C2C12 myotubes, it promotes myofibrillar protein degradation through 868 enhanced by AICAR in C2C12 myotubes, it promotes myofibrillar protein degradation through
869 increased expression of atrogin-1 and MuRF1, facilitated by elevated levels of FOXO TF in 869 increased expression of atrogin-1 and MuRF1, facilitated by elevated levels of FOXO TF in
870 skeletal muscles [44]. Together, this data moved us to consider FOXO1 as a plausible target in 870 skeletal muscles [44]. Together, this data moved us to consider FOXO1 as a plausible target in
871 which to intervene. which to intervene.

872 Considering our results, FOXO1 inhibitors may have the potential to treat TDP-43 or FUS LoF-
873 induced muscle alterations, such as those in ALS. Indeed, FOXO inhibition induces overall 873 induced muscle alterations, such as those in ALS. Indeed, FOXO inhibition induces overall
874 locomotor and survival benefits in fruit flies with specific muscle knockdown of TBPH and caz. 874 locomotor and survival benefits in fruit flies with specific muscle knockdown of *TBPH* and *caz*.
875 Actually, the four different *Drosophila* ALS models used in this study reproduce some ALS 875 Actually, the four different *Drosophila* ALS models used in this study reproduce some ALS
876 outcomes, such as shortened lifespan and impaired neuromuscular function, as described for 876 outcomes, such as shortened lifespan and impaired neuromuscular function, as described for
877 TDP-43 knockdown in *Drosophila* [76]. One of the *TBPH* knockdown models exhibited a 877 TDP-43 knockdown in *Drosophila* [76]. One of the *TBPH* knockdown models exhibited a
878 bharate lethality phenotype. likely resulting from the extensive deneryation of thoracic muscles 878 pharate lethality phenotype, likely resulting from the extensive denervation of thoracic muscles
879 caused by *TBPH* knockdown, which in turn led to inadequate tractor capacity for exiting the 879 caused by *TBPH* knockdown, which in turn led to inadequate tractor capacity for exiting the
880 pupa. Interestingly, this model displayed greater phenotypic severity compared to the others, 880 pupa. Interestingly, this model displayed greater phenotypic severity compared to the others,
881 potentially due to cumulative effects resulting from secondary *caz* dysregulation. The pharate 881 potentially due to cumulative effects resulting from secondary *caz* dysregulation. The pharate
882 lethality in this model was rescued by FOXO1 inhibition, which likely improved the 882 lethality in this model was rescued by FOXO1 inhibition, which likely improved the
883 neuromuscular synaptic contacts, favouring the subsequent pupal period eclosion. These 883 neuromuscular synaptic contacts, favouring the subsequent pupal period eclosion. These
884 findings support the recent theory of non-cell autonomous mechanisms of neurodegeneration in findings support the recent theory of non-cell autonomous mechanisms of neurodegeneration in

885 ALS [21] that implicate distal axonopathy as the initiating event in the disease [41], and provide
886 compelling evidence that treatments aimed at restoring muscle function can alleviate MN 886 compelling evidence that treatments aimed at restoring muscle function can alleviate MN
887 neurodegeneration. However, it should be noted that *Drosophila* has only one *foxo* gene that 1887 neurodegeneration. However, it should be noted that *Drosophila* has only one *foxo* gene that
1888 performs the functions of all members of the human FOXO family, and the beneficial effects of 888 performs the functions of all members of the human FOXO family, and the beneficial effects of
889 the FOXO inhibitor treatment may be partially attributed to FOXO3 inhibition, which may also 889 the FOXO inhibitor treatment may be partially attributed to FOXO3 inhibition, which may also
890 contribute to myoblast differentiation [74]. contribute to myoblast differentiation [74].

891 Overall, the restoration of the myogenic process being concomitant to glycolytic normalisation
892 supports that metabolic defects are linked to the myogenic phenotypes of *TARDBP* and *FUS* 892 supports that metabolic defects are linked to the myogenic phenotypes of *TARDBP* and *FUS*
893 knockdown cells. FOXO1 plays a crucial role in the interplay between metabolism and disease, 893 knockdown cells. FOXO1 plays a crucial role in the interplay between metabolism and disease,
894 as it controls many of the physiological responses to metabolic stimuli, including those 894 as it controls many of the physiological responses to metabolic stimuli, including those
895 mediated by insulin signalling [31]. Therefore, inhibiting FOXO1 could potentially counteract 895 mediated by insulin signalling [31]. Therefore, inhibiting FOXO1 could potentially counteract
896 the key functional consequences of TDP-43 or FUS loss-of-function, specifically in ALS 896 the key functional consequences of TDP-43 or FUS loss-of-function, specifically in ALS
897 muscle cells. Additionally, recent studies have proposed FOXO transcription factors as 897 muscle cells. Additionally, recent studies have proposed FOXO transcription factors as
898 promising therapeutic targets for neurodegenerative diseases [6, 48]. Indeed, we show the 898 promising therapeutic targets for neurodegenerative diseases [6, 48]. Indeed, we show the
899 recovery of muscle differentiation through FOXO1 inhibition in other MN diseases such as 899 recovery of muscle differentiation through FOXO1 inhibition in other MN diseases such as
900 SMA3 and SBMA. Thus, highlighting this mechanism and downstream targets could encourage 900 SMA3 and SBMA. Thus, highlighting this mechanism and downstream targets could encourage
901 the development of new therapeutic approaches for ALS that target skeletal muscle. the development of new therapeutic approaches for ALS that target skeletal muscle.

902

⁹⁰³**ACKNOWLEDGMENTS**

904 The authors thank Dr. Vincent Mouly and the Platform for Immortalization of Human Cells
905 (Myology Institute) for the human immortalised 8220 cell line, and Stéphane Vasseur from the 905 (Myology Institute) for the human immortalised 8220 cell line, and Stéphane Vasseur from the
906 MYOBANK-AFM (Myology Institute) for the human CMT4 myoblasts. We also thank Dr. 906 MYOBANK-AFM (Myology Institute) for the human CMT4 myoblasts. We also thank Dr.
907 Francesco P. Marchese from the Genomics Unit Platform at University of Navarra & Centre for 907 Francesco P. Marchese from the Genomics Unit Platform at University of Navarra & Centre for
908 Applied Medical Research (CIMA) for expertise and assistance in NGS. We want to dedicate 908 Applied Medical Research (CIMA) for expertise and assistance in NGS. We want to dedicate
909 this work specially to all ALS patients and their families. this work specially to all ALS patients and their families.

⁹¹⁰**FUNDING**

911 This research was supported by the Biodonostia Health Research Institute (Biodonostia HRI)
912 and CIBER -Consorcio Centro de Investigación Biomédica en Red- (CB06/05/1126, Group 912 and CIBER -Consorcio Centro de Investigación Biomédica en Red- (CB06/05/1126, Group
913 609), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – 913 609), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea –
914 European Regional Development Fund. This work was funded by *Instituto de Salud Carlos III* 914 European Regional Development Fund. This work was funded by *Instituto de Salud Carlos III*
915 (ISCIII) and co-funded by *the European Union* (projects P18/01066, PI19/00175, PI21/00153, 915 (ISCIII) and co-funded by *the European Union* (projects P18/01066, PI19/00175, PI21/00153,
916 PI22/00433): by *CIBERNED* (CIBER de Enfermedades Neurodegenerativas. project PI2020/08-916 PI22/00433); by *CIBERNED* (CIBER de Enfermedades Neurodegenerativas, project PI2020/08-
917 1); by the Department of Education of the Basque Country through the IKUR strategy 917 1); by the Department of Education of the Basque Country through the IKUR strategy
918 (NEURODEGENPROT); *Diputación Foral de Gipuzkoa* (projects 2020-CIEN-000057-01, 918 (NEURODEGENPROT); *Diputación Foral de Gipuzkoa* (projects 2020-CIEN-000057-01,
919 2021-CIEN-000020-01): by *EiTB Maratoia* (project BIO17/ND/023/BD): and by *Osasun Saila*. 919 2021-CIEN-000020-01); by *EiTB Maratoia* (project BIO17/ND/023/BD); and by *Osasun Saila*,

920 *Eusko Jaurlaritzako* (projects 2015111122, 2017222027, 2018111042, 2019222020, ⁹²⁰*Eusko Jaurlaritzako* (projects 2015111122, 2017222027, 2018111042, 2019222020, 921 2020111032, 2020333043, 2021333050). MZuf, OP-M, MG-A, AJ, AE, JO and UF-P were
922 supported by the Department of Education of the Basque Country (PhD fellowships 922 supported by the Department of Education of the Basque Country (PhD fellowships
923 PRE 2015 1 0023, PRE 2019 1 0339, PRE 2020 1 0122, PRE 2020 1 0191, 923 PRE_2015_1_0023, PRE_2019_1_0339, PRE_2020_1_0122, PRE_2020_1_0191, 924 PRE_2020_1_0119, PRE_2018_1_0095, PRE_2018_1_0253); MM-O by Basque Country
925 University (UPV/EHU) fellowship (PIF18/317); LB by the Spanish National Plan for Scientific 925 University (UPV/EHU) fellowship (PIF18/317); LB by the Spanish National Plan for Scientific
926 and Technical Research and Innovation -Ramon y Cajal- (RYC2018-024397-I) and 926 and Technical Research and Innovation -Ramon y Cajal- (RYC2018-024397-I) and
927 IKERBASQUE (RF/2019/001) research programs; GG by Juan de la Cierva-Incorporación 927 IKERBASQUE (RF/2019/001) research programs; GG by *Juan de la Cierva-Incorporación*
928 (ISCIII, IJC2019-039965-I) and IKERBASOUE (RF/2023/010) research programs: FG-B by 928 (ISCIII, IJC2019-039965-I) and IKERBASQUE (RF/2023/010) research programs; FG-B by
929 Roche Stop Fuga de cerebros (BIO19/ROCHE/017/BD) and IKERBASOUE (PP/2022/003) ⁹²⁹*Roche Stop Fuga de cerebros* (BIO19/ROCHE/017/BD) and IKERBASQUE (PP/2022/003) 930 research programs; and SA-M by *Gipuzkoa Fellow of Talent Attraction and Retention* (2019-
931 FELL-000010-01, 2020-FELL-000016-02-01, 2021-FELL-000013-02-01). FELL-000010-01, 2020-FELL-000016-02-01, 2021-FELL-000013-02-01).

⁹³²**Compliance with ethical standards**

933 **Conflict of interest** SD is a named inventor on patents related to neurological disorders. MZuf,
934 ALM, GG, FGB and SAM are co-inventors of patent PCT/EP2021/064274 and therefore 934 ALM, GG, FGB and SAM are co-inventors of patent PCT/EP2021/064274 and therefore
935 entitled to a share of royalties. MZuf, LB, ALM, GGL, FGB and SAM also have ownership in 935 entitled to a share of royalties. MZuf, LB, ALM, GGL, FGB and SAM also have ownership in
936 Miaker Developments S.L., which is the licensee of that patent related to the research being

Miaker Developments S.L., which is the licensee of that patent related to the research being

- 937 reported. The terms of this arrangement have been reviewed and approved by the University of
938 the Basque Country and Biogipuzkoa Health Research Institute/BIOEF (representing the
- 938 the Basque Country and Biogipuzkoa Health Research Institute/BIOEF (representing the 939 Basque public administration), as co-owners of the patent.
- Basque public administration), as co-owners of the patent.
- **Ethics approval and consent to participate** This study was approved by the Clinical Research

941 Ethics Committees of the Basque Country and Donostia University Hospital (codes: ALM-
- 941 Ethics Committees of the Basque Country and Donostia University Hospital (codes: ALM-
942 EMP-2015-01, PI2016075, PI2019198) (Spain). Written informed consent was obtained from
- ⁹⁴²EMP-2015-01*,* PI2016075, PI2019198) (Spain). Written informed consent was obtained from
- all the subjects included in the study.
- ⁹⁴⁴**Consent for publication** All authors consented to publication of this paper.

945

⁹⁴⁶**REFERENCES**

- 947 1. Balwierz PJ, Pachkov M, Arnold P, Gruber AJ, Zavolan M, Van Nimwegen E (2014)
948 **ISMARA:** automated modeling of genomic signals as a democracy of regulatory motifs. 948 ISMARA: automated modeling of genomic signals as a democracy of regulatory motifs.
949 Genome Res 24:869–884. doi: 10.1101/gr.169508.113 Genome Res 24:869–884. doi: 10.1101/gr.169508.113
- 950 2. Banerjee A, Vest KE, Pavlath GK, Corbett AH (2017) Nuclear poly(A) binding protein 1
951 (PABPN1) and Matrin3 interact in muscle cells and regulate RNA processing. Nucleic 951 (PABPN1) and Matrin3 interact in muscle cells and regulate RNA processing. Nucleic
952 Acids Res 45:10706–10725. doi: 10.1093/NAR/GKX786 ⁹⁵²Acids Res 45:10706–10725. doi: 10.1093/NAR/GKX786
- 953 3. Blasco H, Lanznaster D, Veyrat-Durebex C, Hergesheimer R, Vourch P, Maillot F,
954 Andres CR, Pradat PF, Corcia P (2020) Understanding and managing metabolic 954 Andres CR, Pradat PF, Corcia P (2020) Understanding and managing metabolic
955 dysfunction in Amyotrophic Lateral Sclerosis. Expert Rev Neurother 20:907–919. doi: 955 dysfunction in Amyotrophic Lateral Sclerosis. Expert Rev Neurother 20:907–919. doi:
956 10.1080/14737175.2020.1788389 ⁹⁵⁶10.1080/14737175.2020.1788389
- 957 4. Bois PRJ, Grosveld GC (2003) FKHR (FOXO1a) is required for myotube fusion of primary mouse myoblasts. EMBO J 22:1147–1157. doi: 10.1093/EMBOJ/CDG116 primary mouse myoblasts. EMBO J 22:1147-1157. doi: 10.1093/EMBOJ/CDG116
- 959 5. Bour BA, O'Brien MA, Lockwood WL, Goldstein ES, Bodmer R, Taghert PH, Abmayr
960 SM, Nguyen HT (1995) Drosophila MEF2, a transcription factor that is essential for 960 SM, Nguyen HT (1995) Drosophila MEF2, a transcription factor that is essential for
961 myogenesis. Genes Dev 9:730–741. doi: 10.1101/gad.9.6.730 myogenesis. Genes Dev 9:730–741. doi: 10.1101/gad.9.6.730
- 962 6. Calissi G, Lam EWF, Link W (2021) Therapeutic strategies targeting FOXO transcription
963 factors. Nat Rev Drug Discov 20:21–38. doi: 10.1038/S41573-020-0088-2 ⁹⁶³factors. Nat Rev Drug Discov 20:21–38. doi: 10.1038/S41573-020-0088-2
- 964 7. Candelise N, Caissutti D, Zenuni H, Nesci V, Scaricamazza S, Salvatori I, Spinello Z,
965 Mattei V, Garofalo T, Ferri A, Valle C, Misasi R (2023) Different Chronic Stress 965 Mattei V, Garofalo T, Ferri A, Valle C, Misasi R (2023) Different Chronic Stress
966 Paradigms Converge on Endogenous TDP43 Cleavage and Aggregation. Mol Neurobiol 966 Paradigms Converge on Endogenous TDP43 Cleavage and Aggregation. Mol Neurobiol
967 60:6346–6361. doi: 10.1007/S12035-023-03455-Z ⁹⁶⁷60:6346–6361. doi: 10.1007/S12035-023-03455-Z
- 968 8. Chang K, Ling JP, Redding-Ochoa J, An Y, Li L, Dean SA, Blanchard TG, Pylyukh T,
969 Barrett A, Irwin KE, Moghekar A, Resnick SM, Wong PC, Troncoso JC (2023) Loss of 969 Barrett A, Irwin KE, Moghekar A, Resnick SM, Wong PC, Troncoso JC (2023) Loss of
970 TDP-43 splicing repression occurs early in the aging population and is associated with 970 TDP-43 splicing repression occurs early in the aging population and is associated with
971 Alzheimer's disease neuropathologic changes and cognitive decline. Acta Neuropathol 971 Alzheimer's disease neuropathologic changes and cognitive decline. Acta Neuropathol
972 147. doi: 10.1007/S00401-023-02653-2 ⁹⁷²147. doi: 10.1007/S00401-023-02653-2
- 973 9. Chiang P-M, Ling J, Jeong YH, Price DL, Aja SM, Wong PC (2010) Deletion of TDP-43
974 down-regulates Tbc1d1, a gene linked to obesity, and alters body fat metabolism. Proc 974 down-regulates Tbc1d1, a gene linked to obesity, and alters body fat metabolism. Proc
975 Natl Acad Sci U S A 107:16320–4. doi: 10.1073/pnas.1002176107 Natl Acad Sci U S A 107:16320-4. doi: 10.1073/pnas.1002176107

-
- 976 10. Chiò A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, Traynor BG, On
977 Behalf of the Eurals Consortium (2009) Prognostic factors in ALS: A critical review. 977 Behalf of the Eurals Consortium (2009) Prognostic factors in ALS: A critical review.
978 Amyotrophic Lateral Sclerosis 10:310–323. doi: 10.3109/17482960802566824
- ⁹⁷⁸Amyotrophic Lateral Sclerosis 10:310–323. doi: 10.3109/17482960802566824
- 979 11. Danielson E, Lee SH, Fox MA (2014) SynPAnal: software for rapid quantification of the
980 density and intensity of protein puncta from fluorescence microscopy images of neurons. 980 density and intensity of protein puncta from fluorescence microscopy images of neurons.
981 PLoS One 9. doi: 10.1371/JOURNAL.PONE.0115298 ⁹⁸¹PLoS One 9. doi: 10.1371/JOURNAL.PONE.0115298
- 982 12. Dobrowolny G, Lepore E, Martini M, Barberi L, Nunn A, Scicchitano BM, Musarò A
983 (2018) Metabolic Changes Associated With Muscle Expression of SOD1G93A. Front 983 (2018) Metabolic Changes Associated With Muscle Expression of SOD1G93A. Front
984 Physiol 9:831. doi: 10.3389/fphys.2018.00831 ⁹⁸⁴Physiol 9:831. doi: 10.3389/fphys.2018.00831
- 985 13. Dobrowolny G, Martini M, Scicchitano BM, Romanello V, Boncompagni S, Nicoletti C,
986 Pietrangelo L, De Panfilis S, Catizone A, Bouchè M, Sandri M, Rudolf R, Protasi F, 986 Pietrangelo L, De Panfilis S, Catizone A, Bouchè M, Sandri M, Rudolf R, Protasi F,
987 Musarò A (2018) Muscle Expression of SOD1G93A Triggers the Dismantlement of 987 Musarò A (2018) Muscle Expression of SOD1G93A Triggers the Dismantlement of
988 Neuromuscular Junction via PKC-Theta. Antioxid Redox Signal 28:1105–1119. doi: 988 Neuromuscular Junction via PKC-Theta. Antioxid Redox Signal 28:1105–1119. doi:
989 10.1089/ars.2017.7054 ⁹⁸⁹10.1089/ars.2017.7054
- 990 14. Ervilha Pereira P, Schuermans N, Meylemans A, LeBlanc P, Versluys L, Copley KE,
991 Rubien JD. Altheimer C. Peetermans M. Debackere E. Vanakker O. Janssens S. Baets J. 991 Rubien JD, Altheimer C, Peetermans M, Debackere E, Vanakker O, Janssens S, Baets J,
992 Verhoeven K, Lammens M, Symoens S, De Paepe B, Barmada SJ, Shorter J, De Bleecker 992 Verhoeven K, Lammens M, Symoens S, De Paepe B, Barmada SJ, Shorter J, De Bleecker
993 JL, Bogaert E, Dermaut B (2023) C-terminal frameshift variant of TDP-43 with 993 JL, Bogaert E, Dermaut B (2023) C-terminal frameshift variant of TDP-43 with
994 pronounced aggregation-propensity causes rimmed vacuole myopathy but not ALS/FTD. 994 pronounced aggregation-propensity causes rimmed vacuole myopathy but not ALS/FTD.
995 Acta Neuropathol 145:793–814. doi: 10.1007/S00401-023-02565-1 Acta Neuropathol 145:793-814. doi: 10.1007/S00401-023-02565-1
- 996 15. Fortini P, Ferretti C, Iorio E, Cagnin M, Garribba L, Pietraforte D, Falchi M, Pascucci B,
997 Baccarini S, Morani F, Phadngam S, De Luca G, Isidoro C, Dogliotti E (2016) The fine 997 Baccarini S, Morani F, Phadngam S, De Luca G, Isidoro C, Dogliotti E (2016) The fine
998 tuning of metabolism, autophagy and differentiation during in vitro myogenesis. Cell 998 tuning of metabolism, autophagy and differentiation during in vitro myogenesis. Cell
999 Death Dis 7. doi: 10.1038/CDDIS.2016.50 Death Dis 7. doi: 10.1038/CDDIS.2016.50
- ¹⁰⁰⁰16. Furuyama T, Kitayama K, Yamashita H, Mori N (2003) Forkhead transcription factor 1001 FOXO1 (FKHR)-dependent induction of PDK4 gene expression in skeletal muscle during
1002 energy deprivation. Biochem J 375:365–371. doi: 10.1042/BJ20030022 energy deprivation. Biochem J 375:365-371. doi: 10.1042/BJ20030022
- 1003 17. Le Gall L, Duddy WJ, Martinat C, Mariot V, Connolly O, Milla V, Anakor E, Ouandaogo
1004 2G, Millecamps S, Lainé J, Vijayakumar UG, Knoblach S, Raoul C, Lucas O, Loeffler 1004 ZG, Millecamps S, Lainé J, Vijayakumar UG, Knoblach S, Raoul C, Lucas O, Loeffler
1005 JP, Bede P, Behin A, Blasco H, Bruneteau G, Del Mar Amador M, Devos D, Henriques 1005 JP, Bede P, Behin A, Blasco H, Bruneteau G, Del Mar Amador M, Devos D, Henriques
1006 A. Hesters A. Lacomblez L. Laforet P. Langlet T. Leblanc P. Le Forestier N. Maisonobe 1006 A, Hesters A, Lacomblez L, Laforet P, Langlet T, Leblanc P, Le Forestier N, Maisonobe
1007 T, Meininger V, Robelin L, Salachas F, Stojkovic T, Querin G, Dumonceaux J, Butler 1007 T, Meininger V, Robelin L, Salachas F, Stojkovic T, Querin G, Dumonceaux J, Butler
1008 Browne G, González De Aguilar JL, Duguez S, Pradat PF (2022) Muscle cells of ¹⁰⁰⁸Browne G, González De Aguilar JL, Duguez S, Pradat PF (2022) Muscle cells of

transgenic mice have less skeletal muscle mass, down-regulated Type I (slow twitch/red
1043 muscle) fiber genes, and impaired glycemic control. J Biol Chem 279:41114–41123, doi: 1043 muscle) fiber genes, and impaired glycemic control. J Biol Chem 279:41114–41123. doi:
1044 10.1074/JBC.M400674200 10.1074/JBC.M400674200

1045 26. Kapeli K, Pratt GA, Vu AQ, Hutt KR, Martinez FJ, Sundararaman B, Batra R, Freese P,
1046 Lambert NJ, Huelga SC, Chun SJ, Liang TY, Chang J, Donohue JP, Shiue L, Zhang J, 1046 Lambert NJ, Huelga SC, Chun SJ, Liang TY, Chang J, Donohue JP, Shiue L, Zhang J,
1047 Zhu H, Cambi F, Kasarskis E, Hoon S, Ares M, Burge CB, Ravits J, Rigo F, Yeo GW 1047 Zhu H, Cambi F, Kasarskis E, Hoon S, Ares M, Burge CB, Ravits J, Rigo F, Yeo GW
1048 (2016) Distinct and shared functions of ALS-associated proteins TDP-43. FUS and 1048 (2016) Distinct and shared functions of ALS-associated proteins TDP-43, FUS and
1049 1049 TAF15 revealed by multisystem analyses. Nat Commun 7:12143. doi: 1049 TAF15 revealed by
1050 10.1038/ncomms12143 ¹⁰⁵⁰10.1038/ncomms12143

1051 27. Kitamura T, Kitamura YI, Funahashi Y, Shawber CJ, Castrillon DH, Kollipara R,
1052 DePinho RA, Kitajewski J, Accili D (2007) A Foxo/Notch pathway controls myogenic 1052 DePinho RA, Kitajewski J, Accili D (2007) A Foxo/Notch pathway controls myogenic
1053 differentiation and fiber type specification. Journal of Clinical Investigation 117:2477– 1053 differentiation and fiber type specification. Journal of Clinical Investigation 117:2477–
1054 2485. doi: 10.1172/JCI32054 2485. doi: 10.1172/JCI32054

1055 28. Kurashige T, Morino H, Murao T, Izumi Y, Sugiura T, Kuraoka K, Kawakami H, Torii
1056 T, Maruyama H (2022) TDP-43 Accumulation Within Intramuscular Nerve Bundles of 1056 T, Maruyama H (2022) TDP-43 Accumulation Within Intramuscular Nerve Bundles of
1057 Patients With Amyotrophic Lateral Sclerosis. JAMA Neurol 79:693–701. doi: ¹⁰⁵⁷Patients With Amyotrophic Lateral Sclerosis. JAMA Neurol 79:693–701. doi: ¹⁰⁵⁸10.1001/JAMANEUROL.2022.1113

- 1059 29. Lasa-Elgarresta J, Mosqueira-Martín L, González-Imaz K, Marco-Moreno P, Gerenu G,
1060 Mamchaoui K, Mouly V, López de Munain A, Vallejo-Illarramendi A (2022) Targeting 1060 Mamchaoui K, Mouly V, López de Munain A, Vallejo-Illarramendi A (2022) Targeting
1061 the Ubiquitin-Proteasome System in Limb-Girdle Muscular Dystrophy With CAPN3 1061 the Ubiquitin-Proteasome System in Limb-Girdle Muscular Dystrophy With CAPN3
1062 Mutations. Front Cell Dev Biol 10:822563. doi: 10.3389/fcell.2022.822563 Mutations. Front Cell Dev Biol 10:822563. doi: 10.3389/fcell.2022.822563
- 1063 30. Latil M, Rocheteau P, Châtre L, Sanulli S, Mémet S, Ricchetti M, Tajbakhsh S, Chrétien
1064 F (2012) Skeletal muscle stem cells adopt a dormant cell state post mortem and retain 1064 F (2012) Skeletal muscle stem cells adopt a dormant cell state post mortem and retain
1065 regenerative capacity. Nat Commun 3. doi: 10.1038/ncomms1890 ¹⁰⁶⁵regenerative capacity. Nat Commun 3. doi: 10.1038/ncomms1890
- 1066 31. Link W, Fernandez-Marcos PJ (2017) FOXO transcription factors at the interface of
1067 metabolism and cancer. Int J Cancer 141:2379–2391. doi: 10.1002/iic.30840 ¹⁰⁶⁷metabolism and cancer. Int J Cancer 141:2379–2391. doi: 10.1002/ijc.30840
- 1068 32. Liu TY, Chen YC, Jong YJ, Tsai HJ, Lee CC, Chang YS, Chang JG, Chang YF (2017)
1069 Muscle developmental defects in heterogeneous nuclear Ribonucleoprotein A1 knockout 1069 Muscle developmental defects in heterogeneous nuclear Ribonucleoprotein A1 knockout
1070 mice. Open Biol 7. doi: 10.1098/RSOB.160303 mice. Open Biol 7. doi: 10.1098/RSOB.160303
- 1071 33. Loeffler J-P, Picchiarelli G, Dupuis L, Gonzalez De Aguilar J-L (2016) The Role of
1072 Skeletal Muscle in Amyotrophic Lateral Sclerosis. Brain Pathol 26:227–36. doi: ¹⁰⁷²Skeletal Muscle in Amyotrophic Lateral Sclerosis. Brain Pathol 26:227–36. doi: ¹⁰⁷³10.1111/bpa.12350

- 1074 34. Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion
1075 for RNA-seq data with DESeq2. Genome Biol 15. doi: 10.1186/s13059-014-0550-8 ¹⁰⁷⁵for RNA-seq data with DESeq2. Genome Biol 15. doi: 10.1186/s13059-014-0550-8
- 1076 35. Mammucari C, Milan G, Romanello V, Masiero E, Rudolf R, Del Piccolo P, Burden SJ,
1077 Di Lisi R, Sandri C, Zhao J, Goldberg AL, Schiaffino S, Sandri M (2007) FoxO3 controls 1077 Di Lisi R, Sandri C, Zhao J, Goldberg AL, Schiaffino S, Sandri M (2007) FoxO3 controls
1078 autophagy in skeletal muscle in vivo. Cell Metab 6:458–471. doi: 1078 autophagy in skeletal muscle in vivo. Cell Metab 6:458–471. doi: 1079 10.1016/J.CMET.2007.11.001
- 1080 36. Manzano R, Toivonen JM, Calvo AC, Oliván S, Zaragoza P, Rodellar C, Montarras D,
1081 0sta R (2013) Altered in vitro Proliferation of Mouse SOD1-G93A Skeletal Muscle 1081 Osta R (2013) Altered in vitro Proliferation of Mouse SOD1-G93A Skeletal Muscle
1082 Satellite Cells. Neurodegener Dis 11:153–164. doi: 10.1159/000338061 ¹⁰⁸²Satellite Cells. Neurodegener Dis 11:153–164. doi: 10.1159/000338061
- 1083 37. Martin LJ, Wong M (2020) Skeletal Muscle-Restricted Expression of Human SOD1 in
1084 Transgenic Mice Causes a Fatal ALS-Like Syndrome. Front Neurol 11:592851. doi: 1084 Transgenic Mice Causes a Fatal ALS-Like Syndrome. Front Neurol 11:592851. doi:
1085 10.3389/fneur.2020.592851 ¹⁰⁸⁵10.3389/fneur.2020.592851
- 1086 38. Masrori P, Van Damme P (2020) Amyotrophic lateral sclerosis: a clinical review. Eur J
1087 Neurol 27:1918–1929. doi: 10.1111/ene.14393 Neurol 27:1918–1929. doi: 10.1111/ene.14393
- 1088 39. McFarlane C, Plummer E, Thomas M, Hennebry A, Ashby M, Ling N, Smith H, Sharma 1089 M, Kambadur R (2006) Myostatin induces cachexia by activating the ubiquitin
1090 proteolytic system through an NF-kB-independent, FoxO1-dependent mechanism. J Cell 1090 proteolytic system through an NF-κB-independent, FoxO1-dependent mechanism. J Cell
1091 Physiol 209:501–514. doi: 10.1002/jcp.20757 ¹⁰⁹¹Physiol 209:501–514. doi: 10.1002/jcp.20757
- 1092 40. Milan G, Romanello V, Pescatore F, Armani A, Paik J-H, Frasson L, Seydel A, Zhao J,
1093 Abraham R, Goldberg AL, Blaauw B, DePinho RA, Sandri M (2015) Regulation of 1093 Abraham R, Goldberg AL, Blaauw B, DePinho RA, Sandri M (2015) Regulation of
1094 autophagy and the ubiquitin-proteasome system by the FoxO transcriptional network 1094 autophagy and the ubiquitin-proteasome system by the FoxO transcriptional network
1095 during muscle atrophy. Nat Commun 6:6670. doi: 10.1038/ncomms7670 during muscle atrophy. Nat Commun 6:6670. doi: 10.1038/ncomms7670
- 1096 41. Moloney EB, de Winter F, Verhaagen J (2014) ALS as a distal axonopathy: Molecular
1097 mechanisms affecting neuromuscular junction stability in the presymptomatic stages of 1097 mechanisms affecting neuromuscular junction stability in the presymptomatic stages of
1098 the disease. Front Neurosci 8. doi: 10.3389/fnins.2014.00252 ¹⁰⁹⁸the disease. Front Neurosci 8. doi: 10.3389/fnins.2014.00252
- ¹⁰⁹⁹42. Mori F, Tada M, Kon T, Miki Y, Tanji K, Kurotaki H, Tomiyama M, Ishihara T, Onodera 1100 C, Kakita A, Wakabayashi K (2019) Phosphorylated TDP-43 aggregates in skeletal and
1101 cardiac muscle are a marker of myogenic degeneration in amyotrophic lateral sclerosis 1101 cardiac muscle are a marker of myogenic degeneration in amyotrophic lateral sclerosis
1102 and various conditions. Acta Neuropathol Commun 7. doi: 10.1186/s40478-019-0824-1 ¹¹⁰²and various conditions. Acta Neuropathol Commun 7. doi: 10.1186/s40478-019-0824-1
- 1103 43. Nagashima T, Shigematsu N, Maruki R, Urano Y, Tanaka H, Shimaya A, Shimokawa T,
1104 Shibasaki M (2010) Discovery of novel Foxo1 inhibitors for treating type 2 diabetes: Shibasaki M (2010) Discovery of novel Foxo1 inhibitors for treating type 2 diabetes:

1105 Improvement of fasting glycemia in diabetic db/db mice. Molecular Pharmacology Fast
1106 Forward Published on August 24. doi: 10.1124/mol.110.065714 ¹¹⁰⁶Forward Published on August 24. doi: 10.1124/mol.110.065714

- 1107 44. Nakashima K, Yakabe Y (2007) AMPK activation stimulates myofibrillar protein
1108 degradation and expression of atrophy-related ubiquitin ligases by increasing FOXO 1108 degradation and expression of atrophy-related ubiquitin ligases by increasing FOXO
1109 transcription factors in C2C12 myotubes. Biosci Biotechnol Biochem 71:1650–1656. doi: 1109 transcription factors in C2C12 myotubes. Biosci Biotechnol Biochem 71:1650–1656. doi:
1110 10.1271/BBB.70057 ¹¹¹⁰10.1271/BBB.70057
- 1111 45. Nath SR, Lieberman ML, Yu Z, Marchioretti C, Jones ST, Danby ECE, Van Pelt KM,
1112 Sorarù G, Robins DM, Bates GP, Pennuto M, Lieberman AP (2020) MEF2 impairment 1112 Sorarù G, Robins DM, Bates GP, Pennuto M, Lieberman AP (2020) MEF2 impairment
1113 underlies skeletal muscle atrophy in polyglutamine disease. Acta Neuropathol 140:63–80. 1113 underlies skeletal muscle atrophy in polyglutamine disease. Acta Neuropathol 140:63–80.
1114 doi: 10.1007/S00401-020-02156-4 doi: 10.1007/S00401-020-02156-4
- 1115 46. Nishiyama T, Kii I, Kudo A (2004) Inactivation of Rho/ROCK signaling is crucial for the
1116 huclear accumulation of FKHR and myoblast fusion. J Biol Chem 279:47311-47319. doi: 1116 nuclear accumulation of FKHR and myoblast fusion. J Biol Chem 279:47311–47319. doi:
1117 10.1074/JBC.M403546200 ¹¹¹⁷10.1074/JBC.M403546200
- 1118 47. Olguín HC, Pisconti A (2012) Marking the tempo for myogenesis: Pax7 and the regulation of muscle stem cell fate decisions. J Cell Mol Med 16:1013-1025. doi: 1119 regulation of muscle stem cell fate decisions. J Cell Mol Med 16:1013–1025. doi:
1120 10.1111/j.1582-4934.2011.01348.x ¹¹²⁰10.1111/j.1582-4934.2011.01348.x
- 1121 48. Orea-Soufi A, Paik J, Bragança J, Donlon TA, Willcox BJ, Link W (2022) FOXO
1122 transcription factors as therapeutic targets in human diseases. Trends Pharmacol Sci transcription factors as therapeutic targets in human diseases. Trends Pharmacol Sci
1123 13:1070–1084. doi: 10.1016/j.tips.2022.09.010 ¹¹²³43:1070–1084. doi: 10.1016/j.tips.2022.09.010
- 1124 49. Oyabu M, Takigawa K, Mizutani S, Hatazawa Y, Fujita M, Ohira Y, Sugimoto T, Suzuki
1125 O. Tsuchiva K. Suganami T. Ogawa Y. Ishihara K. Miura S. Kamei Y (2022) FOXO1 1125 0, Tsuchiya K, Suganami T, Ogawa Y, Ishihara K, Miura S, Kamei Y (2022) FOXO1
1126 cooperates with C/EBPδ and ATF4 to regulate skeletal muscle atrophy transcriptional 1126 cooperates with C/EBPδ and ATF4 to regulate skeletal muscle atrophy transcriptional
1127 program during fasting. FASEB J 36. doi: 10.1096/FJ.202101385RR program during fasting. FASEB J 36. doi: 10.1096/FJ.202101385RR
- 1128 50. Pala F, Di Girolamo D, Mella S, Yennek S, Chatre L, Ricchetti M, Tajbakhsh S (2018)
1129 Distinct metabolic states govern skeletal muscle stem cell fates during prenatal and 1129 Distinct metabolic states govern skeletal muscle stem cell fates during prenatal and
1130 oostnatal myogenesis. J Cell Sci 131. doi: 10.1242/JCS.212977 postnatal myogenesis. J Cell Sci 131. doi: 10.1242/JCS.212977
- ¹¹³¹51. Palamiuc L, Schlagowski A, Ngo ST, Vernay A, Dirrig-Grosch S, Henriques A, 1132 Boutillier A-L, Zoll J, Echaniz-Laguna A, Loeffler J-P, René F (2015) A metabolic
1133 switch toward lipid use in glycolytic muscle is an early pathologic event in a mouse 1133 switch toward lipid use in glycolytic muscle is an early pathologic event in a mouse
1134 model of amvotrophic lateral sclerosis. EMBO Mol Med 7:526–46. doi: 1134 model of amyotrophic lateral sclerosis. EMBO Mol Med 7:526–46. doi:
1135 10.15252/emmm.201404433 ¹¹³⁵10.15252/emmm.201404433

1136 52. Pandya VA, Patani R (2020) Decoding the relationship between ageing and amyotrophic
1137 lateral sclerosis: a cellular perspective. Brain 143:1057–1072. doi: 1137 lateral sclerosis: a cellular perspective. Brain 143:1057–1072. doi: 1138 10.1093/BRAIN/AWZ360

- 1139 53. Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C (2017) Salmon provides fast and
1140 bias-aware quantification of transcript expression. Nat Methods 14:417–419. doi: 1140 bias-aware quantification of transcript expression. Nat Methods 14:417–419. doi:
1141 10.1038/nmeth.4197 ¹¹⁴¹10.1038/nmeth.4197
- ¹¹⁴²54. Pietrangelo T, Demontis R, Santangelo C, Pini N, Bonelli M, Rosato E, Roberti P, 1143 Locatelli M, Tartaglia A, Marramiero L, Verratti V, Bondi D, Fulle S, D'Aloja E,
1144 D'Ovidio C (2022) New Perspectives for Postmortem Human Satellite Cells of Different 1144 D'Ovidio C (2022) New Perspectives for Postmortem Human Satellite Cells of Different
1145 Embryological Origin. Front Physiol 13. doi: 10.3389/FPHYS.2022.886149 Embryological Origin. Front Physiol 13. doi: 10.3389/FPHYS.2022.886149
- 1146 55. Pikatza-Menoio O, Elicegui A, Bengoetxea X, Naldaiz-Gastesi N, López de Munain A,
1147 Gerenu G, Gil-Bea FJ, Alonso-Martín S (2021) The Skeletal Muscle Emerges as a New 1147 Gerenu G, Gil-Bea FJ, Alonso-Martín S (2021) The Skeletal Muscle Emerges as a New
1148 Disease Target in Amvotrophic Lateral Sclerosis. J Pers Med 11:671. doi: 1148 Disease Target in Amyotrophic Lateral Sclerosis. J Pers Med 11:671. doi:
1149 10.3390/JPM11070671 ¹¹⁴⁹10.3390/JPM11070671
- 1150 56. Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, Ling SC,
1151 Sun E, Wancewicz E, Mazur C, Kordasiewicz H, Sedaghat Y, Donohue JP, Shiue L, 1151 Sun E, Wancewicz E, Mazur C, Kordasiewicz H, Sedaghat Y, Donohue JP, Shiue L,
1152 Bennett CF, Yeo GW, Cleveland DW (2011) Long pre-mRNA depletion and RNA 1152 Bennett CF, Yeo GW, Cleveland DW (2011) Long pre-mRNA depletion and RNA
1153 missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci 1153 missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci
1154 14:459–468. doi: 10.1038/NN.2779 ¹¹⁵⁴14:459–468. doi: 10.1038/NN.2779
- 1155 57. Pradat P-F, Barani A, Wanschitz J, Dubourg O, Lombès A, Bigot A, Mouly V, Bruneteau
1156 G, Salachas F, Lenglet T, Meininger V, Butler-Browne G (2011) Abnormalities of 1156 G, Salachas F, Lenglet T, Meininger V, Butler-Browne G (2011) Abnormalities of
1157 satellite cells function in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis 1157 satellite cells function in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis
1158 12:264–271. doi: 10.3109/17482968.2011.566618 ¹¹⁵⁸12:264–271. doi: 10.3109/17482968.2011.566618
- 1159 58. Puthanveetil P, Wang Y, Wang F, Kim MS, Abrahani A, Rodrigues B (2010) The
1160 increase in cardiac pyruvate dehydrogenase kinase-4 after short-term dexamethasone is 1160 increase in cardiac pyruvate dehydrogenase kinase-4 after short-term dexamethasone is
1161 controlled by an Akt-p38-forkhead box other factor-1 signaling axis. Endocrinology 1161 controlled by an Akt-p38-forkhead box other factor-1 signaling axis. Endocrinology
1162 151:2306–18. doi: 10.1210/en.2009-1072 ¹¹⁶²151:2306–18. doi: 10.1210/en.2009-1072
- 1163 59. Relaix F, Zammit PS (2012) Satellite cells are essential for skeletal muscle regeneration:
1164 the cell on the edge returns centre stage. Development 139:2845–2856. doi: 1164 the cell on the edge returns centre stage. Development 139:2845–2856. doi:
1165 10.1242/dev.069088 10.1242/dev.069088
- 1166 60. REYNOLDS ES (1963) The use of lead citrate at high pH as an electron-opaque stain in
1167 electron microscopy. J Cell Biol 17:208–212. doi: 10.1083/JCB.17.1.208 ¹¹⁶⁷electron microscopy. J Cell Biol 17:208–212. doi: 10.1083/JCB.17.1.208

- 1172 62. Rico A, Valls A, Guembelzu G, Azpitarte M, Aiastui A, Zufiria M, Jaka O, López de
1173 Munain A, Sáenz A (2023) Altered expression of proteins involved in metabolism in 1173 Munain A, Sáenz A (2023) Altered expression of proteins involved in metabolism in
1174 LGMDR1 muscle is lost in cell culture conditions. Orphanet J Rare Dis 18, doi: 1174 LGMDR1 muscle is lost in cell culture conditions. Orphanet J Rare Dis 18. doi:
1175 10.1186/S13023-023-02873-5 ¹¹⁷⁵10.1186/S13023-023-02873-5
- 1176 63. Rion N, Castets P, Lin S, Enderle L, Reinhard JR, Eickhorst C, Ruegg MA (2019) mTOR
1177 controls embryonic and adult myogenesis via mTORC1. Development 146. doi: 1177 controls embryonic and adult myogenesis via mTORC1. Development 146. doi:
1178 10.1242/DEV.172460 ¹¹⁷⁸10.1242/DEV.172460
- 1179 64. Rossor AM, Sleigh JN, Groves M, Muntoni F, Reilly MM, Hoogenraad CC, Schiavo G
1180 (2020) Loss of BICD2 in muscle drives motor neuron loss in a developmental form of 1180 (2020) Loss of BICD2 in muscle drives motor neuron loss in a developmental form of
1181 spinal muscular atrophy. Acta Neuropathol Commun 8. doi: 10.1186/S40478-020-00909spinal muscular atrophy. Acta Neuropathol Commun 8. doi: 10.1186/S40478-020-00909-6 ¹¹⁸²⁶
- 1183 65. Sambasivan R, Yao R, Kissenpfennig A, van Wittenberghe L, Paldi A, Gayraud-Morel B,
1184 Guenou H, Malissen B, Tajbakhsh S, Galy A (2011) Pax7-expressing satellite cells are 1184 Guenou H, Malissen B, Tajbakhsh S, Galy A (2011) Pax7-expressing satellite cells are
1185 indispensable for adult skeletal muscle regeneration. Development 138:3647–3656. doi: 1185 indispensable for adult skeletal muscle regeneration. Development 138:3647–3656. doi:
1186 10.1242/DEV.067587 ¹¹⁸⁶10.1242/DEV.067587
- 1187 66. Sanchez AMJ, Candau RB, Bernardi H (2014) FoxO transcription factors: their roles in
1188 the maintenance of skeletal muscle homeostasis. Cell Mol Life Sci 71:1657–1671. doi: 1188 the maintenance of skeletal muscle homeostasis. Cell Mol Life Sci 71:1657–1671. doi:
1189 10.1007/S00018-013-1513-Z ¹¹⁸⁹10.1007/S00018-013-1513-Z
- ¹¹⁹⁰67. Sandri M, Lin J, Handschin C, Yang W, Arany ZP, Lecker SH, Goldberg AL, 1191 Spiegelman BM (2006) PGC-1alpha protects skeletal muscle from atrophy by
1192 suppressing FoxO3 action and atrophy-specific gene-transcription. Proc Natl Acad Sci U 1192 suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci U
1193 S A 103:16260–16265. doi: 10.1073/PNAS.0607795103 S A 103:16260-16265. doi: 10.1073/PNAS.0607795103
- 1194 68. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S,
1195 Lecker SH, Goldberg AL (2004) Foxo transcription factors induce the atrophy-related 1195 Lecker SH, Goldberg AL (2004) Foxo transcription factors induce the atrophy-related
1196 ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117:399–412. doi: 1196 ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117:399–412. doi:
1197 10.1016/S0092-8674(04)00400-3 ¹¹⁹⁷10.1016/S0092-8674(04)00400-3
- 119869. Scaramozza A, Marchese V, Papa V, Salaroli R, Sorarù G, Angelini C, Cenacchi G
1199 (2014) Skeletal Muscle Satellite Cells in Amvotrophic Lateral Sclerosis. Ultrastruct 1199 (2014) Skeletal Muscle Satellite Cells in Amyotrophic Lateral Sclerosis. Ultrastruct
1200 Pathol 38:295–302. doi: 10.3109/01913123.2014.937842 Pathol 38:295-302. doi: 10.3109/01913123.2014.937842

1201 70. Scaricamazza S, Salvatori I, Ferri A, Valle C (2021) Skeletal muscle in als: An unappreciated therapeutic opportunity? Cells 10:1–24. doi: 10.3390/cells10030525 ¹²⁰²unappreciated therapeutic opportunity? Cells 10:1–24. doi: 10.3390/cells10030525

1203 71. Schiaffino S, Dyar KA, Calabria E (2018) Skeletal muscle mass is controlled by the
1204 MRF4-MEF2 axis. Curr Opin Clin Nutr Metab Care 21:164–167. doi: 1204 MRF4-MEF2 axis. Curr Opin Clin Nutr Metab Care 21:164–167. doi:
1205 10.1097/MCO.000000000000456 ¹²⁰⁵10.1097/MCO.0000000000000456

1206 72. Shi XC, Xia B, Zhang JF, Zhang RX, Zhang DY, Liu H, Xie BC, Wang YL, Wu JW
1207 (2022) Optineurin promotes myogenesis during muscle regeneration in mice by 1207 (2022) Optineurin promotes myogenesis during muscle regeneration in mice by
1208 autophagic degradation of GSK3ß. PLoS Biol 20. doi: 1208 autophagic degradation of GSK3β. PLoS Biol 20. doi: ¹²⁰⁹10.1371/JOURNAL.PBIO.3001619

¹²¹⁰73. Soneson C, Love MI, Robinson MD (2016) Differential analyses for RNA-seq: 1211 Transcript-level estimates improve gene-level inferences. F1000Res 4. doi:
1212 10.12688/F1000RESEARCH.7563.2/DOI ¹²¹²10.12688/F1000RESEARCH.7563.2/DOI

1213 74. Soulez M, Tanguay PL, Florence D, Dort J, Crist C, Kotlyarov A, Gaestel M, Ferron M,
1214 Dumont NA, Meloche S (2022) ERK3-MK5 signaling regulates myogenic differentiation 1214 Dumont NA, Meloche S (2022) ERK3-MK5 signaling regulates myogenic differentiation
1215 and muscle regeneration by promoting FoxO3 degradation. J Cell Physiol 237:2271– 1215 and muscle regeneration by promoting FoxO3 degradation. J Cell Physiol 237:2271–
1216 2287. doi: 10.1002/JCP.30695 2287. doi: 10.1002/JCP.30695

1217 75. Stallings NR, Puttaparthi K, Dowling KJ, Luther CM, Burns DK, Davis K, Elliott JL
1218 (2013) TDP-43, an ALS linked protein, regulates fat deposition and glucose homeostasis. 1218 (2013) TDP-43, an ALS linked protein, regulates fat deposition and glucose homeostasis.
1219 PLoS One 8:e71793. doi: 10.1371/journal.pone.0071793 ¹²¹⁹PLoS One 8:e71793. doi: 10.1371/journal.pone.0071793

1220 76. Strah N, Romano G, Introna C, Klima R, Marzullo M, Ciapponi L, Megighian A,
1221 Nizzardo M. Feiguin F (2020) TDP-43 promotes the formation of neuromuscular 1221 Nizzardo M, Feiguin F (2020) TDP-43 promotes the formation of neuromuscular
1222 synapses through the regulation of Disc-large expression in Drosophila skeletal muscles. 1222 synapses through the regulation of Disc-large expression in Drosophila skeletal muscles.
1223 BMC Biol 18. doi: 10.1186/S12915-020-00767-7 ¹²²³BMC Biol 18. doi: 10.1186/S12915-020-00767-7

1224 77. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich
1225 A, Pomerov SL, Golub TR, Lander ES, Mesirov JP (2005) Gene set enrichment analysis: 1225 A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP (2005) Gene set enrichment analysis:
1226 A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl 1226 A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl
1227 Acad Sci U S A 102:15545–15550. doi: 10.1073/pnas.0506580102 Acad Sci U S A 102:15545-15550. doi: 10.1073/pnas.0506580102

1228 78. Taylor AA, Fournier C, Polak M, Wang L, Zach N, Keymer M, Glass JD, Ennist DL,
1229 Pooled Resource Open□Access ALS Clinical Trials Consortium (2016) Predicting 1229 Pooled Resource Open□Access ALS Clinical Trials Consortium (2016) Predicting
1230 disease progression in amvotrophic lateral sclerosis. Ann Clin Transl Neurol 3:866–875. 1230 disease progression in amyotrophic lateral sclerosis. Ann Clin Transl Neurol 3:866–875.
1231 doi: 10.1002/acn3.348 ¹²³¹doi: 10.1002/acn3.348

1232 79. Tixier V, Bataille L, Etard C, Jagla T, Weger M, DaPonte JP, Strahle U, Dickmeis T,
1233 Jagla K (2013) Glycolysis supports embryonic muscle growth by promoting myoblast 1233 Jagla K (2013) Glycolysis supports embryonic muscle growth by promoting myoblast
1234 fusion. Proceedings of the National Academy of Sciences 110:18982–18987, doi: 1234 fusion. Proceedings of the National Academy of Sciences 110:18982–18987. doi:
1235 10.1073/pnas.1301262110 ¹²³⁵10.1073/pnas.1301262110

- 1236 80. Tokutake Y, Yamada K, Ohata M, Obayashi Y, Tsuchiya M, Yonekura S (2015) ALS-
1237 Linked P56S-VAPB Mutation Impairs the Formation of Multinuclear Myotube in C2C12 1237 Linked P56S-VAPB Mutation Impairs the Formation of Multinuclear Myotube in C2C12
1238 Cells. Int J Mol Sci 16:18628–18641. doi: 10.3390/iims160818628 ¹²³⁸Cells. Int J Mol Sci 16:18628–18641. doi: 10.3390/ijms160818628
- ¹²³⁹81. Vogler TO, Wheeler JR, Nguyen ED, Hughes MP, Britson KA, Lester E, Rao B, Betta 1240 ND, Whitney ON, Ewachiw TE, Gomes E, Shorter J, Lloyd TE, Eisenberg DS, Taylor JP,
1241 Johnson AM, Olwin BB, Parker R (2018) TDP-43 and RNA form amyloid-like myo-1241 Johnson AM, Olwin BB, Parker R (2018) TDP-43 and RNA form amyloid-like myogranules in regenerating muscle. Nature 563:508–513. doi: 10.1038/s41586-018-0665-2 ¹²⁴²granules in regenerating muscle. Nature 563:508–513. doi: 10.1038/s41586-018-0665-2
- 1243 82. Wang JW, Brent JR, Tomlinson A, Shneider NA, McCabe BD (2011) The ALS-
1244 associated proteins FUS and TDP-43 function together to affect Drosophila locomotion 1244 associated proteins FUS and TDP-43 function together to affect Drosophila locomotion
1245 and life span. J Clin Invest 121:4118–4126. doi: 10.1172/JCI57883 and life span. J Clin Invest 121:4118-4126. doi: 10.1172/JCI57883
- ¹²⁴⁶83. Wheeler JR, Whitney ON, Vogler TO, Nguyen ED, Pawlikowski B, Lester E, Cutler A, 1247 Elston T, Betta ND, Parker KR, Yost KE, Voge H, Rando TA, Chang HY, Johnson AM,
1248 Parker R, Olwin BB (2022) RNA-binding proteins direct myogenic cell fate decisions. 1248 Parker R, Olwin BB (2022) RNA-binding proteins direct myogenic cell fate decisions.
1249 Elife 11. doi: 10.7554/ELIFE.75844 Elife 11. doi: 10.7554/ELIFE.75844
- 1250 84. Wong M, Martin LJ (2010) Skeletal muscle-restricted expression of human SOD1 causes
1251 motor neuron degeneration in transgenic mice. Hum Mol Genet 19:2284–2302. doi: 1251 motor neuron degeneration in transgenic mice. Hum Mol Genet 19:2284–2302. doi:
1252 10.1093/hmg/ddq106 ¹²⁵²10.1093/hmg/ddq106
- 1253 85. Xu M, Chen X, Chen D, Yu B, Huang Z (2017) FoxO1: A novel insight into its
1254 molecular mechanisms in the regulation of skeletal muscle differentiation and fiber type 1254 molecular mechanisms in the regulation of skeletal muscle differentiation and fiber type
1255 specification. Oncotarget 8:10662–10674 specification. Oncotarget 8:10662-10674
- 1256 86. Yang ZJP, Kenzelmann Broz D, Noderer WL, Ferreira JP, Overton KW, Spencer SL,
1257 Mever T. Tanscott SJ. Attardi LD. Wang CL (2015) p53 suppresses muscle 1257 Meyer T, Tapscott SJ, Attardi LD, Wang CL (2015) p53 suppresses muscle
1258 differentiation at the myogenin step in response to genotoxic stress. Cell Death Differ 1258 differentiation at the myogenin step in response to genotoxic stress. Cell Death Differ
1259 22:560–573. doi: 10.1038/CDD.2014.189 ¹²⁵⁹22:560–573. doi: 10.1038/CDD.2014.189
- 1260 87. Yucel N, Wang YX, Mai T, Porpiglia E, Lund PJ, Markov G, Garcia BA, Bendall SC,
1261 Angelo M. Blau HM (2019) Glucose Metabolism Drives Histone Acetylation Landscape 1261 Angelo M, Blau HM (2019) Glucose Metabolism Drives Histone Acetylation Landscape
1262 Transitions that Dictate Muscle Stem Cell Function. Cell Rep 27:3939-3955.e6. doi: 1262 Transitions that Dictate Muscle Stem Cell Function. Cell Rep 27:3939-3955.e6. doi:
1263 10.1016/j.celrep.2019.05.092 ¹²⁶³10.1016/j.celrep.2019.05.092

1264 88. Zhang T, Baldie G, Periz G, Wang J (2014) RNA-Processing Protein TDP-43 Regulates
1265 FOXO-Dependent Protein Quality Control in Stress Response. PLoS Genet 10:e1004693. 1265 FOXO-Dependent Protein Quality Control in Stress Response. PLoS Genet 10:e1004693.
1266 doi: 10.1371/journal.pgen.1004693 ¹²⁶⁶doi: 10.1371/journal.pgen.1004693

- 1267 89. Zhao J, Brault JJ, Schild A, Goldberg AL (2008) Coordinate activation of autophagy and
1268 the proteasome pathway by FoxO transcription factor. Autophagy 4:378–380. doi: 1268 the proteasome pathway by FoxO transcription factor. Autophagy 4:378–380. doi:
1269 10.4161/AUTO.5633 ¹²⁶⁹10.4161/AUTO.5633
- 1270 90. Zibold J, Lessard LER, Picard F, da Silva LG, Zadorozhna Y, Streichenberger N, Belotti
1271 E, Osseni A, Emerit A, Errazuriz-Cerda E, Michel-Calemard L, Menassa R, Coudert L, ¹²⁷¹E, Osseni A, Emerit A, Errazuriz-Cerda E, Michel-Calemard L, Menassa R, Coudert L, 1272 Wiessner M, Stucka R, Klopstock T, Simonetti F, Hutten S, Nonaka T, Hasegawa M,
1273 Strom TM, Bernard E, Ollagnon E, Urtizberea A, Dormann D, Petiot P, Schaeffer L, 1273 Strom TM, Bernard E, Ollagnon E, Urtizberea A, Dormann D, Petiot P, Schaeffer L,
1274 Senderek J, Leblanc P (2024) The new missense G376V-TDP-43 variant induces late-1274 Senderek J, Leblanc P (2024) The new missense G376V-TDP-43 variant induces late-
1275 onset distal myopathy but not amyotrophic lateral sclerosis. Brain 147. doi: 1275 onset distal myopathy but not amyotrophic lateral sclerosis. Brain 147. doi:
1276 10.1093/BRAIN/AWAD410 ¹²⁷⁶10.1093/BRAIN/AWAD410
- 1277 91. Zufiría M, Gil-Bea FJ, Fernández-Torrón R, Poza JJ, Muñoz-Blanco JL, Rojas-García R,
1278 Riancho J, de Munain AL (2016) ALS: A bucket of genes, environment, metabolism and 1278 Riancho J, de Munain AL (2016) ALS: A bucket of genes, environment, metabolism and
1279 unknown ingredients. Prog Neurobiol 142. doi: 10.1016/j.pneurobio.2016.05.004 unknown ingredients. Prog Neurobiol 142. doi: 10.1016/j.pneurobio.2016.05.004

¹²⁸¹**FIGURE LEGENDS**

¹²⁸²**Figure 1. Pathological and functional abnormalities of primary myoblasts from ALS** 1283 **patients. a** Representative images of primary myoblasts from ALS patients, both familial (fALS) and sporadic ALS (sALS) and healthy controls (CTRL) stained for Myosin Heavy 1284 (fALS) and sporadic ALS (sALS) and healthy controls (CTRL) stained for Myosin Heavy
1285 Chain (MvHC, green) and DAPI (nuclei, blue), **b** Quantitative scatter plots with bar graphs 1285 Chain (MyHC, green) and DAPI (nuclei, blue). **b** Quantitative scatter plots with bar graphs showing fusion and differentiation indices of each individual's cells from at least $n=3$ 1286 showing fusion and differentiation indices of each individual's cells from at least $n=3$
1287 independent differentiation assays. The inner plots depict the comparison of the average values 1287 independent differentiation assays. The inner plots depict the comparison of the average values
1288 of each ALS patient group (fALS and sALS) with the average values of the CTRL group. c The 1288 of each ALS patient group (fALS and sALS) with the average values of the CTRL group. **c** The correlation plot shows a negative association between age and the differentiation index in CTRL 1289 correlation plot shows a negative association between age and the differentiation index in CTRL
1290 myoblasts ($r = -0.61$, $p = 0.059$), indicating that as age increases, the differentiation index tends 1290 myoblasts (r = -0.61, p = 0.059), indicating that as age increases, the differentiation index tends
1291 to decrease. In contrast, there is no significant association in ALS myoblasts (r = -0.33, p = 1291 to decrease. In contrast, there is no significant association in ALS myoblasts ($r = -0.33$, $p = 1292$ 0.214). When the outlier value (fALS 2), identified by Grubb's test, is removed, the correlation 1292 0.214). When the outlier value (fALS_2), identified by Grubb's test, is removed, the correlation
1293 in ALS* myoblasts becomes $r = 0$ ($p = 0.520$), suggesting no relationship between age and 1293 in ALS* myoblasts becomes $r = 0$ ($p = 0.520$), suggesting no relationship between age and differentiation index. Bar graphs represent mean \pm SEM. *p<0.05 compared to the CTRL group 1294 differentiation index. Bar graphs represent mean \pm SEM. $*p$ <0.05 compared to the CTRL group
1295 via Mann-Whitney *U* test. Scale bar: 100 μ m. **d** Representative Western blot images of TDP-43 1295 via Mann-Whitney *U* test. Scale bar: 100 μm. **d** Representative Western blot images of TDP-43
1296 and FUS proteins in CTRL and ALS proliferative myoblasts, and scatter dot-plots with bar 1296 and FUS proteins in CTRL and ALS proliferative myoblasts, and scatter dot-plots with bar
1297 graphs showing the quantification of protein levels. $n=3$ per group. $\frac{k}{2}$ pc0.05 compared to the 1297 graphs showing the quantification of protein levels. n=3 per group. $*p<0.05$ compared to the 1298 CTRL group via Mann-Whitney U test. CTRL group via Mann-Whitney *U* test.

Figure 2. Functional consequences of TDP-43 or FUS silencing in the immortalised human
1300 **control myoblasts. a** Schematic diagram of the myogenic process showing the different phases 1300 **control myoblasts. a** Schematic diagram of the myogenic process showing the different phases
1301 under study, as well as the interventions and measures performed. **b** Representative Western 1301 under study, as well as the interventions and measures performed. **b** Representative Western
1302 blot images of TDP-43. FUS, MYOD1 and MYOG in shTDP-43 or shFUS-silenced myoblasts 1302 blot images of TDP-43, FUS, MYOD1 and MYOG in shTDP-43 or shFUS-silenced myoblasts
1303 at 100% confluence (Mb 100%) and at 3 days after fusion (D3), and scatter dot-plots with bar 1303 at 100% confluence (Mb 100%) and at 3 days after fusion (D3), and scatter dot-plots with bar
1304 graphs showing the quantification of protein levels. $n=3-6$ transductions per group. **c** 1304 graphs showing the quantification of protein levels. n=3-6 transductions per group. **c**
1305 Representative images of human immortalised myoblasts stained for MyHC (Myosin heavy 1305 Representative images of human immortalised myoblasts stained for MyHC (Myosin heavy
1306 chain, green) and DAPI (nuclei, blue), and quantitative scatter plots with bar graphs showing 1306 chain, green) and DAPI (nuclei, blue), and quantitative scatter plots with bar graphs showing
1307 fusion and differentiation indices. Immunofluorescence was performed 8 days (D8) after the 1307 fusion and differentiation indices. Immunofluorescence was performed 8 days (D8) after the 1308 first fusion events of shRNA cells. Scale bar: $100 \mu m$. $n=6-11$ images per group. **d** Proliferation first fusion events of shRNA cells. Scale bar: $100 \mu m$. n=6-11 images per group. **d** Proliferation
1309 curve measured as the fold-change in the number of DAPI-positive nuclei at days 1, 3 and 5 1309 curve measured as the fold-change in the number of DAPI-positive nuclei at days 1, 3 and 5
1310 after cell seeding. $n=4-5$ images per group. **e** Representative Western blot images of Atrogin-1 1310 after cell seeding. n= 4-5 images per group. **e** Representative Western blot images of Atrogin-1
1311 and MURF1 in TDP-43- or shFUS-silenced myoblasts at Mb 100%, and scatter plots with bar 1311 and MURF1 in TDP-43- or shFUS-silenced myoblasts at Mb 100%, and scatter plots with bar
1312 graphs showing the quantification of protein levels. n=3 infections per group. Bar graphs 1312 graphs showing the quantification of protein levels. n=3 infections per group. Bar graphs
1313 represent mean \pm SEM. *p<0.05; **p<0.01 compared to the shRNA group via one-way 1313 represent mean \pm SEM. **p*<0.05; ***p*<0.01 compared to the shRNA group via one-way 1314 ANOVA. a.u., arbitrary units. ANOVA. a.u., arbitrary units.

¹³¹⁵**Figure 3. Metabolic alterations of TDP-43 or FUS silencing in the immortalised human** 1316 **control myoblasts. a** Schematic diagram of the myogenic process illustrating the different
1317 phases under study, as well as the intervention point for glycolysis repression and the measures 1317 phases under study, as well as the intervention point for glycolysis repression and the measures
1318 performed throughout the experiment. **b** Representative images of myogenic differentiation 1318 performed throughout the experiment. **b** Representative images of myogenic differentiation
1319 following 2-deoxyglucose (2-DG) treatment at day 3 after fusion (D3). Myoblasts were stained 1319 following 2-deoxyglucose (2-DG) treatment at day 3 after fusion (D3). Myoblasts were stained
1320 for Myosin Heavy Chain (MyHC, green) and DAPI (nuclei, blue). Scale bar: 100 um, c MYOG for Myosin Heavy Chain (MyHC, green) and DAPI (nuclei, blue). Scale bar: 100 μm. **c** MYOG
1321 protein expression after 2-DG treatment at 100% confluence (Mb 100%). Representative images 1321 protein expression after 2-DG treatment at 100% confluence (Mb 100%). Representative images
1322 of myoblasts stained for MYOG (red) and DAPI (blue). Scatter plots with bar graphs quantify 1322 of myoblasts stained for MYOG (red) and DAPI (blue). Scatter plots with bar graphs quantify
1323 the percentage of MYOG-positive nuclei. ImageJ software ($v2.9$) was used to quantify the 1323 the percentage of MYOG-positive nuclei. ImageJ software $(v2.9)$ was used to quantify the 1324 images, with DAPI staining defining the nuclear boundaries. A nucleus was considered positive 1324 images, with DAPI staining defining the nuclear boundaries. A nucleus was considered positive
1325 for MYOG if its staining intensity was greater than the mean $+1*SD$ of the control (CTRL) 1325 for MYOG if its staining intensity was greater than the mean $+1*SD$ of the control (CTRL)
1326 values. n = 6-7 images per group. Scale bar: 100 µm. **d** MYOD protein expression after 2-DG 1326 values. n = 6-7 images per group. Scale bar: 100 μm. **d** MYOD protein expression after 2-DG
1327 treatment at Mb 100%. Representative images of myoblasts stained for MYOD (red) and DAPI 1327 treatment at Mb 100%. Representative images of myoblasts stained for MYOD (red) and DAPI
1328 (blue). $n = 6-7$ images per group. Scale bar: 100 μ m. e Representative Western blot images of ¹³²⁸(blue). n = 6-7 images per group. Scale bar: 100 μm. **e** Representative Western blot images of 1329 MYOD and Atrogin-1 protein levels, and scatter dot-plots with bar graphs showing the
1330 quantification of protein levels. Myoblasts were treated with 2-DG at Mb 100%. $n = 3$ 1330 quantification of protein levels. Myoblasts were treated with 2-DG at Mb 100%. n = 3
1331 treatments per group. Data are expressed as mean \pm SEM. *p<0.05; **p<0.01 compared to the 1331 treatments per group. Data are expressed as mean \pm SEM. $*p<0.05$; $**p<0.01$ compared to the
1332 Mb 100% group via Mann-Whitney *U* test. a.u., arbitrary units: CTRL, untreated control. **f-h** 1332 Mb 100% group via Mann-Whitney *U* test. a.u., arbitrary units; CTRL, untreated control. **f-h**
1333 Graphs for Extracellular Acidification Rate (ECAR) (**f**). Oxveen Consumption Rate OCR (**g**). 1333 Graphs for Extracellular Acidification Rate (ECAR) (**f**), Oxygen Consumption Rate OCR (**g**), 1334 and ATP production rate (**h**) of silenced myoblasts (shRNA, shTDP-43 or shFUS). The 1334 and ATP production rate (**h**) of silenced myoblasts (shRNA, shTDP-43 or shFUS). The corresponding quantification of basal glycolysis, glycolytic capacity, glycolytic reserve, basal 1335 corresponding quantification of basal glycolysis, glycolytic capacity, glycolytic reserve, basal
1336 respiration, maximal respiration, and spare respiration are presented on the right side of panels 1336 respiration, maximal respiration, and spare respiration are presented on the right side of panels
1337 (f) and (g), respectively. Analyses were performed one day after seeding myoblasts at Mb 1337 (**f**) and (**g**), respectively. Analyses were performed one day after seeding myoblasts at Mb
1338 100%, $n = 4$, 3, and 1 independent experiments, respectively, gluc, Glucose; olig, Oligomycin; 1338 100%. n = 4, 3, and 1 independent experiments, respectively. gluc, Glucose; olig, Oligomycin;
1339 FCCP, Carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone; rot/AA, Rotenone/Antimycin 1339 FCCP, Carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone; rot/AA, Rotenone/Antimycin
1340 A. Bar graphs represent mean \pm SEM, $\frac{k}{20}$ -0.05: $\frac{k}{20}$ -0.01 compared to the shRNA group via 1340 A. Bar graphs represent mean \pm SEM. $*p<0.05$; $**p<0.01$ compared to the shRNA group via
1341 one-way ANOVA. one-way ANOVA.

Figure 4. FOXO transcription factors and related signalling pathways are dysregulated upon TDP-43 or FUS silencing. a Venn diagram illustrates the number of overlapped 1343 **upon TDP-43 or FUS silencing. a** Venn diagram illustrates the number of overlapped
1344 differentially expressed genes (DEGs) between the shTDP-43 and the shFUS-silenced 1344 differentially expressed genes (DEGs) between the shTDP-43 and the shFUS-silenced
1345 myoblasts at 100% confluence. **b** Scatternlot for log₂-transformed fold changes of the 1345 myoblasts at 100% confluence. **b** Scatterplot for log₂-transformed fold changes of the
1346 overlapping DEGs, showing a significant correlation between shTDP-43 and shFUS-silenced 1346 overlapping DEGs, showing a significant correlation between shTDP-43 and shFUS-silenced
1347 mvoblasts. R^2 and linear function are indicated in the graph. Genes upregulated and 1347 myoblasts. R^2 and linear function are indicated in the graph. Genes upregulated and 1348 downregulated in both datasets are indicated in red and blue, respectively. The grey shade area 1348 downregulated in both datasets are indicated in red and blue, respectively. The grey shade area
1349 represents the 95% confidence interval. c Bubble chart of ranked enrichment analysis of shTDP-1349 represents the 95% confidence interval. **c** Bubble chart of ranked enrichment analysis of shTDP-¹³⁵⁰43 plotted against shFUS gene expression signatures using the Hallmark database by the GSEA

1351 multilevel enrichment test; GSEA score rank is based on normalised enrichment score (NES)
1352 and $-\log_{10}FDR$ *p*-value for each gene set. Bubble size represents the average $-\log_{10}FDR$ *p*-1352 and −log₁₀FDR *p*-value for each gene set. Bubble size represents the average −log₁₀FDR *p*-
1353 value. Gene sets upregulated and downregulated in both shTDP-43 and shFUS mvoblasts are 1353 value. Gene sets upregulated and downregulated in both shTDP-43 and shFUS myoblasts are
1354 indicated in red and blue, respectively. Enrichment analysis of gene expression signatures using indicated in red and blue, respectively. Enrichment analysis of gene expression signatures using
1355 KEGG, GO Biological Process and GO Molecular Function can be viewed in *Supplementary* 1355 KEGG, GO Biological Process and GO Molecular Function can be viewed in *Supplementary* 1356 *Fig.* 7. **d** Common transcription factors (TF) across the shTDP-43 and shFUS myoblasts with 1356 *Fig. 7*. **d** Common transcription factors (TF) across the shTDP-43 and shFUS myoblasts with
1357 predicted significant activity change by ISMARA motif analysis (based on Z score and average 1357 predicted significant activity change by ISMARA motif analysis (based on Z score and average
1358 gene target expression change). MYOG/TCF3, MYOD1 and MEF2A/C/D are highlighted 1358 gene target expression change). MYOG/TCF3, MYOD1 and MEF2A/C/D are highlighted
1359 among the TF motifs with downregulated target gene expression change (left panel). FOXO1/6, 1359 among the TF motifs with downregulated target gene expression change (left panel). FOXO1/6,
1360 CREB1, TP53, MZF1 and PRDM1 are highlighted among the TF motifs with upregulated target 1360 CREB1, TP53, MZF1 and PRDM1 are highlighted among the TF motifs with upregulated target
1361 eene expression change (right panel). e Representative images of human control immortalised 1361 gene expression change (right panel). **e** Representative images of human control immortalised
1362 myoblasts at 100% confluence stained for FOXO1 (green) and DAPI (nuclei, blue), and scatter 1362 myoblasts at 100% confluence stained for FOXO1 (green) and DAPI (nuclei, blue), and scatter
1363 dot-plot with a bar graph showing the percentage of cells positive for nuclear FOXO1 staining. 1363 dot-plot with a bar graph showing the percentage of cells positive for nuclear FOXO1 staining.
1364 Quantification was made with ImageJ v2.9 software using DAPI staining to delimit nuclei. 1364 Quantification was made with ImageJ v2.9 software using DAPI staining to delimit nuclei.
1365 Nuclei with integrated density values above the cut-off point (set as the value of mean +1 *SD of 1365 Nuclei with integrated density values above the cut-off point (set as the value of mean $+1*SD$ of shRNA cells) were considered positive for FOXO1. Scale bars: 50 μ m. n=6-9 images per cell 1366 shRNA cells) were considered positive for FOXO1. Scale bars: 50 μm. n=6-9 images per cell
1367 line. Scale bar: 25 μm. n=3-4 images per group, 2 independent experiments. *p<0.05, **p<0.01 line. Scale bar: 25 μm. n=3-4 images per group, 2 independent experiments. $*p<0.05$, $**p<0.01$
1368 compared to the shRNA group via one-way ANOVA. compared to the shRNA group via one-way ANOVA.

¹³⁶⁹**Figure 5. FOXO1 inhibition corrects myogenic defects and metabolic derangements** 1370 **induced by deficiency of TDP-43 or FUS. a** Representative images of TDP-43 or FUS-
1371 knockdown myoblasts treated or not with shFOXO1 lentiviral particles and stained for MyHC 1371 knockdown myoblasts treated or not with shFOXO1 lentiviral particles and stained for MyHC
1372 (Myosin heavy chain, green) and DAPI (nuclei, blue). Quantitative scatter plots with bar graphs 1372 (Myosin heavy chain, green) and DAPI (nuclei, blue). Quantitative scatter plots with bar graphs showing differentiation and fusion indices (right). Scale bar: 50 μ m. n=5-6 images per group. **b** 1373 showing differentiation and fusion indices (right). Scale bar: 50μ m. n=5-6 images per group. **b**
1374 Representative images of TDP-43 or FUS-knockdown myoblasts treated or not with the 1374 Representative images of TDP-43 or FUS-knockdown myoblasts treated or not with the
1375 selective FOXO1 inhibitor AS1842856 (iFOXO1) at 30 nM and stained for MyHC (green) and 1375 selective FOXO1 inhibitor AS1842856 (iFOXO1) at 30 nM and stained for MyHC (green) and
1376 DAPI (blue). Quantitative scatter plots with bar graphs showing differentiation and fusion 1376 DAPI (blue). Quantitative scatter plots with bar graphs showing differentiation and fusion
1377 indices (right). Immunofluorescence was performed 8 days (D8) after the first fusion events of 1377 indices (right). Immunofluorescence was performed 8 days (D8) after the first fusion events of
1378 shRNA control cells. Scale bar: 50 µm. n=5-6 images per group. c Representative Western blot 1378 shRNA control cells. Scale bar: 50 μm. n=5-6 images per group. **c** Representative Western blot
1379 images of MYOD1 and MYOG protein levels in shTDP-43 or shFUS-silenced myoblasts at 1379 images of MYOD1 and MYOG protein levels in shTDP-43 or shFUS-silenced myoblasts at
1380 100% confluence (Mb 100%) treated with iFOXO, and scatter dot-plots with bar graphs 1380 100% confluence (Mb 100%) treated with iFOXO, and scatter dot-plots with bar graphs
1381 showing the quantification of protein levels, n=3-6 transductions per group, a.u., arbitrary units. 1381 showing the quantification of protein levels. n=3-6 transductions per group. a.u., arbitrary units.
1382 **d** Representative graphs showing Extracellular Acidification Rate (ECAR) of TDP-43 or FUS-1382 **d** Representative graphs showing Extracellular Acidification Rate (ECAR) of TDP-43 or FUS-
1383 knockdown myoblasts treated or not with the selective iFOXO1 at 30 nM, and the basal 1383 knockdown myoblasts treated or not with the selective iFOXO1 at 30 nM, and the basal
1384 glycolysis and basal respiration calculated by the data obtained in these analyses. Analyses were 1384 glycolysis and basal respiration calculated by the data obtained in these analyses. Analyses were
1385 performed one day after seeding myoblasts at Mb 100%. n=3 independent experiments. Bar 1385 performed one day after seeding myoblasts at Mb 100%. n=3 independent experiments. Bar
1386 graphs represent mean \pm SEM. *p<0.05: **p<0.01 compared to the shRNA control group via graphs represent mean \pm SEM. **p*<0.05; ***p*<0.01 compared to the shRNA control group via

1387 one-way ANOVA; $\frac{h}{p}$ < 0.05 ; $\frac{h}{p}$ < 0.01 compared to the non-treated group via one-way ANOVA. 1388 gluc, Glucose; olig, Oligomycin; 2-DG, 2-deoxyglucose; OCR, Oxygen Consumption Rate,
1389 FCCP, Carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone; rot/AA, Rotenone/Antimycin FCCP, Carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone; rot/AA, Rotenone/Antimycin A. 1390

¹³⁹¹**Figure 6. FOXO1 is dysregulated in primary myoblasts from ALS patients and its inhibition alleviates myogenic defects. a** FOXO1 protein expression in myoblasts from ALS
1393 patients and controls. Left panel: Representative images of primary myoblasts at 100% 1393 patients and controls. Left panel: Representative images of primary myoblasts at 100%
1394 confluence (Mb100%) from ALS patients, both familial (fALS) and sporadic ALS (sALS), and 1394 confluence (Mb100%) from ALS patients, both familial (fALS) and sporadic ALS (sALS), and
1395 healthy controls (CTRL) stained for FOXO1 (green) and DAPI (nuclei, blue). Right panel 1395 healthy controls (CTRL) stained for FOXO1 (green) and DAPI (nuclei, blue). Right panel
1396 shows a dual representation of FOXO1 staining: scatter plot showing the distribution of cells 1396 shows a dual representation of FOXO1 staining: scatter plot showing the distribution of cells
1397 positive for nuclear FOXO1 (top), and bar graph depicting the mean optical density (OD) of 1397 positive for nuclear FOXO1 (top), and bar graph depicting the mean optical density (OD) of
1398 cytosolic FOXO1 staining (bottom). Quantifications were done using ImageJ v2.9 software. 1398 cytosolic FOXO1 staining (bottom). Quantifications were done using ImageJ v2.9 software.
1399 DAPI staining was used to define nuclear boundaries. Nuclei with a staining intensity greater 1399 DAPI staining was used to define nuclear boundaries. Nuclei with a staining intensity greater
1400 than the mean +1*SD of CTRL values were considered positive for FOXO1. The inner plots 1400 than the mean $+1*SD$ of CTRL values were considered positive for FOXO1. The inner plots
1401 depict the comparison of the average values of each ALS patient group (fALS and sALS) with 1401 depict the comparison of the average values of each ALS patient group (fALS and sALS) with
1402 the CTRL group. Bar graphs represent mean \pm SEM. n = 3-5 images per group. *p<0.05 1402 the CTRL group. Bar graphs represent mean \pm SEM. n = 3-5 images per group. **p*<0.05 compared to CTRL via Mann-Whitney *U* test. Scale bars: 100 µm. **b** Effect of FOXO1 1403 compared to CTRL via Mann-Whitney *U* test. Scale bars: 100 μm. **b** Effect of FOXO1
1404 inhibition on myogenic differentiation. Left panel: Representative images of primary myoblasts 1404 inhibition on myogenic differentiation. Left panel: Representative images of primary myoblasts
1405 from ALS patients and CTRLs, treated or not (NT) with the selective FOXO1 inhibitor 1405 from ALS patients and CTRLs, treated or not (NT) with the selective FOXO1 inhibitor
1406 AS1842856 (iFOXO1) at 30 nM, stained for Myosin Heavy Chain (MyHC, green) and DAPI 1406 AS1842856 (iFOXO1) at 30 nM, stained for Myosin Heavy Chain (MyHC, green) and DAPI
1407 (nuclei, blue). Right panel: Quantitative scatter plot with bar graphs showing fusion and 1407 (nuclei, blue). Right panel: Quantitative scatter plot with bar graphs showing fusion and
1408 differentiation indices. Immunofluorescence was performed 8 days (D8) after the first fusion 1408 differentiation indices. Immunofluorescence was performed 8 days (D8) after the first fusion
1409 events observed in untreated CTRL cells. Scale bars: 100 μ m. n = 5-6 images per group. Bar 1409 events observed in untreated CTRL cells. Scale bars: 100 μm. n = 5-6 images per group. Bar
1410 graphs represent mean ± SEM. *p<0.05 compared to the NT group via Mann-Whitney U test. c 1410 graphs represent mean \pm SEM. **p*<0.05 compared to the NT group via Mann-Whitney *U* test. **c** 1411 Effect of FOXO1 inhibition on glycolysis in primary myoblasts. Representative graphs show 1411 Effect of FOXO1 inhibition on glycolysis in primary myoblasts. Representative graphs show
1412 the Extracellular Acidification Rate (ECAR) of primary myoblasts from a selection of ALS 1412 the Extracellular Acidification Rate (ECAR) of primary myoblasts from a selection of ALS
1413 patients and an age-matched healthy CTRLs, treated or not with the selective iFOXO1 at 30 1413 patients and an age-matched healthy CTRLs, treated or not with the selective iFOXO1 at 30
1414 nM. The basal glycolysis and glycolytic capacity were calculated based on these analyses. 1414 nM. The basal glycolysis and glycolytic capacity were calculated based on these analyses.
1415 Analyses were performed one day after seeding myoblasts at 100% confluence. n = 3 1415 Analyses were performed one day after seeding myoblasts at 100% confluence. n = 3
1416 independent experiments. Bar graphs represent mean \pm SEM. $*_{p}$ <0.05, $*_{p}$ <0.01 compared to 1416 independent experiments. Bar graphs represent mean \pm SEM. $*p<0.05$, $**p<0.01$ compared to the NT CTRL group via one-way ANOVA; $\#tp<0.01$ compared to the NT group via one-way 1417 the NT CTRL group via one-way ANOVA; ##*p*<0.01 compared to the NT group via one-way 1418 ANOVA. gluc, Glucose; olig, Oligomycin; 2-DG, 2-deoxyglucose. ¹⁴¹⁸ANOVA. gluc, Glucose; olig, Oligomycin; 2-DG, 2-deoxyglucose.

¹⁴¹⁹**Figure 7. FOXO1 inhibitor AS1842856 treatment reverses phenotypical-functional** 1420 **parameters in** *Drosophila melanogaster* **models with muscle-conditioned TDP-43/FUS**
1421 **downregulation. a** Schematic illustration of the different fly models used in this study and the **downregulation. a** Schematic illustration of the different fly models used in this study and the

1422 analyses performed. Flies were orally treated (feeding) with the FOXO1 inhibitor AS1842856
1423 (iFOXO1) from the larval stage onwards. **b** Scatter dot-plots with median and interquartile 1423 (iFOXO1) from the larval stage onwards. **b** Scatter dot-plots with median and interquartile range showing climbing activity of the different fly models on adult days 5, 10 and 15. $n = 5$ 1424 range showing climbing activity of the different fly models on adult days 5, 10 and 15. n= 5
1425 flies per tube, 10 tubes per group. Each value is calculated as the average of three trials. 1425 flies per tube, 10 tubes per group. Each value is calculated as the average of three trials.
1426 $*_{p<0.05}$; $*_{p<0.01}$ compared to control (CTRL) flies via one-way ANOVA. c Kaplan-Meier 1426 $*p<0.05$; $*p<0.01$ compared to control (CTRL) flies via one-way ANOVA. **c** Kaplan-Meier
1427 curves of *caz*- or *TBPH*-silenced flies. n=100 flies per group: $*p<0.01$ compared to any of the 1427 curves of *caz*- or *TBPH*-silenced flies. n=100 flies per group; ** p <0.01 compared to any of the 1428 knockdown flies via log-rank test. **d** Scatter dot-plots with median and interquartile range 1428 knockdown flies via log-rank test. **d** Scatter dot-plots with median and interquartile range
1429 showing climbing activity of the different fly models treated with iFOXO1 at 30 μ M. n= 5 flies 1429 showing climbing activity of the different fly models treated with iFOXO1 at 30 μ M. n= 5 flies
1430 per tube, 9 tubes per group. Each value is calculated as the average of three trials. *p<0.05; 1430 per tube, 9 tubes per group. Each value is calculated as the average of three trials. $*p<0.05$;
1431 $*p<0.01$ compared to non-treated flies via two-way ANOVA. **e-g** Kaplan-Meier curves of *caz*-1431 ***p*<0.01 compared to non-treated flies via two-way ANOVA. **e-g** Kaplan-Meier curves of *caz-*¹⁴³²(**e**) or *TBPH*-silenced flies (**f-g**) treated (feeding) with iFOXO1. n=90 flies per group. **p*<0.05; ⁴⁸*p*<0.01 compared to non-treated flies via log-rank test. **h** Representative images of pharate
1434 lethality in the fly model $iTBPH^{pk(108354)}$ with or without treatment (feeding) with iFOXO1. 1434 lethality in the fly model $iTBPH^{pkk(108354)}$ with or without treatment (feeding) with iFOXO1.
1435 Note that the pupae of CTRL flies are empty and adult flies are at the top of the tube. However, 1435 Note that the pupae of CTRL flies are empty and adult flies are at the top of the tube. However,
1436 adult pharates of the *iTBPH^{pkk(108354)* model remain trapped inside the pupa. The scatter dot-plots} 1436 adult pharates of the *iTBPH^{pkk(108354)* model remain trapped inside the pupa. The scatter dot-plots with median and interquartile range in the right shows the effect of iFOXO1 on adult pharate} 1437 with median and interquartile range in the right shows the effect of iFOXO1 on adult pharate
1438 survival. n= 75 pupae per tube, 6 tubes per group. **p<0.01 compared to non-treated flies via 1438 survival. n= 75 pupae per tube, 6 tubes per group. $*^*p<0.01$ compared to non-treated flies via
1439 Student's t test. **i** Representative images of *Drosophila* indirect flight muscles stained with 1439 Student's t test. **i** Representative images of *Drosophila* indirect flight muscles stained with
1440 Phalloidin (blue), neuronal marker HRP (pink) and Bruchpilot (green). Scale bar: 50 um. 1440 Phalloidin (blue), neuronal marker HRP (pink) and Bruchpilot (green). Scale bar: 50 µm.
1441 Digitally zoomed images show Bruchpilot+ synaptic boutons along motoneuron terminals. **i**, **k** 1441 Digitally zoomed images show Bruchpilot+ synaptic boutons along motoneuron terminals. **j, k**
1442 Scatter dot-plots with median and interquartile range shows the quantification of the synaptic 1442 Scatter dot-plots with median and interquartile range shows the quantification of the synaptic
1443 area (i) and neuron (HRP+) density (k). $n=12$ flies per group. **p<0.01 compared to CTRL 1443 area (**j**) and neuron (HRP+) density (**k**). n=12 flies per group. ***p*<0.01 compared to CTRL
1444 flies; $\frac{\text{#p}}{2}$ <0.01 compared to *iTBPH^{pkk(108354)* flies via two-way ANOVA.} 1444 flies; $\#p<0.01$ compared to *iTBPH*^{pkk(108354)} flies via two-way ANOVA.

¹⁴⁴⁶**SUPPLEMENTARY INFO**

¹⁴⁴⁷**Supplementary Tables:**

- 1448 Supplementary Table 1: Primary antibodies.
- 1449 Supplementary Table 2: DEGs of shTDP-43 and shFUS myoblasts from RNA-seq experiment.
- 1450 Supplementary Table 3: GO and KEGG enriched pathways of shTDP-43 and shFUS myoblasts
1451 from RNA-seq experiment.
- from RNA-seq experiment.
- 1452 Supplementary Table 4: ISMARA TF motifs analysis.

¹⁴⁵³**Supplementary Figures:**

- 1454 Supplementary Figure 1. Haematoxylin and eosin staining for ALS and control muscle sections.
- 1455 Supplementary Figure 2. Further characterization of primary myoblasts from ALS patients.
- 1456 Supplementary Figure 3. Examination of cytoplasmic granules of TDP-43 and FUS in ALS
1457 primary human myoblasts.
- primary human myoblasts.
- 1458 Supplementary Figure 4. Ultrastructural characteristics of human myoblasts with TDP-43 or
1459 FUS silencing. FUS silencing.
- 1460 Supplementary Figure 5. Dynamics of TDP-43 and FUS along the myogenic process in the immortalised human myoblasts. immortalised human myoblasts.
- 1462 Supplementary Figure 6. Metabolic characterization of the immortalised human myoblasts.
- 1463 Supplementary Figure 7. Extended Figure 4c. a-c
- 1464 Supplementary Figure 8. Dynamics of FOXO transcription factors throughout myogenesis and
1465 metabolic challenges in human myoblasts. metabolic challenges in human myoblasts.
- 1466 Supplementary Figure 9. Levels of nuclear FOXO3 in myoblasts models of ALS.
- 1467 Supplementary Figure 10. Effect of FOXO1 silencing on the levels of nuclear FOXO1 in human
1468 myoblasts silenced for TDP-43 or FUS.
- myoblasts silenced for TDP-43 or FUS.
- 1469 Supplementary Figure 11. FOXO1 is not dysregulated in primary myoblasts from non-ALS
1470 neurogenic atrophies and myopathies. neurogenic atrophies and myopathies.

1471 Supplementary Figure 12. Extended Fig. 7.

¹⁴⁷²**Supplementary Videos:**

- 1473 Supplementary Video 1. Locomotor activity test in non-treated (NT) CONTROL flies
- 1474 Supplementary Video 2. Locomotor activity test in non-treated (NT) iCaz flies
- 1475 Supplementary Video 3. Locomotor activity test in iFOXO1-treated iCaz flies
- 1476 Supplementary Video 4. Locomotor activity test in non-treated (NT) iTBPH^{attp40} flies
- 1477 Supplementary Video 5. Locomotor activity test in $iFOXO1$ -treated $iTBPH^{attp40}$ flies
- 1478 Supplementary Video 6. Locomotor activity test in non-treated (NT) iTBPH^{p(GD6943)} flies
- 1479 Supplementary Video 7. Locomotor activity test in iFOXO1-treated iTBPH^{p(GD6943)} flies

1480

a

It is made available under a CC-BY-NC-ND 4.0 International license. medRxiv preprint doi: [https://doi.org/10.1101/2024.07.17.24309945;](https://doi.org/10.1101/2024.07.17.24309945) this version posted July 17, 2024. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted me

 $\mathbf C$

RNAseq Analysis of myogenic capacity Metabolic fitness **shRNA** $\frac{a}{b}$ shTDP-43 Mb 30% Mb 100% Fusion D8 D3 shFUS

S

MYOG-D3 Mb 100% TDP-43 - Mb100% **FUS - Mb100%** $MYOD1 - Mb100\%$ D₃

Proliferation

S

a

 \blackcap

 \blacktriangleright

 $\mathbf C$

 C^2

 $\frac{1}{2}S^3$

Glycolytic **Reserve**

 $\star\star$

15-

10-ll

 $5¹$

 ∞

ATP production rate

 $\frac{1}{2}$

 x^2

 C

 $\boldsymbol{\mathsf{\Omega}}$

 \blacktriangleright

TF motif analysis - downregulated

 \curvearrowright

 \blacktriangleright

 $\overline{\mathsf{C}}$

Mb 100%

 $MYOD1 - Mb100%$

 $MYOG - Mb100\%$

 S^{\prime}

0.07

**

 $\#$

Glycolysis

Basal Glycolysis

Mitochondrial **ATP**

 \blackcap

৫ ১

 $16.$

ITBPH^{pkk(108354)}

OCTRL

o iTBPH^{pkk(108354)}+iFOXO1

OCTRL+iFOXO1 \bullet iTBPH ^{pkk(108354)} o iTBPH P ^{pkk(108354)} +iFOXO1